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Summary 
Premature cardiovascular (CV) death is the commonest cause of death in patients 
with end stage renal disease (ESRD), which includes those receiving or close to 
requiring renal replacement therapy.   In ESRD patients, CV deaths are most 
commonly caused by cardiac arrhythmia and sudden cardiac death compared to the 
general population where myocardial ischaemia and infarction predominate.  Higher 
CV disease burden is due to accumulation of “conventional” risk factors (e.g. 
hypertension, diabetes mellitus, smoking) and “novel” risk factors (e.g. oxidative 
stress, proteinuria, anaemia, inflammation) in ESRD patients.  In addition, risk 
factors specific to patients with renal disease have been identified including 
alteration in left ventricular (LV) structure, called uraemic cardiomyopathy.  These 
structural abnormalities are common in patients with ESRD (between 60-80% of 
subjects upon initiation of dialysis) and include left ventricular hypertrophy (LVH), 
systolic dysfunction (LVSD) and dilatation. These changes in LV structure confer 
adverse CV outcome in ESRD patients and have proven difficult to reverse. 
 
Detection of these abnormalities is usually performed using echocardiography, 
however this technique is inaccurate in ESRD patients due to significant alterations 
in LV shape and geometric assumptions made during calculation of myocardial 
mass.  Cardiovascular MRI (CMR) negates these assumptions and is the most 
accurate, reproducible and reliable method of assessing LV dimensions independent 
of intravascular volume, particularly in patients with altered myocardial architecture.  
Furthermore, maximal left atrial volume can be measured using CMR.    The 
principle aims of the studies presented in this thesis were to elucidate prognostic and 
pathophysiological features of uraemic cardiomyopathy using CMR. 
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In a large study (n=246) of haemodialysis patients, the determinants of each LV 
abnormality of uraemic cardiomyopathy were identified from past clinical history, 
haemodialysis and blood parameters and other LV measurements.   For LV changes, 
major determinants were clinical features associated with advanced renal disease, 
namely expansion of intravascular/ extracellular fluid compartment, abnormal bone 
mineral biochemistry and hypertension.  Furthermore, presence of one LV 
abnormality was one of the strongest predictors of presence of another, perhaps 
indicating differing stages of uraemic cardiomyopathy development.  In a subsequent 
prognostic study including these patients (n=446), presence of LVSD and LV 
dilatation on CMR were significantly associated with poorer all cause and CV 
mortality.   Presence of LVH, which is by far the most common structural change, 
was associated with poorer cardiovascular survival only.  In addition, presence of 
two or three abnormalities (commonly LVH with another abnormality) had a 
significantly poorer prognosis and independently predicted CV and all cause 
mortality.  This has implications for therapeutic strategies which should aim to slow 
or reverse cardiac changes of ESRD and prevent progression from one cardiac 
abnormality to 2 or more.  In a further study (n=201) investigating additional 
prognostic features of ESRD patients with LVH, maximal left atrial volume (LAV) 
was measured using the bi-plane area length method at end LV systole.  Elevated 
LAV and presence of LVSD were significantly associated with poorer all cause 
survival and were independent predictors of death.  The most likely causes of 
elevated LAV in ESRD patients are LV diastolic dysfunction and expanded 
extracellular compartment and may provide a target for therapeutic intervention. 
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The electrophysiological features of uraemic cardiomyopathy were assessed using 
microvolt T wave alternans (MTWA) which is a novel, non-invasive method of 
measuring small variations in surface electrocardiogram (ECG) T wave morphology 
and thus ventricular repolarisation.  This technique has been used to stratify other 
cohorts at elevated risk of sudden cardiac death (such as ischaemic and non 
ischaemic cardiomyopathy, hypertensive LVH).  A study presented in this thesis, 
compared MTWA results between ESRD (n=200) and hypertensive patients with 
LVH on echocardiography (n=30).  Abnormal MTWA result was significantly more 
common in ESRD patients compared to hypertensive patients with LVH.  
Furthermore, abnormal MTWA result was significantly associated with myocardial 
abnormalities of uraemic cardiomyopathy and a history of macrovascular 
atheromatous disease in ESRD patients.  Despite preservation of LV function on 
CMR, the frequency of abnormal MTWA result in ESRD patients was similar to 
previous studies in subjects with heart failure.  31Phosphorus magnetic resonance 
spectroscopy is a novel, non-invasive technique of estimating cardiac energetic 
status and high energy phosphate (HEP) metabolism in a myocardial area of interest 
and has previously been used to assess patients with global myocardial disease 
(dilated cardiomyopathy, hypertensive LVH).  High energy phosphate metabolism 
was compared between patients with ESRD (n=53) and hypertensive LVH (n=30) 
and despite similar LV mass between both groups, PCr: ATP (an indicator of HEP 
metabolism) was significantly reduced in ESRD patients.  These findings are most 
likely due to cardiac interstitial fibrosis and the alteration of tissue composition 
within the area of interest, and changes in metabolic function within cardiomyocytes 
of uraemic hearts. Finally, a small study (n=50) investigated the effect of successful 
renal transplantation on LV mass measured by CMR.  On comparison of patients 
26 
 
who remained on the renal transplant waiting list, there was no significant difference 
in LV mass in patients who received a renal transplant.  It is likely that previous 
echocardiography studies that demonstrated significant regression of LVH, measured 
improvement in fluid control rather that actual reduction in myocardial mass. 
 
Future studies investigating benefit of therapeutic intervention may require 
identification of individuals at higher CV risk and the results of studies presented in 
this thesis aim to provide information for selecting such ESRD patients.    With these 
results in mind, further prospective studies will be able to carefully select groups of 
ESRD patients with differing left ventricular, left atrial, electrophysiological and 
biochemical properties to demonstrate survival benefit with interventional agents.  In 
this way, future therapies for ESRD patients can be tailored to improve 
cardiovascular survival. 
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Chapter 1 
 
Introduction 
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During the latter part of the 20th century, better understanding of renal disease, 
dialysis techniques and renal transplantation have significantly improved prognosis 
of patients with end stage renal disease (ESRD).  However, as survival has 
improved, other conditions have contributed significantly to the morbidity and 
mortality of ESRD patients. Cardiovascular (CV) disease, including cardiac 
arrest/arrhythmia, acute myocardial infarction (AMI), congestive heart failure and 
stroke, is the commonest cause of premature death in patients with ESRD.  In 
addition, early stages of chronic kidney disease (CKD) have also been associated 
with poorer cardiovascular prognosis compared to the general population (1;2).   
 
1.1 Progression and classification of chronic kidney disease 
The natural history of patients with renal disease is shown in Figure 1.1.  After a 
period of deteriorating renal function (which can last many years), some patients 
develop ESRD.  These patients can receive dialysis in the form of haemodialysis 
(which is commonly in-hospital and thrice weekly) or peritoneal dialysis.   Patients 
can receive a renal transplant just before requiring or, more commonly, whilst 
receiving dialysis.  Patients with transplants which fail can return to dialysis until 
they are re-transplanted.  Cardiovascular risk is higher than the general population at 
each stage of this disease process (Figure 1.1). 
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Figure 1.1 Natural history of patients with CKD and estimated increase in 
CV risk compared to the general population.  Modified from (3). 
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To allow better evaluation and stratification of patients with renal dysfunction, the 
Kidney Disease Outcome Quality Initiative (K/DOQI) guidelines have classified 
CKD into 5 stages based on glomerular filtration rate (GFR) and evidence of kidney 
damage (by imaging, histology, or urinalysis).  These have more recently been 
modified to include kidney transplant recipients and dialysis patients (Table 1.1).  
The main aim of implementing this system is to allow early recognition of kidney 
dysfunction and commence preventative measures to slow CKD and CV disease 
progression (2). 
 
 
Table 1.1 Classification of CKD 2004 (2).  GFR= glomerular filtration rate 
 
Stage Description GFR 
(ml/min/1.73m2) 
Related Terms Treatment 
1 Damage with 
normal or ↑GFR 
≥90 Albuminuria 
Haematuria 
Proteinuria 
 
 
2 Damage with 
Mild ↓ GFR 
60-89 Albuminuria 
Haematuria 
Proteinuria 
 
3 Moderate↓ GFR 30-59 Chronic renal 
insufficiency 
 
4 Severe ↓ GFR 15-29 Chronic renal 
insufficiency 
 
5 Kidney Failure <15 or dialysis Renal Failure,ESRD D if receiving 
dialysis 
 
 
T if 
kidney 
transplant 
recipient 
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1.2 Epidemiology of cardiovascular disease in ESRD patients 
 
1.2.1 Prevalence of cardiovascular deaths in ESRD 
According to data from the United States Renal Data System (USRDS), in 2008 
annual mortality rates for ESRD patients and prevalent dialysis patients were 165.6 
and 220.7 per 1000 patient-years respectively.  Cardiac disease accounted for 41% of 
deaths in dialysis patients and 40% of deaths in ESRD patients (comprising all CKD 
5 subjects: predialysis and dialysis). In dialysis patients 65.9% of cardiac deaths 
(26.9% of all deaths) were due to cardiac arrhythmia or sudden cardiac death 
representing the major cause of CV death (Figure 1.2).  This pattern is also present in 
all ESRD patients (including peritoneal and pre-dialysis) and, to a lesser extent, in 
successfully transplanted patients (4). 
 
Figure 1.2 Mortality rate by primary cause of mortality.  (per 1000 patient 
years at risk, 2008).  
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Throughout all age groups CV risk is higher than the general population.  
Furthermore, increased relative risk of CV death is greatest in younger patients, who 
have a CV risk similar to elderly (70-80 years) non renal patients (5).  
 
A significant problem of epidemiological studies from renal registries (both US and 
European) is defining the primary cause of death.  In many cases autopsies are not 
performed, death certificates are not accurately completed, definitions used to define 
CV death tend to underestimate true cardiovascular deaths and it is often difficult to 
isolate a single cause of death in many patients.  Nonetheless, these data demonstrate 
significant pathophysiological differences in CV death between the general 
population (where atherosclerosis and subsequent myocardial ischaemia and 
infarction are most common) and ESRD patients (where sudden, presumed 
arrhythmic death predominates CV mortality) (6). 
 
1.2.2 Risk factors for CVD in ESRD patients 
Large population based studies have identified a number of risk factors for CVD in 
the general population (Table 1.2).  Furthermore large interventional studies have 
shown that modification of some of these risk factors improves CV survival.  For 
example, lipid lowering using HMG Co-A reductase inhibitors has been shown to 
provide significant survival benefit for both primary and secondary prevention of CV 
events (7;8) and have been included in current clinical practice for many years. 
 
In ESRD patients, premature cardiovascular death has been associated with higher 
prevalence of these “conventional” risk factors; but the relationship between these 
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risk factors and CVD is much less clear than in the general population.  In addition, 
novel risk factors, which are often associated with the presence of uraemia, appear to 
have a more influential role on subsequent CV events than in the general population 
(Table 1.2).   The majority of studies investigating CV risk factors in ESRD patients, 
have been performed in patients receiving regular haemodialysis, however many of 
these risk factors are also relevant to peritoneal dialysis or predialysis patients.   
 
Table 1.2 Risk Factors for CVD in general population and ESRD patients 
(1;5) 
Traditional CV Risk Factors-  
General Population 
Novel/ Uraemia Specific Risk Factors 
Advancing age Haemodynamic/metabolic factors ESRD 
Hypertension Proteinuria 
Dyslipidaemia ↑ Extracellular fluid volume 
Diabetes Mellitus Electrolyte imbalance/fluctuation 
Sedentary Lifestyle Vascular calcification 
Previous IHD/CVA/PVD Bone mineral disorders 
Smoking Homocysteine 
Oxidative stress Anaemia 
LVH/LVSD Inflammation 
 Uraemic cardiomyopathy 
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1.2.2a Advancing age and gender 
The mean age of patients commencing RRT has gradually increased over the last 
decade.  Furthermore increasing age is commonly an independent predictor of 
mortality in most studies investigating associations with (CV) death.  In all age 
groups male CKD patients have a significantly higher risk (x2.5) of acute myocardial 
infarction compared to female patients.  However, female CKD patients have a 3-5x 
higher risk of acute myocardial infarction  when compared to age and sex matched 
patients with no renal disease (5).   
 
1.2.2b Hypertension 
In the general population without co-existing CV disease, prospective observational 
studies have demonstrated that increments of 5-6mmHg in diastolic blood pressure 
(DBP) or 10mmHg systolic blood  pressure (SBP) are associated with a 20-25% 
increased risk of ischaemic heart disease, 35-40% greater risk of stroke and 50% 
increased risk of heart failure (9).  Furthermore, reduction of blood pressure reduces 
cardiovascular risk significantly (10).   A number of large prospective trials have 
demonstrated that treatment with calcium channel blockers, diuretics, beta blockers 
and drugs affecting the renin- angiotensin system improve cardiovascular outcome in 
hypertensive patients (11-13).   
 
Hypertension is very common in patients with CKD and is caused by a combination 
of reduced arterial compliance related to vascular calcification, endothelial 
dysfunction, fluid overload, and autonomic dysfunction (14). Furthermore, 
controlling blood pressure in patients with early stages of CKD has also been shown 
to slow progression of renal dysfunction and improve cardiovascular outcome 
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(15;16).  However, similar prospective studies performed in dialysis patients have 
not consistently demonstrated a beneficial role for reducing blood pressure.  Some 
studies have demonstrated that low and high blood pressure are associated with 
higher mortality. 
   
• In a cohort study of 40933 haemodialysis patients followed for 15 months, pre 
dialysis systolic BP<110mm Hg and diastolic BP <50mmHg were associated with a 
hazard ratio for all cause mortality of 1.60 and 2.00 respectively (17).   
• Similarly, an observational study in 16959 haemodialysis patients demonstrated that 
systolic BP< 120mmHg was associated with higher mortality after 1 and 2 years.  
However, after surviving 3 years on dialysis, higher systolic BP (>150mmHg)  was 
associated with adverse prognosis suggesting that the relationship between blood 
pressure and survival may alter with time (18). 
 
This “U” or “J” shaped relationship between blood pressure and mortality is most 
likely due to the association between hypotension and co-morbid conditions such as 
cardiac failure, diabetes mellitus, malnutrition and sepsis in dialysis patients,.  As has 
been demonstrated in other studies involving chronic conditions (heart failure, 
advanced age), low blood pressure is associated with adverse outcome.  This 
phenomenon is known as “reverse epidemiology” and has been demonstrated with 
other risk factors in ESRD patients (see below) (19). 
 
There are few trials that have identified optimal targets and treatment for 
hypertension in ESRD patients.  Promising studies have demonstrated that 
longer/more frequent dialysis may provide tight blood pressure control in 
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haemodialysis patients (20), however more studies are required to determine optimal 
targets and measures to control BP in patients receiving renal replacement therapy. 
 
1.2.2c Dyslipidaemia  
As renal dysfunction deteriorates there are complex disturbances in lipoprotein 
metabolism which are influenced by patient nutritional status, degree of renal 
dysfunction, presence of proteinuria, and diabetes mellitus. In patients with ESRD, 
plasma triglyceride levels are elevated and cholesterol levels may be high, normal or 
low dependent on nutritional status and modality of renal replacement.  For example, 
patients on haemodialysis commonly have low total and low density lipoprotein 
(LDL) cholesterol.  Peritoneal dialysis patients have elevated total and LDL 
cholesterol.  In general, ESRD is associated with high levels of atherogenic particles 
(eg small dense LDL) independent of total or LDL cholesterol and reduced levels of 
atheroprotective high density lipoprotein (HDL) cholesterol. 
 
As stated before, in the general population reduction of cholesterol using statins has 
been associated with primary and secondary prevention of CV events (7;8). In 
addition, the anti-inflammatory role of statins may contribute to their reduction in 
CV events.  The JUPITER trial demonstrated that rosuvastatin reduced LDL-
cholesterol and high sensitivity C reactive protein (CRP) levels. Whilst CV events 
and all cause mortality were significantly reduced in individual groups, the greatest 
reduction in events was found in the patients group that achieved both (21).  In vitro 
studies have demonstrated that statins reduce inflammatory cell endothelium 
adhesion, alter smooth muscle cell behaviour in developing atheromas and aid 
stabilisation of atherogenic plaques (21;22). 
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The relationship between dyslipidemia and CV events/mortality in ESRD patients 
remains less clear.  Data from renal registries suggest that, similar to hypertension, a 
“J” or “U” shaped relationship exists between serum cholesterol and survival in 
haemodialysis patients.  As with blood pressure, this “reverse epidemiology” relates 
to high prevalence of malnutrition or other co-morbid conditions (inflammation) in 
patients with low levels of cholesterol. These data have contributed to the under 
usage of statins in dialysis patients, despite the high proportion of patients with 
diabetes and coronary heart disease (23;24).    
 
Two randomised placebo controlled trials have failed to demonstrate significant 
reduction in CV events or death in haemodialysis patients treated with statins. 
 
• The Deutsche Diabetes Dialyse Studie (4D) was a prospective randomised controlled 
trial investigating the effect of atorvastatin therapy on cardiovascular outcome in 
1225 type 2 diabetic haemodialysis patients.  Although LDL cholesterol was reduced 
(42% reduction), there was no statistical significant reduction of the composite 
primary endpoint (death from all cardiac causes, fatal stroke, non fatal MI, or non 
fatal stroke).  Interestingly myocardial infarction events were reduced in the 
treatment arm.   Post hoc analyses, however, revealed that adjudicated deaths due to 
coronary artery disease only accounted for 9% of deaths and sudden death accounted 
for 26% of all cause mortality (25).   
• The AURORA trial was a prospective randomised study investigating therapy with 
rosuvastatin in 2776 haemodialysis patients.  LDL cholesterol was reduced by 43% 
in the therapy arm but there was no significant effect on primary outcome 
(adjudicated death from cardiovascular causes, non fatal MI, non fatal stroke).  In the 
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statin treated group, deaths from cardiovascular cause occurred at a rate of 7.2 
events/100 patient-years compared to 7.3 events/100 patient–years in the placebo 
group (p=0.97) and death from definite coronary heart disease was not significantly 
different (26).  
 
In both of these studies, the investigators postulated that lack of benefit in the treated 
cohort highlighted the difference between cardiovascular disease in patients with 
ESRD/diabetes and the general population.  To explore the difference in 
cardiovascular disease in ESRD and the non-renal population, the results for placebo 
arms of the AURORA, 4D and 4S studies are shown in Table 1.3.  The 4S study was 
a randomised placebo controlled study investigating the effect of simvastatin in 
patients who had proven coronary artery disease (8). 
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Table 1.3  Results from placebo arms of AURORA, 4D and 4S studies. 
 
 
 
These data show that patients receiving haemodialysis have a much higher risk of 
cardiac death than non fatal MI.  However in a post MI, non dialysis-dependent 
cohort of patients, non fatal MI is the most prevalent CV event to occur; cardiac 
death is much less common.  When we look at data from USRDS (see Figure 1.2) 
these haemodialysis patients are much more likely to suffer a cardiac arrhythmic 
death. The features that increase risk of sudden cardiac death/cardiac arrhythmia will 
be discussed later in this chapter. 
 
1.2.2d Diabetes mellitus 
According to UK Renal Registry and USRDS data, diabetes is the most common 
primary renal disease in patients receiving RRT and in the developed world diabetic 
nephropathy has become the most common cause of ESRD (between 20-35% of 
patients).  In addition, the prevalence of diabetic patients with ESRD is rising which 
likely reflects improved survival of type 2 diabetic patients (27).  Interestingly,  
recent reports from Finland and US suggest that the number of type 1 diabetic 
 
Study/ 
Cause of Death 
AURORA 
% 
4D 
% 
4S 
% 
Placebo n=1378 Placebo n=636 Placebo n=2223 
Study Population Haemodialysis DM+ haemodialysis Post AMI 
Cardiac Death 5.4 19.5 8.5 
Non Fatal MI 2.5 11.8 16.9 
Non- CV Death 8.1 28.5 3.0 
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patients requiring dialysis is decreasing possibly due to improved glycaemic, blood 
pressure and proteinuria control (28).  
 
Diabetic patients who start dialysis have many CV risk factors including 
dyslipidaemia, hypertension, chronic inflammation and elevated oxidative stress 
leading to a poor prognosis on dialysis.  Presence of diabetes at the start of dialysis is 
significantly associated with poorer survival, an independent risk factor for all cause 
and CV death,  and it is estimated that cumulative risk for diabetes (2-3x compared 
to non diabetic ESRD patients) and presence of ESRD increases the overall risk of 
death to 50x that of the general non diabetic population (29).  Accelerated coronary 
artery disease (CAD) is the greatest contributor to elevated CV morbidity and 
mortality in diabetic ESRD patients (30).  In one study looking at 155 diabetic 
patients being assessed for renal transplantation (who are commonly positively 
selected due to their fitness to have a transplant), significant occlusion (>50%) in at 
least one vessel was found in 45% of patients despite 28% being asymptomatic of 
angina (31). 
 
1.2.2e Cigarette smoking 
Initial studies suggested that smoking had little effect on CV disease in ESRD 
patients and clinicians were reluctant to impose further restrictions on chronically 
unwell patients.    However, two studies have demonstrated an association between 
smoking and CV disease similar to the general population.   
 
• In an observational study investigating baseline CV risk factors and pre-existing 
disease in dialysis patients, smoking was independently associated with higher 
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relative risk of CV disease (32). In addition, a prospective study investigating 
development if CV events in a population of haemodialysis patients over 5 years 
showed that being a smoker at screening significantly increased risk of a subsequent 
CV events (33). 
 
As a result of these and other studies, smoking cessation is encouraged in ESRD 
patients to improve CV survival. 
 
1.2.2f Ischaemic heart disease 
As stated above, sudden cardiac death and cardiac arrhythmia are the commonest 
cause of death in the ESRD population.  Nonetheless, accelerated CAD and its 
sequelae account for almost 20% of CV deaths and is a significant feature of CV 
disease in ESRD patients.  Cause of death classification is not always supported by 
post mortem evidence and it is likely that a significant proportion of deaths 
attributed as “arrhythmic” in origin are due to silent, undiagnosed CAD.   
 
The classical triad to identify myocardial infarction: namely symptoms, ECG 
changes and myocardial enzyme elevation, can be misleading in this patient 
population making design of trials very difficult. Resting ECG abnormalities 
(particularly T wave and left ventricular axis changes) are common in ESRD 
patients and can be mistaken for ischaemia.  In addition, significant myocardial 
ischaemia may be present in dialysis patients despite atypical or absent symptoms.  
Finally, myocardial enzymes such as troponin I and T may be elevated in renal 
impairment despite the absence of significant myocardial damage. 
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Nonetheless, several observational studies have highlighted elevated burden of CAD 
in ESRD patients.  It has been estimated that in patients commencing dialysis, 30% 
of patients will experience AMI in the first year and 52% after the second (34).  
Furthermore, follow up data of these patients (35) has demonstrated poor prognosis 
in patients who suffered an MI with only 40% alive at 12 months and post-MI 
cardiac arrhythmias contributing to a very high in- hospital mortality (21% vs.  8% 
in the general population)   
 
Poor post-MI prognosis may be due to under- or late diagnosis of MI at the time of 
presentation and delay in appropriate treatment.  Even when patients with AMI are 
identified, a significantly lower number of patients are treated with thrombolytic 
therapy or referred for primary percutaneous intervention (PCI) compared to the non 
dialysis population.  When discharged, these patients are under prescribed standard 
secondary preventative therapy: only 50-75% of patients receive aspirin, 22% 
receive β- blockers and 26% receive statin therapy (36).  Reluctance to prescribe 
these drugs is presumably due to absence of evidence supporting their use in ESRD 
patients, who were commonly excluded from large studies for secondary prevention 
of CV events.  However, a number of small observational studies have demonstrated 
significant benefit of treatment with aspirin, β- blockers or angiotensin converting 
enzymes in the 30 day post MI period compared to those not treated (37). 
 
At the time of presentation, both thrombolytic therapy and primary PCI have been 
shown to significantly improve survival in ESRD patients. From USRDS data, 
Herzog et al showed that thrombolysis therapy for ST elevation MI was associated 
with a 28% relative risk reduction in all cause mortality at 48 months (38).    
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Furthermore, if the centre that patients present has access to primary PCI, ESRD 
patients should be treated similarly to the general population.  In a large 
observational study of 4758 CKD patients who presented to hospital with acute 
coronary syndrome, Keeley et al demonstrated a significant improvement in long 
term mortality in patients with CKD 4-5 treated with primary PCI compared to 
medical therapy (39). 
 
In dialysis patients with significant symptomatic CAD there is survival benefit of 
coronary artery bypass grafting (CABG) compared to PCI with angioplasty (± stent). 
Dialysis patients from the USRDS who received their first coronary revascularisation 
procedure between 1995 and 1998 were compared in a large retrospective study.  All 
cause 2 year survival was significantly higher in patients who underwent CABG 
(56.4%) compared to PCI and PCI and stent groups (48.2% and 48.4% respectively; 
p<0.01).  Multivariate survival analyses, demonstrated a 20% reduction in all cause 
mortality in patients treated with CABG and 6% reduction with PCI and stenting 
compared to PCI alone.  However, the benefits of CABG over PCI need to be 
balanced with higher peri-operative complication rate of these procedures (8.6% for 
CABG vs. 6.4% for angioplasty and 4.1% for stenting) (35).  
 
These studies suggest that coronary artery intervention is appropriate in the acute 
setting and/or in patients with critical coronary artery stenoses.  In ESRD patients 
with less severe but flow limiting CAD, the role of coronary intervention is less clear 
due to a lack of prospective randomised controlled trials.  In the CARP 
(asymptomatic patients undergoing high risk vascular surgery) and COURAGE 
studies (asymptomatic patients with stable CAD), PCI conferred no significant 
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survival benefit compared to patients treated with optimal medical therapy 
highlighting the need for careful selection of patients who undergo coronary 
revascularisation (40;41).  At present, a prospective randomised controlled trial is 
planned in the US to determine the possible benefit of coronary revascularisation in 
ESRD patients. 
 
1.2.2g Sedentary lifestyle 
ESRD patients are at risk of physical deconditioning due to a number of reasons 
including large burden of co-morbidity (diabetes mellitus, peripheral vascular 
disease, CAD), recurrent hospital admissions, myopathy related to uraemia, 
hyperparathyroidism and anaemia.  The UK Renal Association recommends regular 
exercise programmes for dialysis patients usually 3-5 times a week despite a lack of 
convincing evidence of benefit (42).  Results from the Dialysis Morbidity and 
Mortality Wave 2 study demonstrated a significantly higher mortality in patients 
with severe limitations in physical activity.  When different patient groups were 
exposed to varying levels of exercise, frequent exercise (4-5/week) was associated 
with improved survival (43). 
 
1.2.2h Oxidative stress 
Essential steps in development of atherosclerosis include perioxidation of 
membrane-bound, lipoprotein-associated fatty acids (in particular LDL- cholesterol) 
and oxidation of proteins by reactive oxygen species (ROS).  Furthermore, ROS play 
a part in ischaemia-reperfusion injury during myocardial ischaemia/infarction.  In the 
general population, interventional randomised trials have investigated the effect of 
antioxidants (e.g. acetylcysteine), which significantly reduce oxidation of LDL-
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cholesterol and impair cellular response to oxidised LDL-cholesterol.  Unfortunately, 
these studies have shown no significant clinical benefit (44). 
 
A number of studies have demonstrated that patients receiving RRT (particularly 
haemodialysis) have higher levels of oxidative stress which may be amenable to 
intervention with antioxidant therapy.  Although evidence is lacking, two small 
studies have demonstrated some benefit: 
 
• In one study investigating 196 haemodialysis patients with known cardiac disease, 
treatment with oral vitamin E significantly reduced composite CV events during a 
median follow up of 519 days.  However this study was limited by small numbers of 
patients and subsequent events (45). In a smaller randomised, placebo controlled 
study (n=134), acetylcysteine therapy was also associated with a lower all cause and 
CV mortality in haemodialysis patients (46). 
 
Unfortunately, the use of these agents in ESRD patients has been limited by the 
absence of larger studies demonstrating a convincing clinical benefit. 
 
1.2.2i Uraemic cardiomyopathy 
Abnormalities of myocardial structure, detected by echocardiography, are very 
common (approximately 85%) in patients starting renal replacement therapy and are 
strongly associated with poorer outcome.  These changes in myocardial architecture 
and function have been termed “uraemic cardiomyopathy”.  Parfrey et al (47) studied 
432 patients on initiation of dialysis and characterised three patterns of 
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cardiomyopathy:  left ventricular hypertrophy (LVH), left ventricular systolic 
dysfunction (LVSD), and left ventricular dilatation (Table 1.4): 
 
Table 1.4 Prevalence and survival of uraemic cardiomyopathy (47). 
 
Abnormality LV 
Hypertrophy 
LV Dilation LV Systolic 
Dysfunction 
Normal 
Prevalence (%) 41 28 16 15 
 
Median Survival 
(months) 
48 56 38 66 
 
 
Only 15% of patients in this cohort had normal LV dimensions.  On 2 year follow 
up, each abnormality was significantly associated with poorer survival compared to 
patients with normal echocardiograms after adjustment for age, and presence of 
diabetes and CAD.   Additional data from USRDS have also demonstrated poorer 
survival in dialysis patients with LVH on echocardiogram (48). 
 
LVH is the commonest abnormality of uraemic cardiomyopathy and a precursor for 
the development of other cardiac abnormalities.  The development of LVH in ESRD 
patients will be discussed in detail in Chapter 3.  Briefly, LV thickening is an 
adaptive process to: 
 
• Increased pressure load leading to uniformly increased LV wall thickening with 
preservation of LV cavity size (concentric hypertrophy). 
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• Increased volume load causing LV dilatation and LV wall thickening to maintain 
wall stress.  This leads to eccentric hypertrophy (49).   
 
A number of factors associated with ESRD (e.g. anaemia, hyperparathyroidism) may 
also promote myocardial fibrosis in addition to sarcomere formation.  Thus, the key 
histological features of uraemic cardiomyopathy which have been demonstrated in 
animal and patient biopsy studies are increased cardiomyocyte volume and 
interstitial myocardial fibrosis (50;51). 
 
1.2.2j Anaemia 
The presence of anaemia has been associated with significant morbidity and 
mortality in ESRD patients. Historically, anaemia has been associated with increased 
cardiac workload and subsequent development of LVH and LV dilatation in CKD 
patients. Despite observational studies demonstrating improved cardiovascular 
outcome, prospective randomised studies have failed to demonstrate significant 
reduction of LV mass or improved outcome in patients whose anaemia has been 
corrected.  Furthermore, elevated haemoglobin levels have been associated with 
increased mortality in a number of prospective studies: 
 
• In dialysis patients with cardiac disease treated with erythropoietin, the Normal 
Hematocrit Study (NHS) was stopped early due to a trend toward poorer outcome in 
the high haematocrit compared to the low haematocrit group (52).  Furthermore, 
Foley et al demonstrated no difference in LV mass of dialysis patients treated with 
erythropoietin to achieve full or partial correction of haemoglobin levels (53). 
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• In pre-dialysis patients, two randomised prospective studies (CHOIR and CREATE) 
have demonstrated poorer cardiovascular outcome and/or higher mortality in patient 
groups treated with erythropoietin to achieve higher haemoglobin levels (54;55). 
 
Given that patients with lower haemoglobin include those with more comorbidities, 
including ongoing inflammation and malnutrition, it is not surprising that anaemia is 
associated with poorer survival in ESRD patients.   However, optimum level of 
haemoglobin and time of commencement of erythropoietin therapy remain 
controversial.  The relationship between anaemia and features of uraemic 
cardiomyopathy will be discussed in further detail in Chapter 3. 
 
1.2.2k Proteinuria 
Proteinuria is defined as urinary protein excretion greater than 300mg over 24 hours.  
A number of observational studies have demonstrated that proteinuria is an 
independent risk factor for all cause and cardiovascular mortality in patients with and 
without diabetes mellitus: 
• Post hoc analyses of the RENAAL (Reduction in Endpoint in Non-insulin dependent 
diabetes mellitus patients with the Angiotensin II Antagonist Losartan) trial showed 
that proteinuria>3g/24 hours was associated with doubling of serum creatinine or 
ESRD in 85% and cardiovascular morbidity or mortality in 44% of patients.  These 
endpoint rates were significantly higher compared to patients with proteinuria 
<1.5g/24hours (28% and 29% respectively) (56).   
• In a 16 year study of non diabetics of the Framingham cohort, evidence of significant 
proteinuria (>2+ on dipstix) increased mortality threefold (57). 
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• Tonelli et al (58) demonstrated in patients with ischaemic heart disease, that those 
with reduced eGFR or dipstick urinalysis positive proteinuria (≥1+) were at highest 
risk of dying from a CV event compared to those without these risk factors.  
Furthermore, those subjects with both had the worse survival and highest CV event 
rate. 
 
These and other studies support a significant association between presence of 
proteinuria and CV events or death in diabetic and non diabetic patients.  The link 
between proteinuria and CV risk in CKD patients is multi-factorial and felt to 
represent pathophysiological associations rather than a causal relationship.  These 
factors include: 
• Extracellular volume overload 
• Hypertension and activation of the renin angiotensin aldosterone system 
• Vascular calcification 
• Endothelial dysfunction/oxidative stress 
 
1.2.2l Bone mineral disorders and vascular calcification 
As renal function deteriorates, chronic hyperphosphataemia and hypocalcaemia 
cause secondary and occasionally tertiary hyperparathyroidism.  Disturbances of 
calcium and phosphate homeostasis have been reported as early as CKD stage 3 and 
a number of large observational studies have identified serum markers of bone 
mineral disorders as risk factors of poor outcome: 
 
• Data from the USRDS demonstrated that hyperphosphataemia and calcium- 
phosphate product were strong independent predictors of mortality in 7096 
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haemodialysis patients when corrected for age, sex, race, smoking status, and 
presence of diabetes mellitus or neoplasm.  Elevated serum PTH was also associated 
with death (59). 
• Hyperparathyroidism not only increases risk of fractures, but also has adverse effects 
on all cause and cardiovascular mortality.  In a much larger US dialysis study, 
moderate to severe hyperparathyroidism (PTH>600pg/ml) was independently 
associated with mortality, CV hospitalisation and fracture when corrected for age, 
sex, race, diabetes and dialysis vintage (60).  PTH has been associated with adverse 
cardiovascular outcome due to its effects demonstrated in vitro.  PTH specific 
receptors present on myocardial and vascular cells isolated from rat perfusion 
models, have demonstrated positive inotropic and chronotropic effects due to altered 
intracellular calcium handling when stimulated.  Furthermore in vitro effects of 
elevated PTH (as in patients with CKD) demonstrate stimulation of cardiac 
fibroblasts to produce collagen type 1 with subsequent interstitial fibrosis (61). 
 
The development of vascular calcification (VC) has been associated with increased 
cardiovascular morbidity and mortality.  Vascular calcification is associated with 
calcium deposition within the medial and intimal layers of arterial walls.  Medial 
deposition, which is very common in dialysis patients, results in reduced arterial 
compliance, widened pulse pressure, decreased coronary perfusion, and associated 
autonomic and endothelial dysfunction.  Intimal deposition, which can also occur in 
patients with normal renal function, is associated with atherosclerotic plaques, 
subsequent myocardial infarction and other thrombotic events. Intimal layers of 
cardiac valves can also be affected leading to significant aortic and mitral valve 
stenosis.  In patients with CKD, VC is commonly localised to coronary, aortic and 
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ileo-femoral vascular regions and can be detected using plain X rays and computed 
tomography (usually electron beam; EBCT).  Vascular calcification can be observed 
in young dialysis patients and its presence and extent are strong predictors of CV and 
all cause mortality: 
 
• In a prospective study of 110 dialysis patients, Blacher et al measured VC using 
ultrasonography and scored patients according to presence of VC at different sites.  
Each increase in 1 unit score was independently associated with all cause and CV 
mortality (62). 
• Using EBCT to prospectively assess 101 dialysis patients, Matsuoka et al 
demonstrated that all cause and CV mortality was higher in patients with evidence of 
coronary artery calcification (63).  
 
Although bone mineral disorders are associated with development of VC, most 
investigators do not believe that this is merely due to precipitation of calcium and 
phosphate within vessel walls.  In vitro studies have demonstrated transformation of 
vascular smooth muscle cells to osteoblasts mediated by phosphate, calcium and 
other osteogenic protein such as ostecalcin, ostenectin, alkaline phosphatase, and 
collagen type 1.  This is also associated with reduced serum levels of VC inhibitors 
such as Gla-protein, fetuin- A and ostepontin in ESRD patients (64).  In CKD 
patients the reason for alteration in vessel wall activity remains unclear and is an area 
of intense research interest. 
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1.2.2m  Inflammation and C- reactive protein 
In the general population, the presence of a chronic inflammatory process has been 
implicated as an important contributor to atherogenesis and plaque rupture.  A 
number of studies have demonstrated C-reactive protein (CRP), which is an acute 
phase reactant produced by hepatocytes in response to interleukin-1 and 6 (IL-1, IL-
6) and tumour necrosis factor alpha (TNFα), as a predictor of adverse cardiovascular 
outcomes.  Whether CRP is a non-specific marker of an ongoing inflammatory 
response or directly involved in the atherogenic process remains unclear.  
Nonetheless, presence of elevated CRP is a marker of poor primary and secondary 
CV outcome in the general population: 
 
• In a Danish study of over 50000 individuals in whom high sensitivity CRP (hs-CRP) 
was measured, CRP>3mg/L was associated increased risk of ischaemic heart disease 
(RR1.6) and stroke (RR 1.3) compared to patients with CRP<1mg/L (65). 
• In patients with ischaemic heart disease, elevated CRP measured 12-24 hours post 
acute coronary syndrome (n=448) was associated with a significantly higher 30-day 
mortality, greater infarct size and higher risk of subsequent heart failure (66). 
• In a case control study of 22071 healthy male physicians who had a single 
measurement of CRP and were followed for 17 years, baseline CRP was 
significantly associated with sudden cardiac death.  In addition, individuals with 
CRP in the highest quartile had the highest risk of sudden cardiac death (RR 2.78) 
compared to the lowest quartile (67). 
 
Patients with ESRD are in a state of chronic inflammation and various studies have 
demonstrated inflammatory biomarkers such as CRP, IL-6 and TNF α as 
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independent predictors of CV mortality.  In addition, hypoalbuminaemia often 
accompanies chronic inflammation and is also associated with adverse outcome: 
 
• In 224 maintenance dialysis patients, elevated CRP concentrations measured at study 
recruitment were significantly associated with poorer survival and independently 
predicted death when adjusted for age, sex race, dialysis vintage, smoking and 
cardiac history, and dialysis adequacy (68). 
• In a prospective study of 176 ESRD patients, lower serum albumin and elevated IL-6 
independently predicted development of CV morbidity and all cause mortality over a 
follow up of 26 months (69).  
 
As in the general population, it is unclear whether these pro-inflammatory proteins 
are directly involved in initiation and progression of atherosclerosis in CKD/ dialysis 
patients or are markers of ongoing atheromatous formation, endothelial dysfunction, 
vascular calcification and insulin resistance.  In vitro evidence suggests IL-6 and 
TNFα directly stimulate endothelial cells to promote atherogenesis by increasing 
monocyte adhesion, smooth muscle proliferation and LDL-oxidation (69).   
 
1.2.2.n  Haemodynamic instability during haemodialysis  
Intermittent haemodialysis (HD), particularly when large volumes of ultrafiltration 
are attempted, exerts significant haemodynamic imbalance and it is estimated that 
approximately 25% of patients develop episodes of intradialytic hypotension (IDH) 
(70).  Patients receiving haemodialysis are also susceptible to myocardial ischaemia, 
as discussed above, due to: 
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• Large vessel epicardial CAD 
• Micro-coronary artery occlusion and myocyte- capillary circulatory mismatch 
associated with LVH 
• Impaired diastolic coronary blood flow due to reduced vascular compliance. 
 
ECG studies have demonstrated the presence of asymptomatic ST segment changes 
during HD at rates between 15-40%.  More recently, intradialytic LV functional 
analyses using echocardiography or cardiac positronic emission tomography, have 
demonstrated development of myocardial wall stunning during HD, usually in the 
absence of symptoms.  These abnormalities develop in the absence of significant 
CAD or cardiovascular disease.  In a small study (n=70) of HD patients assessed 
during dialysis, intradialytic hypotension and volume of ultrafiltration were 
independent predictors of myocardial stunning.  After 1 year follow up, presence of 
intradialytic myocardial stunning was associated with higher mortality and poorer 
LV function compared to those with no intradialytic LV changes (71). 
 
Promising measures to reduce myocardial stunning during dialysis have been 
pursued including reduced temperature dialysis (35°C instead of 37°C) and 
biofeedback dialysis (BFD) which reduces ultrafiltration rates in response to small 
changes in blood pressure (72;73).  Both techniques significantly reduce IDH and are 
associated with reduced RWMA number. The effect that these measures have on 
long term outcomes is awaited. 
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1.3 Sudden cardiac death in ESRD patients 
 
As previously discussed, CV disease in ESRD patients differs from the general 
population.  The predominant cause of death in ESRD patients is cardiac arrest or 
cardiac arrhythmia (Figure 1.1), as opposed to complications of coronary 
atherosclerotic disease which accounts for most deaths in the non-renal disease 
population.  Event rates for SCD in the general non-renal population have been 
estimated at 1.89/ 1000 patient years, in contrast to ESRD rates of 48 per 1000 
patient years and dialysis rates of 60 per 1000 patient years (74).  Treatment of risk 
factors (e.g. dyslipidaemia, hypertension) which have been shown to reduce CV 
morbidity and mortality in the general population, has little, if any effect on ESRD 
patients suggesting that pathogenesis is inherently different. 
 
1.3.1 Definition 
Various criteria have been employed to define SCD.  For the purposes of this thesis 
sudden cardiac death is defined as an unexpected death of cardiac aetiology, which 
occurs within one hour from the start of any cardiac-related symptoms due to cardiac 
arrest or arrhythmia.  These deaths are commonly due to ventricular arrhythmias, 
namely ventricular tachycardia (VT) or fibrillation (VF).  Although SCD can occur 
in patients with structurally normal hearts, it is more common in patients with 
underlying myocardial structural abnormalities such as hypertrophic 
cardiomyopathy, or less commonly LVH.    
 
In general terms, development of a fatal cardiac arrhythmia requires abnormal 
“substrate” (e.g. LVH, cardiomyopathy) interacting with a “triggering mechanism” 
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(e.g. ischaemia, hyperkalaemia).  Both substrate and triggers are common in ESRD 
patients. 
Sustained VT has been studied extensively in post MI patients and occurs due to 
slowed cardiac action potential (AP) propagation between areas of ventricular 
scarring, followed by re-entry into excitable, viable myocardium.  As a result a rapid 
ventricular circuit is established.  In patients with reduced LV function, rapid 
ventricular rate results in significant haemodynamic compromise (75).  Whether VT 
directly leads to SCD or more life threatening cardiac arrhythmias remains 
debatable, however the presence of sustained VT on 24 hour ECG (from ICD 
monitoring) has been significantly associated with SCD (76).  The development of 
VF is not as well understood and usually requires more diffuse underlying cardiac 
disease.  Currently, VF is thought to be due to multiple small regions of disorganised 
re-entry resulting in abnormal depolarisation fronts and dispersion of ventricular 
repolarisation.  Since there is no ordered ventricular depolarisation, there is no co-
ordinated contraction resulting in failure to generate adequate cardiac output (77).  
 
1.3.2 Epidemiology of sudden cardiac death in ESRD patients 
Data from the US demonstrate the huge impact on mortality of SCD in ESRD 
patients.  Sudden cardiac death is the commonest cause of death in all ESRD patients 
accounting for 20-30% of all deaths.  Similar rates are seen for dialysis (haemo- and 
peritoneal) patients.  These figures are similar to rates of sudden cardiac deaths (25-
30%) reported in the HEMO and 4D trials (25;78). 
 
The risk of SCD after initiation of dialysis increases with dialysis vintage.  In a 
retrospective study of incident dialysis patients from the US who had survived at 
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least 1 year after dialysis initiation, event rate rose from 93 per 1000 patient years at 
2 years to 164 per 1000 patient years after 5 years from dialysis initiation.   
Comparison of dialysis modality reveals that in the first 3 months of dialysis, 
patients receiving haemodialysis have a 50% higher risk of SCD compared to 
peritoneal dialysis patients.  However after 18 months, event rates are similar and by 
36 months peritoneal dialysis are higher by less than 10% (79;80). 
 
1.3.3 Aetiology of sudden cardiac death in ESRD patients 
Section 1.2 has described many of the risk factors commonly associated with CV 
disease in ESRD patients.  However, high prevalence of these risk factors in ESRD 
patients only partially accounts for elevated risk of SCD.  Figure 1.3 highlights some 
of the features associated with SCD in ESRD patients.  In particular, factors which 
promote changes in myocardial structure (substrate) or cardiac environment 
(triggers) have been implicated (81). 
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Figure 1.3 Factors associated with SCD in ESRD patients.  CAD= coronary 
artery disease.  Modified from (81). 
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1.3.3a Uraemic cardiomyopathy and sudden cardiac death 
Myocardial structural changes associated with uraemic cardiomyopathy (described in 
section 1.2.2i) have been associated with sudden cardiac death.  In post MI 
populations, LV systolic dysfunction is the greatest predictor of sudden cardiac death 
and has been used as the most important factor to determine primary prevention of 
cardiac arrest in this patient population:   
 
• The Multicenter Automatic Defibrillator Implantation Trial (MADIT II) recruited 
1232 post MI patients with reduced LV ejection fraction (LVEF<30%) on 
echocardiography.  Patients were assigned to receive implantable cardioverter 
defibrillator (ICD) or conventional therapy.  Patients in the ICD arm had a 
significantly lower mortality rate (14.2% ICD vs 19.8% conventional medical 
therapy, p=0.016) (82)  
• The Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) assigned 2521 
patients with symptomatic heart failure (from ischaemic and non-ischaemic causes) 
and LVEF less than 35% to conventional therapy, conventional therapy and 
amiodarone or conventional therapy and ICD.  Mortality rate was significantly lower 
in the ICD group (22% ICD, 28% medical therapy with amiodarone, 29% medical 
therapy without amiodarone).  ICD therapy was associated with a 23% relative 
reduction in risk of death and absolute reduction in mortality of 7.2% after 5 years 
compared to the medical therapy without amiodarone group (83). 
 
Both of these studies have been instrumental in American College of 
Cardiology/American Heart Association (ACC/AHA) guidelines stating that ICD  
insertion should be considered in patients with “LVEF less than or equal to 35% and 
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mild to moderate symptoms of heart failure and in whom survival with good 
functional capacity is otherwise anticipated to extend beyond 1 year” (84).    
 
Unfortunately, patients with ESRD were excluded from these trials.  Severe LV 
systolic dysfunction has been reported to be present in 15-20% of ESRD patients, and 
has not been demonstrated as a significant predictor of SCD.   
 
• A retrospective analysis of dialysis patients in the US who died of sudden cardiac 
death, showed that 71% had normal or only mild-moderate LV dysfunction on 
echocardiogram (85).  Furthermore, Genovesi et al demonstrated that LVEF <40% 
was not a significant predictor of SCD in ESRD patients (86). 
 
Left ventricular hypertrophy has been associated with SCD in patients with 
hypertension and ischaemic heart disease.  The Framingham Study demonstrated a 5 
fold increase risk in men and 3 fold increase risk in woman of SCD in patients with 
LVH on ECG compared to those with normal resting ECG (87).  LVH is believed to 
increase risk of ventricular arrhythmias and SCD due to a number of factors: 
 
• Microvascular ischaemia- reduced subendocardial blood flow due to elevated 
diastolic blood pressure, inadequate capillary angiogenesis (causing myocyte-
capillary mismatch) and increased oxygen requirement due to elevated wall tension 
result in ventricular ischaemia. 
• Electrophysiological changes- irregular myofibril architecture and fibrosis may 
partially impede AP propagation leading to non uniform ventricular de- and 
repolarisation. 
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• Abnormalities of hypertrophied myocyte- cellular changes tend to increase 
arrhythmogenic properties including alteration in intercalated disc spaces involved in 
cell to cell AP propagation and changes in transverse tubule system which 
communicate between surface cell membrane and the sarcomere.  It remains unclear 
if these changes in structure are related to specific structural changes. 
• External pressure- cardiac myocytes respond to external pressure (eg increased wall 
tension) via stretch activated channels which stimulate cytoplasmic ionic changes 
and lower AP excitation threshold. 
 
As stated before, LVH is very common (60-80%) in ESRD patients and is associated 
with sudden cardiac death in dialysis patients, independent of blood pressure: 
 
• Post hoc analyses of the 4D study demonstrated that in 1253 patients, those with 
ECG evidence of LVH had a 60% increased risk of SCD after 4 years (88). 
• Poaletti et al demonstrated that worsening of LVH on echocardiogram (per 1g/m2) 
independently predicted SCD in haemodialysis patients followed for 10 years (89). 
 
It should be noted that in these and other studies, presence of LVH has been 
demonstrated using ECG criteria or M-mode echocardiography. As will be 
discussed, these techniques are inaccurate when estimating LV mass, particularly in 
ESRD patients. 
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1.3.3b Coronary artery disease and sudden cardiac death 
As previously discussed, accelerated CAD is common in patients with ESRD and 
accounts for a significant proportion of CV morbidity.  As in the general population, 
it is likely that CAD also contributes, albeit not as significantly, to SCD.  This has 
been highlighted in a study in patients with ESRD and significant occlusive coronary 
disease.  Despite revascularisation, subsequent annual mortality due to arrhythmic 
deaths was considerably higher than non-renal populations (8.5% and 7% after PCI 
and stenting and CABG respectively) suggesting that improving coronary blood flow 
may not reduce risk of SCD and alternative factors may play an important role (90).  
Furthermore, agents that modify established risk factors for CAD in non renal 
patients (e.g. dyslipidaemia) have not altered CV outcome of ESRD patients. 
 
1.3.3c Electrolyte fluctuation and hyperkalaemia 
Due to the non-physiological and intermittent nature of maintenance HD, rapid 
electrolyte shifts and hyperkalaemia (due to accumulation of potassium) increase risk 
of cardiac arrhythmias.  This elevated risk is unsurprising given the significant 
electrolyte imbalance present immediately before HD and the haemodynamic stress 
produced during an HD session.  These changes are reflected in many studies 
investigating the temporal risk of SCD in maintenance HD patients which have 
shown that risk is highest immediately before and after the first weekly HD session.  
One study reported a 3-fold increase in risk of sudden death in the immediate 12 
hours before the end of the long weekend and a 1.7-fold increased risk of SCD in the 
12 hours from the start of dialysis after the long weekend (85;91). As expected 
elevation of serum potassium, which is highest just before the start of dialysis, was 
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shown to be an independent risk factor for SCD in HD patients (K+>6mmol/l; RR 
2.74). 
 
1.3.3d Autonomic dysfunction 
Autonomic dysfunction, resulting in enhanced sympathetic activity, has been 
associated with SCD in post MI and heart failure patients.  Furthermore, autonomic 
function in ESRD patients is characterised by sympathetic over activity: 
 
• In one study, sympathetic nerve discharge was higher in HD patient compared to 
normal controls.  Interestingly sympathetic activity in HD patients with bilateral 
nephrectomies was similar to controls, leading the investigators to believe that 
autonomic imbalance arose from the failing kidneys (92). 
• In a prospective study of 228 HD patients, plasma norephinephrine level was 
elevated compared to previously published levels and significantly associated with 
adverse outcome and CV events (93). 
 
Thus it is likely that autonomic dysfunction may play a role in promoting cardiac 
arrhythmias in ESRD patients. 
 
1.3.3e Factors promoting myocardial fibrosis 
As stated above, the creation of a non-uniform wavefront of myocyte de- and 
repolarisation promotes the development of VTA.  Due to differences in action 
potential conductivity between myocyte plasma membrane and collagen fibres, 
myocardial fibrosis promotes VTA formation (94).  Post mortem endomyocardial 
biopsies of ESRD and renal transplant patients have demonstrated significantly 
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elevated levels of interstitial fibrosis compared to non diabetic, non hypertensive 
controls.  In these studies, severity of fibrosis was correlated with dialysis vintage 
and was demonstrable years after renal transplantation (51). 
 
A number of animal models have isolated humoral and mechanical factors, some of 
which have previously been discussed, that may promote cardiac fibrosis in uraemic 
patients including fluid overload, oxidative stress, inflammation with excess of 
cytokines such as cardiotrophin-1 and transforming growth factor β (TGFβ), 
hyperphosphataemia, hyperparathyroidism, anaemia, vitamin D deficiency and other 
uraemic “toxins” yet to be identified (95;96). 
 
1.3.4 Identification of the ESRD patient at risk of SCD 
Identification of patients at high risk is desirable in order to implement prophylactic 
measures to reduce the rate of SCD in ESRD patients.  However, this remains very 
difficult due to the multifactorial nature of SCD within this patient group.  If criteria 
from the heart failure population are applied to ESRD patient (i.e. reduced LVEF) 
we will not only expose patients to an invasive procedure (ICD insertion) without 
adequate evidence from prospective trials, but also potentially omit patients that may 
be at risk (as mentioned above LVSD has been noted to be present in only 15% of 
patients). 
 
In heart failure/post MI patients, reduced LVEF alone has been shown to have low 
sensitivity and specificity for predicting SCD.  As an adjunct, electrophysiological 
(EP) tests have been evaluated to identify heart failure patients at higher risk of SCD 
and reduce the number of unused ICDs. It is estimated, based on reduced LVEF 
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alone, almost 18 ICDs need to be implanted to save one life in the post MI 
population  Furthermore, in early primary prevention trials, EP tests involved 
invasive direct cardiac stimulation to induce VT, however more recently non 
invasive techniques have been evaluated (97;98).  Evidence is  absent for the use of 
EP tests (both invasive and non-invasive) for prospectively assessing risk of cardiac 
arrhythmia in ESRD patients since these patients were excluded from initial 
prospective studies using SCD as the primary endpoint.  Some studies have 
attempted to identify high risk ESRD patients. 
   
1.3.4a Ambulatory electrocardiography 
Presence of non sustained VT (defined as 3 or more consecutive beats of ventricular 
origin with a rate >120bpm and lasting greater than 30s) with structural heart disease 
or complex ventricular premature beats (R on T, runs of 2 or more, multiform or 
bigeminal beats) in patients post MI has been demonstrated to increase risk of SCD 2 
to 5- fold compared to patients without such arrhythmias (99;100). 
 
In patients with ESRD, ventricular arrhythmias are commonly observed on 
ambulatory ECG especially during and immediately after HD sessions when there 
are significant changes in patient electrolyte and haemodynamic status (101).  
However the role of ventricular arrhythmias detected by ambulatory monitoring for 
predicting future arrhythmic events is not well established in ESRD patients. 
 
1.3.4b Microvolt T wave alternans 
Beat to beat variation in ECG wave amplitude and shape has been observed for over 
a century.  Specifically, T wave alternans (TWA) is defined as fluctuations in T 
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wave shape or amplitude and macroscopic TWA has anecdotally associated with 
onset of VTA, especially VF, in a variety of clinical situations including MI, 
electrolyte derangements, and long QT syndrome (102). 
 
At both cellular and tissue level, TWA has been shown to be closely associated with 
repolarisation alternans (RA) which describes regular variation between two patterns 
of ventricular repolarisation on an every-other- beat basis, each with a constant cycle 
length.  Repolarisation alternans is thought to underlie development of TWA.  
Pastore et al used optical mapping of the guinea pig heart to demonstrate that with 
increasing atrial pacing, TWA developed on surface ECG with the development of 
RA at the level of the cardiomyocyte (103). Magnitude of RA is much larger than 
corresponding 12-lead ECG TWA and development of ECG digital processing  has 
allowed very small (at the microvolt level) changes in T wave amplitude and 
morphology (called Microvolt T Wave alternans: MTWA) to be quantified.  It is 
important to appreciate that RA is a physiological rate dependent property of 
cardiomyocytes that develops during tachycardia in structurally normal heart, but 
develops at much lower heart rates in diseased hearts.  
 
The cellular basis of RA is the focus of intense experimental study and remains 
controversial, but aims to provide insight into the arrhythmogenic state of different 
cardiac conditions.  Briefly, generation of RA is believed to be due to action 
potential duration alternans (whereby premature stimulation of myocytes that have 
altered properties greatly affect their diastolic/refractory interval and thus affects 
subsequent action potential duration) and abnormal handling of intracellular Ca2+ 
(termed calcium transient alternans) (104). Presence of RA is thought to produce 
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arrhythmogenicity due to development of discordant RA between neighbouring 
cardiomyocytes.  Normally, RA develops in a uniform (concordant) fashion that 
ensures all myocytes alternate in phase (long-short-long).  However, at elevated 
heart rates or after ventricular ectopy, some myocytes move out of phase, resulting in 
discordant alternans between adjacent cardiomyocytes (long-short vs short-long) 
thus increasing the chance that a cardiomyocyte will attempt to conduct AP to a 
neighbouring cell in a refractory state.  This amplifies any non-uniformity in 
ventricular repolarisation and increases risk of VF in structurally normal heart and 
VT or torsades de pointes in abnormal hearts. 
 
Initial clinical studies of MTWA during invasive atrial pacing demonstrated an 
increase risk of VTA.  MTWA is currently performed during exercise using 
commercially available systems (CH2000 or HearTwave II, Cambridge Heart, 
Bedford, MA).  Exercise ECGs are digitally acquired at stable heart rate and aligned 
according to the start of the QRS complex, allowing measurement of T wave 
amplitude.  Spectral analyses are performed to quantify fluctuations in alternate beat 
T wave size.  Fast Fourier transformation, a computer mathematical modelling 
system to quantify variations in frequency for continuous variables, is performed and 
T wave alternans is said to be present and result classified according to established 
electrophysiological criteria.  Tests are classified as positive, negative or 
indeterminate by the commercial system and for clinical purposes as negative or 
non-negative/abnormal (positive or indeterminate result) depending on the study.  
More details for classification of tests are provided in Section 2.6.  Presence of atrial 
fibrillation does not allow MTWA testing as unequal R-R wave intervals interfere 
with frequency analysis.   
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 Initial studies showing a significant association between MTWA result and SCD 
were performed in high risk post-MI patients with reduced LVEF.  More recent 
studies assessing the use of MTWA for primary prophylactic ICD insertion have 
shown improved efficiency for intervention: 
 
• In a prospective US study of 549 patients with reduced LVEF, 49% of patients had 
documented CAD and an abnormal MTWA result was an independent predictor (HR 
6.5) of the primary end point of all cause mortality and non sustained VT after 2 
years (105). 
• Similarly, Chow et al demonstrated in 768 patients with ischaemic cardiomyopathy 
and LVEF<35%, that an abnormal MTWA result was a significant predictor of all 
cause and arrhythmic mortality (HR 2.24 and 2.29 respectively) (106). 
• The Alternans Before Cardioverter Defibrillator (ABCD) trial was the first study to 
use MTWA to guide prophylactic insertion ICD insertion.  566 patients were 
recruited with ischaemic cardiomyopathy and documented non sustained VT.  
Patients underwent EP studies or MTWA testing and ICDs were inserted if tests 
were positive.  One year survival showed that positive and negative predictive values 
for MTWA results were comparable to more invasive EP studies.  Furthermore 
primary end point (ICD discharge or SCD) event rates were similar after 1 year.  
Interestingly, predictive values were much better if patients had positive EP and 
MTWA tests suggesting that these tests were complementary (107). 
 
These studies have suggested that MTWA may improve the inefficient practice of 
ICD insertion based on reduced LVEF alone.  Most studies estimate that MTWA 
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testing may improve efficiency of number needs to treat to save one life from 18 to 9 
103:104). 
 
Two more recent studies have suggested that the predictive value of MTWA may not 
be as encouraging as initial studies suggested: 
 
• The MASTER I (Microvolt T Wave Alternans Testing for Risk Stratification of Post 
MI Patients) failed to demonstrate an increase in ICD detected VTAs in patients with 
abnormal MTWA result.  However in this study, abnormal MTWA test 
independently predicted death (108;109). 
• A MTWA sub study (n=490) of the SCD-HeFT demonstrated no significant 
predictive value of an abnormal MTWA result for VTA’s or mortality after 14 
months.  However in the original study the survival curves did not begin to separate 
until 14 months in favour of ICD group suggesting that the MTWA sub study may 
have been stopped too early (110). 
 
Nonetheless, these two large trials have cast doubt on the usefulness of MTWA in 
heart failure patients.  Some investigators believe that MTWA should only be part of 
risk stratification process which also includes assessment of LV function and possible 
EP testing.   
 
There have been very few studies investigating other groups at risk of SCD.  In type 2 
diabetics without evidence of CV disease, abnormal result was found in 25.4% of 
patients compared to only 5.7% in healthy age and sex matched controls (111).  
Similarly, in athletes with previous evidence of VTA (ventricular ectopics or NSVT) 
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referred for EP studies, abnormal MTWA was detected in 32% of subjects and there 
was significant correlation between EP studies and MTWA results (112).   
 
Only one small (n=9) study has been performed in HD patients immediately before 
and after an HD session.  This study demonstrated that the number of patients with an 
abnormal MTWA result increased immediately after an HD session (113).  
 
1.3.4c QT dispersion 
QT dispersion has emerged in recent years as another non-invasive method of 
predicting development of ventricular arrhythmias.  QT dispersion is defined as the 
difference between the shortest and the longest heart rate corrected QT interval on a 
standard 12 lead ECG; it represents variation in ventricular repolarisation (like 
MTWA) and predisposition to ventricular tachyarrhythmias.  As with MTWA, a 
wide QT dispersion (above 65-74ms) has been shown to be a risk factor for cardiac 
arrhythmia in patients starting dialysis, with biventricular cardiac failure after 
myocardial infarction and drug induced VTAs (114;115).   
 
A study in haemodialysis patients measured QT dispersion over a single 
haemodialysis session.  Compared to healthy individuals, QT dispersion was 
significantly higher in haemodialysis patients (63.1 +/- 20.6ms before haemodialysis 
vs 36.0 +/- 13.7ms in controls).  After haemodialysis, QT dispersion rose to levels 
measured in post MI patients suggesting that haemodialysis patients are at greater 
risk of arrhythmias and sudden death in the post dialysis period (101). There has 
been ambivalence among cardiac electrophysiologists regarding the relevance of 
QTD predicting risk of arrhythmia in high risk groups (eg.post myocardial 
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infarction). However a considerable amount of literature supports its use and this 
technique has not been completely evaluated within the ESRD group. 
 
1.3.4d Heart rate variability 
As mentioned above, autonomic dysfunction is associated with SCD in ESRD 
patients.  Heart rate variability (HRV) measures autonomic influence on the heart by 
quantifying R-R intervals or heart rate changes over a specified number of cardiac 
cycles. The commonest way to assess HRV uses ambulatory ECG to determine time 
and frequency domain measurements.  Time domains provide continuous 
measurements of R-R intervals, whilst frequency domains estimates changes in heart 
rate as a frequency function using fast Fourier transformation. 
 
In healthy individuals HRV is high due to respiration (parasympathetic control) and 
higher values are associated with a functionally efficient autonomic nervous system. 
However, reduced HRV independently predicts mortality and SCD in patients with 
underlying CV disease and healthy controls (116).  Studies measuring HRV in 
dialysis populations have demonstrated reduced heart rate variation as an 
independent predictor of all cause or CV mortality.  
  
• Oikawa et al assessed 383 HD patients and demonstrated that decreased HRV on 
ambulatory ECG monitoring was an independent predictor of CV death adjusting for 
the presence of diabetes mellitus.  A similar study (n=196) has also shown decreased 
HRV as a predictor of SCD in dialysis patients(117;118). 
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In these studies the ratio of low frequency (indicating sympathetic activity) to high 
frequency (parasympathetic/vagal activity) HRV provides an estimate of autonomic 
control of the sino-atrial node and has been shown to predict SCD in the dialysis 
population. 
 
Other tests to assess autonomic dysfunction (baroreceptor reflex, heart rate 
turbulence) and myocardial impulse conduction (signal averaged ECG) have been 
attempted in small studies of dialysis patients.  Unfortunately, outcome data does not 
convincingly demonstrate a discriminatory role for these tests in ESRD patients.  
 
1.3.5  Prevention of sudden cardiac death in ESRD patients 
Primary and secondary prevention of SCD had been extensively investigated in high 
risk groups such as post MI and heart failure patients.  However, data are absent for 
ESRD patients due to their exclusion from interventional studies and absence of post 
hoc sub group analyses.  Nonetheless, some interventions have been evaluated. 
 
1.3.5a β adrenergic blockers 
The use of β blockers to prevent SCD has been established by many interventional 
trials for high risk cohorts (post MI, congestive cardiac failure).  In a large 
retrospective study from the USRDS, β blocker therapy was associated with reduced 
all cause mortality in haemodialysis patients followed for 7 years (119).  Cice et al 
demonstrated reduced CV deaths (68% reduction over 24 months) in haemodialysis 
patients with dilated cardiomyopathy (n=114) randomised to receive carvedilol 
instead of placebo (120).  In this study there was a trend towards reduced rates of 
SCD, but this did not reach statistical significance.  In a further study of 
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haemodialysis patients who had survived cardiac arrest (n=729), β blocker therapy 
was significantly associated with improved survival after 6 months and the effect 
was greater at higher doses of treatment (121). 
 
1.3.5b ACE inhibitors/Angiotensin II receptor blockers 
ACE inhibitors and ARBs have been shown to reduce mortality in patients with 
significant myocardial diseases and normal renal function (122). Unfortunately, there 
have been few adequately powered, randomised trials in ESRD patients, and thus a 
significant effect in reducing sudden death has not been convincingly demonstrated.  
In dialysis patients, use of ACE inhibitors has not been significantly associated with 
improved survival of ESRD in the absence of heart failure. 
 
• In a randomised control trial of fosinopril in ESRD patients with normal LV function 
on echocardiography (n=397), there was no significant difference in rates of CV 
events between treatment and placebo groups, although there was a trend towards 
lower CV events in the fosinopril treated arm (123). 
 
AIIRBs have been shown in two prospective trials to improve CV prognosis in 
ESRD patients.  However numbers of patients recruited were small: 
 
• Takahashi et al showed in 80 haemodialysis, that treatment with candersartan 
significantly reduced CV events compared to placebo (7/43 candersartan vs. 17/37 
placebo; p<0.01) (124). 
• In a larger prospective study (n=366), Suzuki et al demonstrated treatment with ARB 
reduced fatal and nonfatal CV events (HR 0.51), when adjusted for sex, age, 
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presence of diabetes, and systolic blood pressure compared to placebo treated 
patients.  There was a lower mortality rate in the treatment group compared to 
placebo, however this did not achieve statistical significance (125). 
 
For ACE inhibitors and ARBs, larger prospective studies are needed to establish 
their role in reducing SCD in ESRD patients. 
 
1.3.5c Statins 
As mentioned in section 1.2.2b, statin therapy in patients with no renal disease has 
been shown to be effective in preventing CV events including sudden cardiac death 
(126). However, as demonstrated by the 4D and AURORA studies (24; 25), although 
therapy with statins significantly reduces total and LDL-cholesterol serum 
concentrations, it does not significantly reduce SCD rates in haemodialysis patients, 
highlighting the differing mechanisms of SCD between uraemic and other 
cardiomyopathies. 
 
1.3.6d Implantable defibrillators 
No prospective trials have demonstrated benefit of ICD insertion in ESRD patients 
for primary prevention of SCD.  These patients were excluded from original ICD 
trials or sub group analyses have not been published.  In addition, it is not clear 
whether criteria used in the non renal populations to identify high risk groups (e.g. 
low ejection fraction) are relevant to ESRD patients.  
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In contrast to results from observational in heart failure populations, it has been 
difficult to demonstrate a statistically significant benefit of ICD insertion in ESRD 
patients due to co-morbid conditions: 
 
• In a study of 585 ICD recipients, 19 were previously receiving haemodialysis and 
although dialysis was a significant predictor of VTA or ICD discharge (HR 2.30), 
median survival was significantly lower in the dialysis patients compared to the non-
dialysis cohort.  The authors concluded that other co-morbidities contributed to 
reduced survival in the dialysis cohort (127). 
• In retrospective analyses from the USRDS of ESRD patients that survived a VTA, 
ICD insertion was shown to improve survival.  Although rates of insertion were low 
in patients where ICD was indicated according to AHA/ACC guidelines (8%), ICD 
implantation was significantly associated with reduced mortality (HR 0.58) when 
adjusted for other co-morbid conditions (128). 
• In a smaller, single centre study (n=78) comparing stage 3 CKD to dialysis patients, 
ICD insertion was significantly associated with improved survival in the non dialysis 
population.  There was no survival benefit conferred by ICD insertion in the dialysis 
cohort (n=45) (129). 
 
Although, life table estimates for survival probability after ICD insertion published 
by the USRDS have demonstrated a theoretical benefit for primary and secondary 
prevention of death, sufficient prospective data are lacking.  The AHA/ACC 
guidelines do not exclude ESRD patients from ICD insertion for primary prevention 
of SCD.  Nonetheless, only 15% of ICDs inserted in ESRD patients were for primary 
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prevention between 1996 and 2003 suggesting underutilisation in patients in whom 
ICD would be indicated (128).   
 
Overall, there is a reluctance of cardiologists to insert these devices because of a lack 
of prospective data and high complication rates (bleeding, infection) in ESRD 
patients (130).  ICD insertions may have a role in primary and secondary prevention 
of SCD in ESRD patients and appropriate prospective studies (e.g. ICD2 study) are 
currently underway.  In addition, appropriate selection of patients based on LV 
function +/- EP characteristics may be needed to demonstrate a significant effect of 
ICD insertion on patient survival. 
 
1.4 Assessment of uraemic cardiomyopathy 
 
In this section clinical methods of assessing abnormalities of uraemic 
cardiomyopathy will be discussed. 
 
1.4.1 Echocardiography 
Echocardiography remains the most convenient, inexpensive and best tolerated 
imaging method to assess myocardial function.  It uses ultrasound at wave 
frequencies between 2-20 MHz to penetrate through non-homogenous tissue.  These 
waves are reflected at different acoustic impedance which are recorded and 
displayed as monochromic dots.  The position of dots is determined by location of 
the reflecting tissue and intensity of image dependent on acoustic impedance.  
Ultrasound energy is generated by a transducer that not only emits but detects 
reflected waves to produce an image. 
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Since its introduction in 1954, most studies employ M- mode echocardiography 
since it is the easiest form of image to produce and analyse.  M-mode 
echocardiography involves the use of a single beam of ultrasound to produce a one 
dimensional image of the moving heart along the plane of interest.  Scrolling images 
over the time period of acquisition are generated, and thus allows measurements of 
cardiac dimensions and detailed information of motion patterns depending on 
transducer angulation.  Time relationship analyses are also performed when ECGs 
and heart sounds are collected at image acquisition.  Although resolution of images 
in M-mode echocardiography is good, it does not allow structural visualisation of the 
heart or spatial relationships of the structures during the cardiac cycle.  Two 
dimensional echocardiography (2DE) scans are obtained from the transducer in 2 
perpendicular planes to give detailed information on cardiac anatomy including LV 
geometry.   
 
In both the clinical setting and research studies, M-mode images are still used to 
calculate LV mass (usually reported as LV mass index which is corrected for body 
surface area and recorded as g/m2).  Measurements of posterior wall, internal LV 
dimensions at end diastole, and interventricular septal thickness are recorded and 
conventional “cube” calculations (see Formula 1 below) performed to estimate LV 
mass (131).  These calculations have been validated in normal shaped hearts from 
human autopsies, however are not as accurate in distorted ventricles (such as specific 
cardiomyopathies) (132).  In this situation, it has been recommended that more 
complex calculations using 2DE images be utilised. 
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Penn Formulae LV mass = 1.04 ([LVIDD + PWTD + IVSTD] 3- [LVIDD] 3) -13.6 g 
LVIDD= LV internal diameter diastole,  
PWTD= posterior wall thickness diastole 
IVSTD= interventricular septum thickness diastole 
 
Formula 1  Example of “cube” calculation for estimating LV mass from M 
mode measurements (131) 
 
LV function can be estimated from M-mode LV end diastolic and end systolic 
internal diameters to calculate LV ejection fraction.  Previously used parameters 
such as fractional shortening have been discarded since this overestimates 
contractility in patients with abnormal myocardial due to differential transmural 
contractility.  Two-dimensional echocardiography also allows accurate estimation of 
LV function using the biplane method of disc (Simpson’s rule) to calculate end 
systolic and diastolic volumes after tracing of LV epi- and endocardial borders from 
2 and 4-chamber views. Furthermore, left atrial volume (LAV) can reliably be 
determined using similar techniques from 2DE and has been validated in coronary 
angiography and contrast enhanced CT studies (133).  This will be discussed in more 
detail in Chapters 2 and 5. 
 
Original studies demonstrating significant cardiac structural changes in patients with 
CKD and ESRD used echocardiography.  These abnormalities included detection of 
uraemic pericardial effusions, valvular calcification and ventricular wall thickening.   
As mentioned before, studies from Newfoundland, Canada by Parfrey and Foley 
published in the 1980s and 90s were the first to demonstrate a convincing association   
with echocardiographic abnormalities and poor outcome in dialysis patients 
(47;134).   
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However echocardiographic assessment of LV mass depends on LV internal 
dimensions, which in turn depend on cardiac preload.  In dialysis patients there are 
great variations in volume status during the inter-dialytic period resulting in 
significant changes in LV chamber dimensions.  Furthermore, due to the cubed 
calculations used to estimate LV mass, any potential errors may be magnified 
(Formula 1).  As stated above, calculations based on M-mode measurements have 
been validated in healthy hearts.  Geometric assumptions of these calculations (such 
as cubic shaped LVs) make LV mass estimation inaccurate in patients with LVH and 
thus do not apply to ESRD patients who often have features of uraemic 
cardiomyopathy (132;135).  The inaccuracies of echocardiography to assess LV 
mass in ESRD patients will be discussed below.  
 
Newer techniques to assess LV mass in distorted ventricles are currently being 
assessed including 3D echocardiography (usually real time) which requires no 
geometric assumption to assess LV size and has been shown to have reduced inter-
observer variation and improved reproducibility (136).  There have been few studies 
using this technique in patients with CKD or ESRD.   
 
1.4.2 Cardiovascular magnetic resonance imaging 
Cardiovascular MRI (CMR) is the “gold standard” method for measuring cardiac 
dimensions and function.  Due to rapid development in hardware and software, CMR 
has been established as a reliable and clinically relevant imaging modality in 
cardiology. 
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1.4.2a Principles of magnetic resonance imaging 
MRI is based on the principle of nuclear magnetic resonance.  Protons and neutrons 
spin on their own axis within atomic nuclei.  When a nucleus has an odd mass 
number, the nucleus is left with a net spin and as a result of the (positive) charge and 
spin, develops a magnet field (the direction and size can be represented by a 
magnetic moment).  The human body has very high water content.  When protons 
(hydrogen nuclei derived from water) are placed in an external magnetic field, their 
magnetic moments align themselves (either parallel or anti-parallel) in line with the 
direction of the external magnet.  The net magnetisation vector (NMV) is dependent 
on which directions of magnetic moment are in excess within the field.  Each nuclei 
begins to precess (or wobble) on its own axis and the speed of rotation is dependent 
on the size of the external magnetic field.  
 
When a radiofrequency (RF) pulse is applied at the same frequency of the specific 
precessional frequency of the hydrogen nuclei and at 90° to the external magnetic 
field, the nuclei begin to resonate (absorb energy from the RF) which causes the 
NMV to rotate to a position towards the plane of the external RF.  Other nuclei are 
not affected because they require RFs pulses of a different frequency to cause their 
nuclei to resonate.  Once the RF pulse stops, the NMV recovers to its former position 
releasing an MR signal that is recorded by a receiver coil.  Image acquisition, 
contrast, and signal intensity are dependent on the relaxation of the NMV producing 
T1 (longitudinal) recovery and T2 (transverse) decay at the same time and the 
density of protons in the tissue.  In broad terms, the properties of air, fat and fluid 
allow for sufficient image contrast to provide high resolution images.    
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Images are obtained using pulsed sequences which consists of a series of RF pulses 
applied at different duration, strength and intervening time periods with external 
magnetic field gradients adjusted for the tissue of interest.  In CMR, spin-echo and 
gradient-echo pulsed sequences are used and image acquisition is gated to the 
patient’s ECG at different stages of the cardiac cycle to obtain cinematic (cine) 
images of the full cardiac cycle.  ECG gating can be prospective, where the scans are 
acquired and triggered by the R wave at the time of scanning or retrospective, where 
ECG and images are acquired at the same time and digitally reconstructed after data 
collection.  These gating techniques are required to reduce movement artefacts 
caused by cardiac and respiratory movement.  These can also partially be removed 
by breath holding during image acquisition which usually last 10-15seconds. 
 
1.4.2b CMR and uraemic cardiomyopathy 
CMR remains the most accurate, reliable and reproducible method of assessing LV 
function and chamber size available to cardiologist and radiologists (137).  Long and 
short axis views (Chapter 2) of the LV are obtained, epicardial and endocardial 
borders are delineated on thin slices of the short axis LV images,  and using a 
Simpson’s rule based algorithm, calculation of LV ejection fraction, chamber size 
and mass are obtained without the need for geometric assumptions.  Importantly, 
these measurements are not dependent on the patient’s extracellular/intravascular 
volume status.  In a similar way CMR can reliable assess maximal left atrial volume 
by measuring LA area and maximal length at end ventricular systole.     The CMR 
protocol is described in detail in Chapter 2.   
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Cardiovascular magnetic resonance imaging can also reliably detect the presence of 
myocardial fibrosis using gadolinium for contrast enhanced CMR.  Late gadolinium- 
diethylenetriamine- pentaacetic acid (Gd-DTPA) enhancement (LGE) has been 
shown to correlate well with endomyocardial biopsy findings of interstial myocardial 
fibrosis with a sensitivity of 74% and specificity of 81% (138).  In ESRD patients, 
Mark et al demonstrated that presence of LVSD was significantly associated with 
presence of a subendocardial pattern of LGE on contrast CMR (139).  
Subendocardial LGE represents areas of previous (commonly silent) myocardial 
infarction.  Based on these results it was postulated that LVSD of uraemic 
cardiomyopathy is mostly due to atherosclerotic coronary artery disease and its 
sequelae.  Unfortunately, the use of gadolinium based contrast agents in advanced 
CKD patients has been halted due to the association of their use with development of 
nephrogenic systemic fibrosis; however newer agents are currently in development.  
Unfortunately, CMR is not as readily available as echocardiography in many centres 
due to high cost.  In addition, many patients are unable to undergo scanning due to 
claustrophobia, inability to breathe hold, or presence of ferromagnetic implants 
(cardiac pacemakers or ICD, intracerebral clips).  Given these reasons, the transition 
from research tool to widely available clinical test has been slow. 
 
1.4.3 Echocardiography vs. CMR for assessing uraemic cardiomyopathy 
As stated above, echocardiography derived measurements of LV function and mass 
are inherently flawed in ESRD patients and other patient groups who have 
significant alterations in cardiac shape.    M-mode echocardiography, which is the 
most commonly used means of assessing LV mass, overestimates LVMI compared 
to CMR: 
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• In ESRD patients, Stewart et al showed in 35 HD patients assessed within 24 hours 
of their last HD session, that as LV mass and chamber size increased 
echocardiographic measurements overestimated mass (Figure 1.4) (135). 
• Similar studies performed in hypertensive patients and patients with aortic stenosis 
and LVH without CKD have also shown that M-mode echocardiography derived 
measurements of LV mass overestimate LV mass compared to CMR values (132). 
 
In HD patients, pre and post dialysis measurement of LV mass show small changes 
(up to 10g) on CMR (140).  Echocardiogram changes of up to 45g have been 
recorded and it is likely that, whilst some change may be due to removal of fluid from 
cardiac interstitial tissues, the large disparities between echocardiography and CMR 
are due to changes in chamber dimensions during HD and ultrafiltration (141). These 
changes are amplified due to further cubed computations performed to calculate LV 
mass. 
 
Figure 1.4 Comparison of LVMI measurement techniques (142) 
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Greater precision and reproducibility of CMR to detect small, non artefactual changes 
in LV mass allows studies to recruit much smaller cohorts.  For example, Keenan et 
al have estimated that to detect a 10g drop in LVMI after a therapeutic intervention at 
a power of 80% and p value of 0.05, the sample size would have to be 505 patients 
with 2D echo and only 14 using CMR,(137).  Although these theoretical power 
calculations provide significantly exaggerated results, they adequately highlight the 
benefit that CMR would provide over echocardiography.  
 
1.5 Cardiac magnetic resonance spectroscopy 
Magnetic resonance spectroscopy (MRS) uses the spin property of nuclei to allow 
non-invasive assessment of the biochemical composition and metabolic activity of 
tissues of interest without the need of external contrast media/tracers.  MRS provides 
this information for nuclei that contain atoms with nuclear spin. As stated before, the 
nuclear spin of atoms with odd mass numbers results in development of magnetic 
fields/moment and thus susceptibility to nuclei specific (dependent on the 
gyromagnetic frequency of the nucleus) radiofrequency waves to cause wobble of 
these nuclei on their axis.  In cardiac MRS, 31P is the most extensively studied 
nucleus.  Other nuclei of interest include 1H, 13C and 23Na.  
  
MRS has been used experimentally for over 30 years, however its use in clinical 
practice has been limited due to the very low concentration of nuclei and subsequent 
low resolution of metabolic/biochemical images acquired.  Nonetheless, 31P MRS of 
the human heart has been obtained to study cardiac high energy phosphate (HEP) 
metabolism. 
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1.5.1 Principles of 31P MRS 
Hydrolysis of adenosine triphosphate (ATP) provides free energy for energy 
consuming reactions in cells:  
ATP ↔ ADP  + Pi 
ADP= adenosine diphosphate 
Pi= inorganic phosphate. 
 
Phosphocreatine (PCr) is a high energy phosphate compound which acts as an 
energy transfer molecule in the “creatine kinase (CK)/PCr energy shuttle” (see 
Figure 1.5). The high energy phosphate bond is transferred from areas of ATP 
production (mitochondria) to the myofilaments or other sites of ATP utilisation by 
PCr where the back reaction is performed.  Newly formed ATP is then used for 
cardiomyocyte contraction. 
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Figure 1.5 Schematic representation of creatine kinase (CK)/PCr energy 
shuttle.   
 
 
 
This shuttle is required because free intra- cytoplasmic ADP concentrations are too 
low to allow adequate diffusion into mitochondria for ATP production. Elevated free 
ADP also inhibits intracellular enzyme function, thus when [PCr] is normal the 
shuttle strives to keep [ADP] to as low as possible since the chemical equilibrium 
favours ATP production.  [ADP] will rise only when [PCr] are depleted. During 
myocardial activity when [ATP] is low, the equilibrium shifts to ATP synthesis.  
Thus PCr acts as a buffer to resist changes of intracellular ATP concentration (143).  
31P-MRS allows examination of relative concentrations of PCr, ATP and inorganic 
phosphate (Pi).   
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1.5.2 Methodology of 31P MRS 
MR scanners that allow spectra acquisition use the same magnets used for 
conventional CMR imaging (usually 1.5T or 3T), however nucleus specific coils and 
software to process specific sequences are needed.  Prior to spectra collection, the 
magnetic field must be homogenised as much as possible using shim coils.  
Furthermore, to account for cardiac movement during scanning, scans are performed 
with cardiac gating.   1H images are obtained of the myocardium to allow 
localisation of specific voxels over areas of interest (Figure 1.6). 
 
 After a 31P specific radiofrequency pulse causes spin excitation, the resulting MR 
signal (free induction decay) is recorded.  Subsequent fast Fourier transformation 
splits the time varying decaying MR signal into it frequency components generating 
an MR spectrum.  Small differences in the MR signal for different 31P containing 
molecules are caused by shielding of the nuclei of interest by surrounding nuclei 
(hydrogen, carbon) -so called “chemical shift”.  The area under each resonance peak 
in the spectrum is directly proportional to the concentration of each 31P containing 
molecule in the area of interest allowing measurement of relative concentrations. 
(Figure 1.6)  Absolute concentrations are much more difficult to obtain and involve 
calibration against a 31P containing molecule of known concentration at the time of 
scanning.  More information regarding acquisition of 31P-MRS is provided in section 
2.5. 
88 
 
RF impulse
RF response
Fourier transformation
Figure 1.6 Acquisition on 31P spectra in a healthy volunteer 
 
 
 
 
 
A typical 31P spectrum is shown in Figure 1.6 depicting the resonances of interest: 
three 31P atoms of ATP (α, β and γ), phosphocreatine (PCr), inorganic phosphate (Pi) 
and phosphodiesters (PDE)/ membrane phospholipids (PME).  Although not shown 
due to its proximity to the Pi resonance, 2, 3-diphosphoglycerate (2,3-DPG) 
resonances can be detected due to the presence of red blood cells in the voxel of 
interest. 
 
The most common way of quantifying 31P spectra from the human heart is by 
calculating PCr: ATP ratios which are considered a measure of the cardiac energetic 
state.  The CK/PCr chemical equilibrium favours ATP over PCr synthesis by a factor 
of almost 100.  Thus ATP concentrations will only decrease when PCr concentration 
is substantially depleted i.e. the buffer is exhausted. However, PCr: ATP ratio is 
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limited since it may underestimate changes in PCr if ATP levels are reduced and 
does not provide information of changes in relative ATP concentrations.  A further 
limitation of 31P MRS is that the entire heart cannot be investigated due to limitation 
in acquisition voxel size.  Most studies in patients with homogenous myocardial 
changes (eg valve disease, dilated cardiomyopathy) have investigated the LV antero-
apical wall (144;145).  Another measurement which has been evaluated is 
phosphodiester/ATP ratio which is believed to measure cell membrane integrity in 
animal models; however its use in clinical studies is limited.   
 
1.5.3 Clinical studies on 31P-MRS 
In healthy volunteers, PCr:ATP ratios have been measured with values of 1.0-2.6 
(mean 1.8) and this wide range is most likely due to differing spectra acquisition 
systems and analyses software.  Nonetheless, PCR: ATP levels have a reciprocal 
relationship with age and have been demonstrated to fall in healthy individuals after 
atropine-dobutamine stress to 85% maximal heart rate (146).   
 
Patients with stable symptomatic heart failure, reduced LVEF, and valvular heart 
disease have been shown to have reduced PCr: ATP ratios (145).  Furthermore,   in 
patients with dilated cardiomyopathy, PCr: ATP ratio <1.6 has been significantly 
associated with poorer survival (144).  Heart failure is associated with impaired 
energy metabolism due to alteration in substrate consumption (fatty acid, 
carbohydrate), impaired oxidative phosphorylation, and reduced HEP metabolism 
(147). Furthermore, treatments with β blockers and ACE inhibitors/ARBs have been 
associated with elevation of PCr: ATP ratios and symptomatic improvement in 
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patients with dilated cardiomyopathy, suggesting that improved cardiac HEP 
metabolism may provide one of the pharmacological benefits of these drugs.   
 
As one would expect, patients with current or past history of coronary artery disease 
have reduced resting and stress PCr:ATP ratios in areas of myocardial scarring or 
regional wall motion abnormalities.  Similarly, in symptomatic women with normal 
coronary arteries and echocardiograms exercise PCr:ATP ratios are reduced 
compared to resting levels and presumed a consequence of microvascular ischaemia 
(148). 
 
Athletes with  physiological LV hypertrophy do not have reduced PCr: ATP ratios.  
However, studies in patients with hypertension related LVH have demonstrated 
reduced PCr: ATP ratios at rest and during exercise.  Patients with type 1 and 2 
diabetes mellitus and normal LVEF have reduced PCr: ATP ratios suggesting that 
altered cardiac phosphate metabolism (presumably due to small vessel myocardial 
ischaemia and handling of free fatty acids) may partially account for higher levels of 
heart failure within this population(143).   
 
Two observational studies has investigated resting PCr: ATP levels in patients with 
kidney disease.   
 
• In type 1 diabetic uraemic patients.  Perseghin et al (149) studied 43 patients (11 
diabetic uraemic patients, 5 non diabetic uraemic patients, 11 diabetic kidney 
transplant recipients, and 16 diabetic kidney pancreas recipients) and 24 non diabetic 
controls (11 non diabetic kidney transplant recipients and 13 healthy controls).  
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Patients with uraemia (diabetic and non diabetic) had reduced PCr: ATP ratios 
compared to healthy controls and kidney transplant recipients. Diabetic uraemic 
patients had the lowest PCr: ATP ratios leading the authors to conclude that altered 
myocardial HEP metabolism may contribute to accelerated LV dysfunction in 
diabetic uraemic patients.  The authors also suggested that impaired HEP metabolism 
may be partially reversed by successful transplantation.  
• A small study in haemodialysis patients (n=14) demonstrated a significant reduction 
in PCr: ATP in haemodialysis patients compared to control patients with (n=7) and 
without LVH (n=7).  In this study no association was found between PCr:ATP and 
features of uraemic cardiomyopathy (150). 
 
The clinical use of MRS has been limited due to the availability of CMR and noisy 
signals obtained at lower magnetic field strengths (<1.5T).  As stronger MR systems 
become readily available to clinicians and better resolutions of spectra acquisition 
are achieved, MRS may develop into a useful tool to evaluate biochemical/metabolic 
function in addition to myocardial abnormalities detected by CMR.   
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1.6 Aims of this thesis 
 
The aims of this thesis are to: 
• Identify the determinants of LV abnormalities, measured by CMR, in haemodialysis 
patients from clinical, dialysis and blood characteristics. 
• Assess the effect of these CMR detected LV abnormalities on all cause and CV 
survival. 
• Establish the effect of left atrial volume, measured by CMR, on survival in ESRD 
patients with LVH. 
• Estimate the prevalence of abnormal MTWA in a cohort of ESRD patients and 
identify associations with features of uraemic cardiomyopathy. 
• Establish the effect of LV abnormalities on high energy phosphate metabolism 
measured by 31Phosphorus MR spectroscopy in ESRD patients.. 
• Determine whether renal transplantation has an effect on LV mass measured by 
CMR. 
 
1.6.1 Hypotheses 
These studies are designed to test the hypothesis that uraemic cardiomyopathy is 
associated with specific electrophysiological, biochemical, and other cardiac 
abnormalities which may have an influence on the outcome of ESRD patients.  
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1.7 Outline of this thesis 
Data from six studies are presented in chapters 3 to 8 of this thesis.  These studies 
investigate prognostic and pathophysiological features of uraemic cardiomyopathy: 
 
Chapter 3 : A study of independent predictors of uraemic 
cardiomyopathy in haemodialysis patients 
 
Chapter 4 : A study identifying predictors of cardiovascular death in 
ESRD patients undergoing screening for renal 
transplantation. 
 
Chapter 5 : A study of determinants of mortality in ESRD patients with 
LVH: the role of left atrial volume. 
 
Chapter 6 : A study of Microvolt T Wave Alternans in ESRD patients. 
 
Chapter 7 : A study of 31P magnetic resonance spectroscopy in uraemic 
and hypertensive cardiomyopathy. 
 
Chapter 8 : A study of changes in left ventricular mass after renal 
transplantation. 
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Chapter 2 
 
Material and Methods 
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2.0  Introduction 
The major techniques utilised for this thesis provided information regarding 
myocardial structure and electrophysiology of ESRD patients.  Detailed evaluation 
of cardiac structure was obtained using cardiovascular magnetic resonance imaging 
(CMR).  31Phosphorus magnetic resonance spectroscopy (31P-MRS) was performed 
to evaluate myocardial metabolic activity.  Cardiac electrophysiology was evaluated 
using electrocardiography (ECG) and Microvolt T wave alternans measurement 
during exercise.  In this chapter, the background, apparatus, and protocols for these 
techniques will be described. 
 
2.1 Ethical approval 
Ethical approval was obtained from the West Glasgow Ethics Committee for these 
studies to be performed at the Western Infirmary, Glasgow.  All subjects provided 
written informed consent with forms approved by the Ethics Committee. 
 
2.2 Study subjects 
 
2.2.1 Inclusion criteria 
Patients with ESRD were recruited from the renal unit at the Western Infirmary.   
Patients receiving regular haemodialysis and peritoneal dialysis were assessed. 
Haemodialysis patients were studied on a non-dialysis day.  Since the risk of 
cardiovascular death is similar between those patients who receive and those near to 
requiring renal replacement therapy, patients who would require renal replacement 
therapy within 6 months were also assessed.  According to K/DOQI classification 
(151), these patients would be classified as chronic kidney disease stage 5 (CKD 5).   
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Eligible patients were identified by the renal transplant assessment team for 
cardiovascular screening as part of their preparation for inclusion on the renal 
transplant waiting list.  Death in renal transplant recipients is most commonly a 
result of cardiovascular disease.  In keeping with Renal Association guidelines (42), 
pre- transplant cardiac assessment is necessary to ensure recipient survival is not 
compromised immediately after transplantation.  Furthermore, screening is 
recommended to reduce peri- and post operative cardiac complications.  Factors 
prompting referral for cardiac assessment in our centre are: 
 
• Age≥ 50 years of age 
• Presence of diabetes mellitus 
• Prior history of ischaemic heart, cerebrovascular or peripheral vascular disease 
• Family history of cardiovascular disease in a first degree relative 
• Previous abnormal ECG or cardiac stress test indicating ischaemic heart disease 
• Previous evidence of left ventricular (LV) abnormalities on echocardiography 
• The clinical opinion of the transplant assessment team (which includes a consultant 
transplant surgeon and nephrologist) 
 
The assessment included clinical history, examination, standard 12-lead ECG, 
Standard Bruce Protocol exercise test, assessment of LV structure and function by 
CMR and blood sampling. Clinical history of ischaemic heart disease was defined as 
past or current history of angina pectoris, myocardial ischemia/infarction and/or 
coronary revascularisation procedure. After review of these results by an 
independent cardiologist, myocardial perfusion and/or coronary angiography 
scanning were performed.  The decision regarding addition onto the renal transplant 
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waiting list was made at a separate, independent clinic involving a transplant surgeon 
and physician. The results of non invasive (and invasive, if performed) 
cardiovascular assessment tests were available to the assessing surgeon and 
nephrologists before a final decision was reached. However, no specific 
recommendation was provided regarding the suitability of an individual patient for 
renal transplantation based on cardiovascular assessment results.   
 
2.2.2 Exclusion criteria 
Patients were excluded from these studies if magnetic resonance imaging was 
contraindicated (presence of ferromagnetic implants or permanent cardiac 
pacemaker, claustrophobia and pregnancy).  Patients were also excluded from 
MTWA testing if their underlying cardiac rhythm was atrial fibrillation as this 
precludes testing using HearTwave II system (Cambridge Heart, Bedford, Mass.) 
(152).   
 
2.3  Cardiovascular magnetic resonance scanning 
Patients underwent CMR scanning using a 1.5 Tesla MRI scanner (Sonata, Siemens, 
Erlangan, Germany).  As stated before, this technique provides a detailed, reliable, 
reproducible and volume independent measurement of cardiac structure and is 
considered the most accurate method for assessing ventricular dimensions in 
patients. Scans were performed and analysed by myself or a trained CMR 
radiographer (Tracey Steedman, Glasgow Clinical Research Initiative, Western 
Infirmary, Glasgow). 
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2.3.1 Timing of CMR scan 
To reduce the effect of interdialytic fluid accumulation on ventricular wall thickness, 
haemodialysis patients underwent scanning the day after a dialysis session.  
Peritoneal dialysis patients were scanned at their “dry weight” according to their 
dialysis clinical records.   
 
2.3.2 CMR image acquisition 
 
2.3.2a Patient position 
Patients were placed head first into the scanner in the supine position.  A handheld 
alarm provided patients with the means of contacting the investigator.  Headphones 
were also used to provide noise protection and convey breathing instructions.   An 
anterior chest 6 channel phase array coil was used to acquire images.  
 
2.3.2b Assessment of left ventricular mass, chamber size and function 
An ECG gated fast imaging with steady-state precession (true FISP) sequence during 
end expiratory breath holding was used to acquire cine images in long axis planes 
(vertical long axis, horizontal long axis, left ventricular outflow tract) followed by 
sequential short axis LV cine loops (8 mm slice thickness, 2 mm gap between slices) 
from the atrioventricular ring to the apex.  The formal protocol was (Figures 2.1- 
2.4): 
1. An initial multi-slice localiser was performed at end tidal expiration and the 
optimal transverse section of the LV and inter-ventricular septum was selected 
(Figure 2.1). 
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2. A vertical long axis (VLA) localiser of the LV was obtained from the centre of the 
mitral valve annulus to the apex. From this localiser a subsequent horizontal long 
axis (HLA) localiser was taken from the mitral valve annulus to the apex (Figure 
2.2). 
3. Three short axis (SA) localisers were generated from the HLA localiser.  Images 
were obtained at the level of the atrio-ventricular groove parallel to the mitral and 
tricuspid valve annuli (Figure 2.2). 
4. These SA localisers were used to plan cine images. Four and two-chamber, and left 
ventricular outflow tract (LVOT) cine scans were generated (Figure 2.3). 
5. From the 4 chamber scans, a short axis stack was obtained.  Two mm scans were 
obtained at 8 mm intervals from the atrio-ventricular groove to the LV apex.  
 
Imaging parameters, which were standardized for all subjects, included repetition 
time (TR)/echo time (TE)/flip angle/voxel size/field of view 
(FoV)=3.14 ms/1.6 ms/60°/2.2 x 1.3 x 8.0 mm/340 mm. 
 
2.4 Analysis of CMR scans 
2.4.1 Measurement of left ventricular mass, function and chamber size  
Short axis cinema loops of the LV were used to assess LV function (Figures 2.4 and 
2.5).    LV mass was measured from short axis cine loops using manual tracing of 
epicardial and endocardial end-systolic and end-diastolic borders.  From these 
images, analysis software (Argus, Siemens, Erlangen, Germany) was used to 
calculate left ventricular ejection fraction (LVEF) using the equation: 
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LVEF (%)= End Diastolic Volume (ml)
End Diastolic Volume (ml) –End Systolic Volume (ml)
X  100
 
 
Similarly LV mass (LVM), end diastolic volume (EDV) and end systolic volume 
(ESV) were calculated from these images and indexed according to body surface 
area (LVMI, EDV/BSA, ESV/BSA respectively).  Body surface area was calculated 
using the Dubois formula (153): 
 
Body Surface Area= 0.20247 x Height (m)0.725 x Weight (kg)0.425 
 
2.4.2 Values used to define left ventricular abnormalities 
LV abnormalities were defined by normal published mean (± 2 standard deviations) 
LV measurements in healthy volunteers (154). Left ventricular hypertrophy (LVH) 
was defined as LVMI >84.1 g/m2 (male) or >76.4 g/m2 (female). Left ventricular 
systolic dysfunction (LVSD) was defined as LVEF<55% and LV dilatation was 
defined as end diastolic volume/body surface area  (EDV/BSA)>111.7 ml/m2 (male) 
or 99.3 ml/m2 (female) or end systolic volume /body surface area (ESV/BSA) 
>92.8 ml/m2 (male) or 70.3 ml/m2 (female).   
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Figure  2.1 Multi slice breath hold localiser in end expiration 
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Figure 2.2 Generation of 3 short axis localisers from transverse slice 
multilocaliser, vertical long axis and horizontal long axis 
  
103 
 
Figure 2.3 Generation of long axis cine images from short axis localiser  
 (arrows correspond to planes highlighted in short axis pilots). Coloured lines (blue, 
green, red) correspond to plane of image acquisition 
 
SA Pilots
2 chamber cine
4 chamber cine
LVOT
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Figure 2.4 Generation of short axis stack images from 4 chamber cine 
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Figure 2.6 Short axis view of left ventricle  
(upper panel= basal, lower panel= mid ventricular) with epicardial (green) and 
endocardial (red) borders traced using image analysis software  
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2.4.3 Measurement of left atrial volume 
The bi-plane area length method for ellipsoid bodies was used (155;156) to measure 
left atrial volume (LAV). Horizontal and vertical long axis cine images were used to 
obtain images of the left atrium at maximal filling (Figure 2.7). The atrial lengths 
and areas were measured from both views using image measurement tools (Siemens, 
Erlangen, Germany), and LAV calculated using the equation: 
 
0.85 x LA Area 2 chamber (cm2) x LA Area 4 chamber (cm2) 
Mean LA Length (cm)
LA Volume (ml) =
 
  
LAV was corrected for body surface area (LAV/BSA). Left atrial appendages were 
not included in these measurements. 
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Figure 2.7 Measurement of maximal left atrial volume. 
Panel A measurement of LA length (white) and LA area (red) from 2 chamber view. 
Panel B, measurement of LA length (white) and LA area (red) from 4 chamber view. 
 
A 
 
 
 
 
 
 
 
 
 
 
B
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2.5  31Phosphorus MR spectroscopy 
 
2.5.1 31Phosphorus MR spectroscopy acquisition 
31Phosphorus MR Spectroscopy (31P-MRS) was performed using a 1.5 Tesla MRI 
scanner (Sonata, Siemens, Erlangan, Germany).  A dedicated spectroscopy surface 
coil (dual resonant heart/liver 31P/1H coil) was used. As before, patients were placed 
in the supine position and the coil placed over the left ventricle on the anterior chest 
wall.  
 
After localisation, pilot scans were performed in the cardiac vertical long axis plane 
(fast low angle shot (FLASH) images, slice thickness 10mm, TR/TE 7/7.37ms, FoV 
350mm), 31P-MRS data were obtained with a 2-D chemical shift imaging sequence 
(CSI).  The acquisition matrix size was 25mm x 25mm and TE = 2.3ms, flip angle 
=90º, no signal averaging NSA=60.    The chemical shift imaging (CSI) grid was 
positioned over the left ventricle to ensure one voxel covered the LV apex and the 
remaining voxels provided coverage for the LV superior and inferior walls (Figure 
2.7a).  Prospective ECG gating was used with an acquisition trigger delay of 100ms 
and data was acquired during diastole.  An optimised radiofrequency pulse (length 
2.4ms) centered between γ- and α- adenosine triphosphate (ATP) resonance 
frequencies was used to ensure uniform excitation of all spectral peaks (Figure 2.7b).   
 
2.5.2  Data acquisition 
Spectra were obtained and areas under the curves of interest were measured using 
spectroscopic fitting software (Siemens, Erlangen, Germany).  The spectral 
resonances for β-ATP, 2,3- DPG and phosphocreatine (PCr) were fitted using prior 
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knowledge relating to peak frequencies and J- coupling patterns.  PCr: β-ATP ratios 
(PCr: ATP) were calculated accordingly.  
 
2.5.3 Correction for blood contamination 
A correction for intraventricular blood was performed.  In addition to causing scatter, 
intracorpuscular ATP prevents accurate estimation of true myocardial PCr: ATP.  
Blood contains 2,3 diphosphoglycerate (DPG) which exhibits resonances at roughly 
5.4 and 6.3ppm relative to PCr.   The effect of blood ATP was corrected using 
Equation 2.5, which has been validated in patients with dilated cardiomyopathy and 
healthy volunteers (157). 
 
Equation 2.5:  β-ATPCorrected = β-ATPHEART – (0.15 × 2,3-DPGBLOOD) 
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Figure 2.7  31Phosphorus MR spectroscopy 
(a)  CSI grid positioned over the left ventricle superior and inferior walls  
 
 
 
 
 
 
 
 
 
 
(b) Example of 31P MRS obtained from voxel (blue) above 
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2.6 Microvolt T wave alternans 
 
2.6.1 Exercise testing- microvolt T wave alternans (MTWA) 
All tests were performed by the investigator on the day of CMR scanning.  Skin was 
prepared by shaving and cleansing with abrasive electrode gel to ensure close contact 
with electrodes. Seven standard and seven high resolution electrodes (Microvolt 
Sensors, Cambridge Heart Inc, Bedford, Mass.) were attached to patients in the 
standard 12-lead and Frank orthogonal position (158) and connected to a HearTwave 
II System (Cambridge Heart, Bedford, Mass) for MTWA testing. 
 
An initial check was performed by the device to ensure adequate electrode contact 
and testing began with acquisition of ECG data at rest for 20 seconds.  Patients were 
then asked to undergo gentle treadmill exercise to allow sufficient elevation in heart 
rate (HR).  Increase in speed and incline was performed to ensure HR elevation to 
between 100-110bpm for 150 seconds.  If patients could tolerate more exercise, a 
further 90 seconds of walking was performed in order to achieve heart rate between 
110 and 120bpm. At the end of the exercise period, patients were allowed to sit at 
rest until HR was below 90bpm, after which the test was terminated.   ECG data was 
collected digitally by the HearTwave system (108; 159). 
 
2.6.2 Spectral analyses of ECG data 
Collected ECG data were interpreted according to standard criteria using spectral 
analyses and reported using standard automated classification (HearTwave II 
System, Cambridge Heart, Bedford, Mass). This technique measured amplitude of 
corresponding points of 128 consecutive T waves where each T wave was measured 
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precisely at the same time point relative to the QRS complex start.  Beat- to- beat 
amplitude fluctuations were plotted and a fast Fourier transformation was performed 
to provide quantification of the frequency variation (Figure 2.8).  As measurements 
were taken every beat, the frequencies were in units of cycles per beat.  The point on 
the spectrum corresponding to exactly 0.5 cycles per beat represents the power of T-
wave front alternation.  Significant alternans was calculated from comparison with 
the background noise frequency band (0.44 and 0.49 cycles per beat) (160). 
 
After MTWA testing, a positive MTWA result was defined as presence of sustained 
alternans (sufficient alternans present for at least 1 minute) at heart rates <110bpm 
on exercise or at rest (even if higher than 110 bpm). A negative MTWA test result 
was defined as the absence of positive test criteria with a maximum heart rate≥105 
beats/min.  A test that did not satisfy positive or negative criteria was classified as 
indeterminate (Figure 2.9).  Based on previously published studies (161) results were 
further classified as “abnormal” (for positive and indeterminate test results) or 
“negative” (reported as a negative test).  If initially an indeterminate result was 
obtained, immediate retesting was attempted. Reasons for indeterminate test 
provided by the analysis software were: 
• failure to achieve sufficient heart rate rise 
• excessive ventricular ectopy during exercise 
• a noisy recording due to ECG artefact 
• rapid rise through target heart rate of 105-110bpm 
• unsustained MTWA (≤1 min) 
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Figure 2.8 Spectral analyses of ECG and generation of frequency spectrum 
(162)  
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Figure 2.9 Classification of MTWA result based on duration of sufficient 
alternans and heart rate achieved during exercise.   
Modified from (152). 
 
 
 
 
 
 
 
 
 
 
Significant Alternans 
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HR= 105bpm?Alternans = 1 min ?
Onset =110bpm?
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2.7 Blood sampling 
Thirty millilitres of blood was drawn for biochemical and haematological hospital 
laboratory analyses.  Blood electrolytes, urea, creatinine, glucose, and haemoglobin 
were measured.  Plasma brain natriuretic peptide (BNP) was measured using a one 
step radio immunoassay (ShionoRIA, Shinogi, Japan) after centrifugation of 6 mls of 
blood (this was frozen within 20 minutes of collection and stored at -70°C until 
measurement).  Plasma total cholesterol, triglyceride, low density lipoprotein, high 
density lipoprotein and high sensitivity C-reactive protein (CRP) were measured 
using standard biochemical methods. 
 
2.8 Patient follow up 
Follow- up data, including patient clinical events and deaths, were recorded from 
date of CMR scan until 30th September 2009 using the Western Infirmary, Glasgow 
and Glasgow Royal Infirmary electronic patient records. 
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Chapter 3 
 
A study of independent predictors of uraemic cardiomyopathy in haemodialysis 
patients. 
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3.1 INTRODUCTION 
  
As discussed in the introduction, patients with end stage renal disease (ESRD), 
particularly those receiving dialysis have an increased risk of premature CV disease 
(1).  The features of uraemic cardiomyopathy, namely LVH, LVSD, and LV 
dilatation independently predict poorer survival in ESRD patients (47).   
 
Studies to date assessing independent predictors of uraemic cardiomyopathy have 
used echocardiography. Such studies implicate factors such as hypertension, reduced 
blood vessel compliance, anaemia, phosphate control and dose of dialysis (134;163-
165).  In addition, gadolinium enhanced CMR findings indicating previous 
myocardial ischaemia have been associated with LVSD (139). 
 
However, as discussed before, echocardiography provides an inaccurate assessment 
of LVMI and chamber size particularly in fluid overloaded patients where image 
acquisition and measurements of LV wall thickness (e.g. posterior and 
interventricular septum) can be difficult.  Measurements obtained by 
echocardiography tend to overestimate LV mass particularly at higher values when 
compared to CMR (135).  Few studies have used accurate, volume independent, 
measurements obtained from CMR to assess individual predictors of uraemic 
cardiomyopathy.   
 
Thus the aims of the following study were to demonstrate the predictors of LVH, 
LVSD and LV dilatation, measured by CMR, in a cohort of haemodialysis (HD) 
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patients.  In particular past dialysis and blood data, in addition to CMR features, 
were included in the analyses. 
 
3.2 METHODS 
 
3.2.1 CMR acquisition 
Only ESRD patients receiving thrice weekly haemodialysis therapy were recruited 
into the study.  Scans were consistently performed on the day after an HD session.  
CMR scans were acquired and analysed as previously described.  Definitions for 
LVH, LVSD and LV dilatation have been presented in Chapter 2. 
 
3.2.2 Demographic, dialysis and blood data acquisition 
Demographic information and clinical (including drug) history were recorded at the 
time of CMR.  Retrospective review of the electronic patient record was performed 
to retrieve biochemical and haematological blood results. Haemodialysis information 
including immediate pre (preHD) and post (postHD) dialysis systolic and diastolic 
blood pressure (SBP and DBP respectively); dose of ultrafiltration (UF) and dialysis 
adequacy using urea reduction ratio (URR) were also collected.  Information was 
collected at 30 day intervals up to 180 days before CMR and mean results were 
calculated.  Calcium phosphate product (Ca x PO4) was calculated from blood 
results collected. URR ratio was calculated using established protocol (166). 
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3.2.3 Statistical analyses 
Statistical analyses were performed using SPSS version 15.0 (SPSS Inc. Illinois, 
USA). Correlations between LV measurements and other factors were evaluated by 
Pearson’s and Spearman’s correlation coefficient as appropriate.   Variables 
identified by univariate linear regression analyses as significant predictors were 
entered into a backward stepwise linear regression model to identify independent 
predictors of LVMI, ejection fraction or end diastolic volume/BSA (EDV/BSA).  
Similarly, simple followed by multiple logistic regression analyses were performed 
to identify predictors of LVH, LVSD or LV dilatation.  Due to significant 
interdependence, systolic or diastolic blood pressures and only one cardiac parameter 
(EDV/BSA, ESV/BSA, or ejection fraction) were entered into the model. The most 
predictive regression model was thus generated. 
 
3.3 RESULTS 
 
3.3.1   Patient demographics 
Table 3.1 shows demographic, clinical, drug and blood result data for 246 patients 
who were studied and also highlights the accumulation of traditional cardiovascular 
risk factors within such a patient group. Data regarding dialysis and cardiac 
dimensions are also presented in Table 3.1. 
 
The frequencies of isolated and combined cardiac abnormalities are shown in Figure 
3.1.  One hundred and fifty seven (63.8%) had LVH, 45 (18.3%) had LVSD and 39 
(15.9%) had LV dilatation. Eighty two patients (33.3%) had normal LV structure. 
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Variable Total  N=246 
Age (years) 51.4 (±12.1) 
Male (%) 157 (63.8) 
BMI (kg/m2) 25.6 (±4.6) 
Primary Renal Disease Diabetic Nephropathy 57 (23.2) 
 APCKD 25 (10.2) 
 Glomerulonephritis 52 (21.1) 
 Renovascular Disease 19 (7.7) 
 Chronic Pyelonephritis 26 (10.6) 
 Other 38 (15.4) 
 Unknown 29 (11.8) 
Diabetes mellitus 156 (63.4) 
Ischaemic Heart Disease 51 (20.7) 
Hypertension 223  (90.7) 
Chronic heart failure 15 (6.1) 
Cerebrovascular disease 20  (8.1) 
Peripheral vascular disease 18 (7.3) 
Hypercholesterolemia 113 (46.3) 
Smoking Never 124 (50.4) 
 Current 70 (28.5) 
 Ex 52 (21.1) 
Aspirin 97 (39.4) 
ACEI/ARB 61 (24.8) 
Diuretic 50 (20.3) 
Calcium Channel Antagonist 73 (29.7) 
β Adrenoceptor Blocker 106 (43.1) 
Epo receptor stimulating agent (ESA) 196 (79.7) 
Vitamin D Analogue 99 (40.2) 
Statin 93 (62.2) 
Haemoglobin (g/dL) 11.3 (±1.3) 
Adjusted Calcium (mmol/L) 2.31 (±0.2) 
Phosphate (mmol/L) 1.27 (±0.4) 
Albumin (g/dL) 37.3 (±5.9) 
CaxPO4 Product 2.93 (±1.0) 
Parathyroid Hormone (pmol/L) 28.8 (20.3,34.0) 
Duration on HD (y)  3.0 (±3.0) 
Mean Ultrafiltration Volume (L/session) 2.2 (±1.1) 
Mean PreHD SBP (mmHg)  142.3 (±21.8) 
Mean PostHD SBP (mmHg)  132.3 (±23.1) 
Mean PreHD DBP(mmHg)  79.8 (±14.0) 
Mean PostHD DBP(mmHg)  73.3 (±13.8) 
Mean PreHD PP (mmHg)  62.5 (±17.1) 
Mean PostHD PP (mmHg)  58.9 (±17.6) 
Urea Reduction Ratio (%) 70.8 (±7.5) 
Ejection Fraction % 64.7 (±13.3) 
LVMI (g/m2) 99.4 (±30.0) 
EDV/BSA (ml/ m2) 77.8 (±31.1) 
ESV/BSA (ml/ m2) 29.6 (±21.9) 
LVH 157 (63.8) 
LVSD 45 (18.3) 
LV dilatation 39 (15.8) 
 
Table 3.1  Demographic, clinical, drug, blood and cardiac data for patients.  
Data are number with percentage in parentheses or mean ± standard deviation except 
parathyroid hormone where median and interquartile range are shown.
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Figure 3.1 Frequency of cardiac abnormalities of uraemic cardiomyopathy 
in cohort studied.  
Note the high prevalence of LVH alone and in combination with other abnormalities 
LVH only
41.1%
LVSD only
2.0%LV Dilatation only
0.4%
LVH+LVSD
7.7%
LVH+LV Dilatation
6.9%
LVSD+LV Dilatation
0.4%
LVH+LVSD+LV 
Dilatation
8.1%
None
33.3%
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3.3.2 Left ventricular mass index and hypertrophy 
3.3.2(a) Correlates of LVMI 
There were strong positive correlations between LVMI and EDV/BSA (Pearson’s 
R=0.60, p<0.01), ESV/BSA (Pearson’s R =0.54, p<0.01) and negative correlation 
with LV ejection fraction (Pearson’s R = - 0.37, p<0.01).  In addition, there were 
weaker but significant correlations with mean dose of ultrafiltration (Pearson’s R 
=0.18, p<0.01) and Ca x PO4 (Pearson’s R =0.13, p=0.05).  Factors close to 
statistical significance were postHD DBP (Pearson’s R =0.13, p=0.06), and mean 
preHD SBP (Pearson’s R =0.11, p=0.08). 
   
3.3.2(b) Associations of left ventricular mass index and hypertrophy 
Multivariable linear regression analysis was performed to create the most robust 
predictive model for LVMI (Table 3.2).  Factors considered in the model were those 
identified as significant (or close) correlates with LVMI or factors identified from 
previous studies as predictors of LVMI.  Using a backward stepwise model, the most 
significant model (highest R2=0.49) generated included EDV/BSA, mean pre 
dialysis systolic blood pressure and Ca x PO4 product as significant predictors of 
LVMI.  
 
Patients with or without LVH were compared.  Higher preHD systolic blood 
pressure, preHD pulse pressure (PP) and Ca x PO4 were significantly associated 
with LVH (Table 3.3).   Serum phosphate and mean UF dose were higher in the 
LVH group of patients, but were not statistically significant.  When comparing both 
groups there were no significant differences in age, sex, body mass index (BMI), 
past cardiovascular history, duration on haemodialysis, mean post HD systolic and 
diastolic BP, mean pre HD diastolic BP and URR.  Furthermore, LVH was not 
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significantly associated with a difference in mean haemoglobin, albumin, adjusted 
serum calcium, or parathyroid hormone (PTH) measured over the 180 days before 
CMR.  There was no significant difference in drug usage between both groups. Table 
3.3 also shows measured left ventricular cardiac parameters– ejection fraction, 
EDV/BSA and ESV/BSA.  LVH was significantly associated with lower ejection 
fraction, higher end diastolic and systolic LV volumes, LVSD and LV dilatation.  
 
Univariate followed by multivariate logistic regression analyses were performed to 
determine predictors of LVH (Table 3.4). Univariate analyses identified EDV/BSA, 
mean Ca x PO4 product and mean pre dialysis systolic BP as factors significantly 
associated with presence of LVH.  Multivariate logistic regression modelling (only 
entering one BP variable and cardiac parameter due to their significant 
interdependence) similarly identified EDV/BSA, pre dialysis systolic BP, and 
CaxPO4 as the most robust (R2=0.50) independent predictors of LVH. 
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 Standardised 
coefficient 
p 95% CI  
for β 
 β   
R2=0.49, p<0.01     
Constant - 13.5 0.40 -45.33, 18.3 
EDV/BSA(ml/m2) 0.66 <0.01 0.36, 0.91 
Mean PreHD  SBP (per mmHg)  0.13 0.01 0.09, 0.42 
Ca x PO4 product(mmol2/l2) 0.16 <0.01 0.11,  0.24 
 
Table 3.2 Backward stepwise multivariate linear regression analyses model 
demonstrating independent associations of LVMI (R2= 0.49).   
Variables entered into the model were, age, cardiac parameters (individually), mean 
calcium phosphate product, mean haemoglobin, mean albumin, mean parathyroid 
hormone, mean dose of UF per dialysis session, duration on renal replacement 
therapy and pre or post HD systolic or diastolic BP (individually) 
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  No LVH 
n=89 
LVH 
n=157 
p 
Age (years) 51.8(12.2)  51.2(12.1)  0.20  
Male (%) 55(61.8)  102(65.0)  0.62 
BMI (kg/m2)  25.2(4.2)  25.8(4.8) 0.45  
Ischaemic Heart Disease 21(23.6) 30(19.1) 0.40 
Diabetes Mellitus 58 (65.2) 98(62.4) 0.67 
Chronic Heart Failure 5(5.6) 10(6.4) 0.81 
Cerebrovascular Disease 10 (11.2) 10(6.4) 0.18 
Peripheral Vascular Disease 7(7.9) 11(7.0) 0.80 
Hypertension 79(88.8) 144(91.4) 0.44 
Duration on HD (y)  2.9(3.1)  3.0(2.9) 0.89 
Mean UF Volume (L) 2.1(0.9)  2.3(1.2)  0.08 
Mean PreHD SBP (mmHg)  138.1(24.3)  144.6(20.0)  0.02 
Mean PostHD SBP (mmHg)  129.2(24.8)  133.8(21.9)  0.14  
Mean PreHD DBP(mmHg)  79.1(16.4)  80.3(12.4)  0.52  
Mean PostHD DBP(mmHg)  72.3(15.9)  73.9(12.5)  0.36 
Mean PreHD PP (mmHg)  59.1(17.6) 64.4(16.5) 0.02 
MAP PostHD PP (mmHg)  57.1(18.9) 60.0(16.8) 0.22 
Urea Reduction Ratio (%) 67.6 (11.9) 70.7 (6.4)  0.64 
Haemoglobin (g/dL)  11.3(1.5)  11.3(1.3)  0.95 
Adjusted Ca (mmol/l)  2.29(0.2)  2.31(0.2)  0.61 
Phosphate (mmol/l)  1.20(0.40)  1.32(0.5)  0.06 
Ca x PO4 product  2.72(0.9)  3.05(1.0) 0.03 
Albumin  37.9(6.1)  36.9(5.8)  0.24 
PTH  34.3(13.4,48.3)  31.4(15.2,45.7)  0.54  
Aspirin 38(42.7) 59(37.6) 0.43 
ACEI/ARB 23(25.8) 38(24.2) 0.78 
Diuretic 23(25.8) 27(17.2) 0.11 
CCA 25(28.1) 48(30.6) 0.68 
α Adrenoceptor blocker 9(10.1) 8(5.1) 0.14 
β Adrenoceptor blocker 36 (40.4) 70(44.6) 0.53 
ESA 74(83.1) 122(77.7) 0.46 
Vitamin D analogue 35 (39.3) 64 (40.8) 0.83 
Statin 42 (47.2) 51 (32.2) 0.09 
Ejection Fraction (%) 68.5(7.9) 62.6 (15.1) <0.01 
LVMI (g/m2) 67.2(10.8) 116.9 (31.3) <0.01 
EDV/BSA (ml/ m2) 58.2(18.3) 88.7(34.7) <0.01 
ESV/BSA (ml/ m2) 19.7(10.8) 36.5 (27.5) <0.01 
LVSD 6(6.7) 39 (24.8) <0.01 
LV dilatation 2 (2.2) 37 (23.6) <0.01 
Table 3.3 Comparisons between patients with and without LVH are 
shown.  
Data are number with percentage in parentheses, mean ± standard deviation or 
median interquartile range for PTH. Tests of significance are t-test and Chi-
square (parametric data) or Mann Whitney (non parametric data). Significant 
results are highlighted. 
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 Univariate Analyses Multivariate analyses 
 
Variable OR  95% CI p OR  95% CI P 
EDV/BSA (per ml/m2) 1.08 1.04,1.13 <0.01 1.06 1.04,1.08 <0.01 
Mean Ca x PO4 (per mmol2/l2) 1.37 1.01,1.87 0.04 1.74 1.17,2.57 <0.01 
Mean PreSBP (per mmHg) 1.02 1.01,1.05 0.04 1.02 1.01,1.04 0.01 
Age (per year) 0.99 0.99,1.02 0.70    
Sex (Male vs. Female) 1.55 0.91,2.65 0.11    
BMI (per kg/m2) 0.96 0.89,1.03 0.27    
HD duration (per year) 1.01 0.85,1.20 0.88    
Ischaemic Heart Disease 1.34 0.67,2.60 0.38    
Diabetes Mellitus 1.20 0.69,2.60 0.52    
Chronic Heart Failure 0.88 0.28,2.72 0.82    
Cerebrovascular Disease 2.76 0.96,6.93 0.09    
Peripheral Vascular Disease 0.83 0.29,2.42 0.74    
UF volume (per litre) 1.26 0.95,1.66 0.11    
Urea Reduction Ratio (per %) 1.06 0.91,1.23 0.45    
Mean Post SBP (per mmHg) 0.99 0.97,1.02 0.55    
Mean PreDBP (per mmHg) 0.98 0.95,1.01 0.21    
Mean PostDBP (per mmHg) 1.01 0.98,1.04 0.49    
Mean Pre PP (per mmHg) 1.02 1.01,1.05 0.05    
Mean Post PP (per mmHg) 0.99 0.97,1.01 0.47    
Ejection fraction (per %) 0.95 0.88,1.03 0.21    
ESV/BSA (per ml/m2) 0.93 0.85,1.02 0.12    
Mean Haemoglobin (per g/dL) 0.86 0.60,1.23 0.41    
Mean Adjusted Ca (per mmol/l) 1.61 0.35,7.48 0.54    
Mean Serum PO4 (per mmol/l) 2.10 1.00,4.29 0.06    
Mean Albumin (per g/dL) 1.00 0.96,1.05 0.91    
Mean PTH (per pmol/l) 0.99 0.99,1.01 0.54    
 
Table 3.4 Simple (left) followed by backward stepwise (conditional) 
multiple logistic regression analyses (R2=0.50) demonstrating independent 
predictors of presence of LVH.   
Only variables found to be significant on univariate analyses were entered into the 
multivariate model.  Cardiac and blood pressure parameters were entered 
individually to generate the most predictive model. 
127 
 
3.3.3   LV ejection fraction and systolic dysfunction 
 
3.3.3(a) Correlates with LV ejection fraction 
LV ejection fraction was used as an indicator of left ventricular function.  In addition 
to the correlates demonstrated above, there were strong negative correlations with 
ESV/BSA (Pearson’s R= -0.84; p<0.01) and EDV/BSA (Pearson’s R= -0.53; 
p<0.01) as expected.   There was a weak negative correlation with dose of 
ultrafiltration during dialysis (Pearson’s R= -0.18; p<0.01). 
 
3.3.3(b) Associations of LV ejection fraction and LV systolic dysfunction 
As before, backward stepwise multivariate linear regression analyses were 
performed (Table 3.5).  Factors considered influential based on initial evaluation of 
correlation data or identified from previous studies as predictors of LV function were 
entered into the model. End systolic volume corrected for BSA and pre HD systolic 
BP were the significant independent predictors of LV ejection fraction (R2=0.76). 
 
In patients with LVSD, there was a significantly higher proportion of patients with a 
past medical history of ischaemic heart disease and symptomatic heart failure (Table 
3.6) compared to those with normal LV function. In addition, mean dose of UF, pre 
HD diastolic blood pressure and therapy with aspirin were significantly higher in 
LVSD patients.  As expected from correlations with ejection fraction, LVSD was 
significantly associated with higher LVMI, EDV/BSA, and ESV/BSA. 
 
Logistic regression analyses were performed to determine predictors of LVSD 
(Table 3.7). Univariate analyses identified ESV/BSA, EDV/BSA, LVMI, past 
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history of ischaemic heart disease, symptomatic chronic heart failure, duration 
receiving haemodialysis therapy, and mean dose of ultrafiltration as significant 
predictors of LVSD on CMR.     Multivariate logistic regression analyses was 
performed entering significant factors from univariate analyses and the most 
predictive model (R2=0.43) included ESV/BSA, past history of ischaemic heart 
disease and mean dose of UF.   
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 Standardised 
coefficient 
p 95% CI 
for β 
 β   
R2=0.76, p<0.001     
Constant 89.6 <0.01 75.5, 103.6 
ESV/BSA(ml/m2) -0.80 <0.01 -1.46, -0.29 
Mean PreHD  SBP (per mmHg)  -0.17 0.05 -0.29, -0.06 
 
Table 3.5  Backward stepwise multivariate linear regression analyses to 
identify independent predictors of LV ejection fraction (R2= 0.76).   
Variables entered into the model were age, cardiac parameters (individually), mean 
calcium, mean phosphate, mean haemoglobin, mean albumin, mean parathyroid 
hormone, mean dose of UF per dialysis session, duration on renal replacement 
therapy, pre or post HD systolic or diastolic BP (individually). 
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Table 3.6 Comparisons between patients with and without LVSD  
Data are number with percentage in parentheses or mean ± standard deviation 
or median and interquartile range. Tests of significance are t-test and Chi-
square.   
 
 
  No LVSD 
n=201 
LVSD 
n=45 
p 
Age (years) 51.1 (11.8) 52.3(13.5) 0.37 
Male (%) 124(61.7) 33 (73.3) 0.62 
BMI (kg/m2)  25.8 (4.6) 24.8(4.1) 0.14 
Ischaemic Heart Disease 37 (18.4) 17 (37.8) <0.01 
Diabetes Mellitus 130 (64.7) 26 (57.8) 0.35 
Chronic Heart Failure 8 (4.0) 5 (11.1) 0.05 
Cerebrovascular Disease 17 (8.5) 3 (6.7) 0.69 
Peripheral Vascular Disease 12 (6.0) 6 (13.3) 0.09 
Hypertension 181 (90.0) 42 (93.3) 0.49 
Duration on HD (y)  2.88(3.7) 4.30 (7.2) 0.06 
Mean UF Volume (L) 2.1(1.1) 2.7 (0.7) <0.01 
Mean PreHD SBP (mmHg)  141.4(21.8) 146.0 (21.5) 0.20 
Mean PostHD SBP (mmHg)  131.6(23.5) 135.6(21.0) 0.29 
Mean PreHD DBP(mmHg)  78.8(13.9) 83.6(13.8) 0.04 
Mean PostHD DBP(mmHg)  72.6 (13.9) 83.3(13.8) 0.20 
Mean PreHD PP (mmHg)  62.5(17.5) 62.4(15.2) 0.96 
MAP PostHD PP (mmHg)  58.9(17.9) 59.1(15.3) 0.94 
Urea Reduction Ratio (%) 70.7(7.1) 68.0(9.3) 0.49 
Haemoglobin (g/dL)  11.4(1.4) 11.0(1.3) 0.12 
Adjusted Ca (mmol/l)  2.31(0.2) 2.32(0.3) 0.77 
Phosphate (mmol/l)  1.25 (0.4) 1.35(0.5) 0.21 
Ca x PO4 product  2.95 (1.0) 2.88(0.9) 0.72 
Albumin  37.1(6.2) 38.2(4.7) 0.31 
PTH  32.7(11.6,45.3) 31.7(14.2,53.7) 0.87 
Aspirin 17 (35.3) 26 (57.8) <0.01 
Warfarin 8 (4.0) 3 (6.7) 0.43 
ACEI/ARB 47 (23.4) 14 (31.1) 0.27 
Diuretic 42 (20.9) 8 (17.8) 0.64 
CCA 58 (28.9) 15 (33.3) 0.55 
α Adrenoceptor blocker 14 (7.0) 3 (6.7) 0.14 
β Adrenoceptor blocker 85 (42.3) 21 (46.7) 0.59 
ESA 157 (78.1) 39 (86.7) 0.19 
Vitamin D analogue 80(39.8) 19(45.2) 0.28 
Statin 73 (36.3) 20 (44.4) 0.31 
Ejection Fraction % 67.1(10.9) 52.0(17.3) <0.01 
LVMI (g/m2) 94.3(31.1) 122.8(50.5) <0.01 
EDV/BSA (ml/ m2) 72.7(26.8) 100.9(38.6) <0.01 
ESV/BSA (ml/ m2) 25.1(16.7) 49.6(30.4) <0.01 
LVH 118 (58.7) 39 (86.7) <0.01 
LV dilatation 18 (9.0) 21 (46.7) <0.01 
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 Univariate Analyses Multivariate analyses 
Variable OR  95% CI p OR  95% CI P 
ESV/BSA (per ml/m2) 1.05 1.03,1.06 <0.01 1.07 1.04,1.10 <0.01 
Ischaemic Heart Disease 2.62 1.33,5.42 <0.01 4.68 1.60,13.7 <0.01 
UF volume (per litre) 1.47 1.05,2.08 0.03 2.06 1.02,1.06 0.03 
EDV/BSA (per ml/m2) 1.03 1.02,1.04 <0.01    
LVMI (per g/m2) 1.01 1.01,1.03 <0.01    
HD duration (per year) 1.03 1.01,1.06 0.04    
Chronic Heart Failure 4.44 1.52,12.9 <0.01    
Mean Albumin (per g/dL) 1.14 1.01,1.28 0.10    
Age (per year) 1.02 0.98,1.04 0.38    
Sex (ref Female) 1.78 0.83,3.51 0.15    
Diabetes Mellitus 0.74 0.38,1.44 0.39    
BMI (per kg/m2) 0.95 0.85,1.05 0.31    
Cerebrovascular Disease 0.78 0.22,2.76 0.69    
Peripheral Vascular Disease 2.42 0.85,6.84 0.09    
Urea Reduction Ratio (per %) 1.06 0.95,2.07 0.76    
Mean PreSBP (per mmHg) 1.00 0.97,1.03 0.82    
Mean Post SBP (per mmHg) 1.01 0.98,1.04 0.63    
Mean PreDBP (per mmHg) 1.02 0.98,1.06 0.37    
Mean PostDBP (per mmHg) 1.00 0.96,1.05 0.86    
Mean Pre PP (per mmHg) 1.00 0.97,1.03 0.89    
Mean Post PP (per mmHg) 1.00 0.97,1.03 0.88    
Mean Haemoglobin (per g/dL) 0.79 0.51,1.21 0.79    
Mean Adjusted Ca (per mmol/l) 0.18 0.01,6.14 0.34    
Mean Serum PO4 (per mmol/l) 0.93 0.26,3.25 0.92    
Mean Ca x PO4 (per mmol2/l2) 1.30 0.44,3.81 0.63    
Mean PTH (per pmol/l) 1.00 0.98,1.02 0.94    
 
Table 3.7 Simple (left) followed by backward stepwise (conditional) 
multiple logistic regression analyses (R2=0.43) demonstrating independent 
predictors of presence of LVSD.   
Only variables found to be significant on univariate analyses were entered into the 
multivariate model.  Cardiac parameters were entered individually to generate the 
most predictive model. 
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3.3.4 End diastolic volume/BSA and left ventricular dilatation 
 
3.3.4(a)  Correlates with EDV/BSA 
EDV/BSA was used to define LV chamber volume and LV dilatation.  EDV/BSA 
was positively correlated with LVMI (Pearson’s R=0.63; p<0.01) and ESV/BSA 
(Pearson’s R=0.84; p<0.01) and negatively correlated with LV ejection fraction as 
mentioned before.  There was a weaker correlation with mean dose of UF (Pearson’s 
R=0.22; p<0.01). 
 
3.3.4(b) Associations of EDV/BSA and LV dilatation 
Multiple backward stepwise linear regression analyses were also performed to 
provide the most predictive (R2=0.47) model of EDV/BSA.  Independent predictors 
of EDV/BSA were LV ejection fraction and mean dose of UF during dialysis (Table 
3.8). 
 
Patients with and without LV dilatation were compared (Table 3.9).  Presence of LV 
dilatation was significantly associated with higher dose of UF during haemodialysis 
therapy.  As demonstrated before, LV dilatation was significantly associated with 
higher LVMI (and presence of LVH), end diastolic and systolic LV volumes and 
lower ejection fraction (and presence LVSD).  Independent predictors of presence of 
LV dilatation were left ventricular ejection fraction and mean dose of ultrafiltration 
during haemodialysis (Table 3.9). 
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 Standardised 
coefficient 
p 95% CI 
for β 
 β   
R2=0.47, p<0.001     
Constant 143.6 <0.01 111.8, 175.4 
LV ejection fraction (per %) -0.49 <0.01 -0.64, ,-0.22 
Mean Ultrafiltration (per L) 0.16 0.05 0.10, 0.78 
    
 
Table 3.8 Backward stepwise multivariate linear regression analyses model 
demonstrating independent associations of EDV/BSA (R2= 0.47).   
Variables entered into the model were, age, cardiac parameters (individually), mean 
calcium, mean phosphate, mean haemoglobin, mean albumin, mean parathyroid 
hormone, mean dose of UF per dialysis session, duration on renal replacement 
therapy, pre or post HD systolic or diastolic BP (individually). 
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 No LV 
Dilatation 
N=207 
LV Dilatation 
N=39 
P 
Age (years) 51.5(12.1) 50.9(12.2) 0.77 
Male (%) 130 (62.8) 27 (69.2) 0.44 
BMI (kg/m2)  25.7(4.7) 25.2(3.6) 0.65 
Ischaemic Heart Disease 43 (20.8) 8 (20.5) 0.97 
Diabetes Mellitus 133 (64.3) 23 (59.0) 0.53 
Chronic Heart Failure 11 (5.3) 4 (10.3) - 
Cerebrovascular Disease 17 (8.2) 3 (7.7) - 
Peripheral Vascular Disease 16 (7.7) 2 (5.1) - 
Hypertension 186 (89.9) 37 (94.9) 0.32 
Duration on HD (y)  4.98 (6.8) 5.96 (6.7) 0.45 
Mean UF Volume (L) 2.1(1.1) 2.8(0.7) <0.01 
Mean PreHD SBP (mmHg)  142.7(22.2) 139.7(18.3) 0.43 
Mean PostHD SBP (mmHg)  132.4(24.0) 139.7(18.3) 0.81 
Mean PreHD DBP(mmHg)  79.5(14.1) 131.2(17.3) 0.59 
Mean PostHD DBP(mmHg)  73.5(13.9) 72.2(13.9) 0.74 
Mean PreHD PP (mmHg)  63.1(17.6) 58.9(13.3) 0.15 
MAP PostHD PP (mmHg)  58.9(18.2) 58.8(14.0) 0.96 
Urea Reduction Ratio (%) 71.8(34.5) 76.9(33.3) 0.76 
Haemoglobin (g/dL)  11.3 (1.4) 11.1(1.2) 0.33 
Adjusted Ca (mmol/l)  2.31(0.2) 2.31(0.3) 0.99 
Phosphate (mmol/l)  1.28 (0.4) 1.22(0.4) 0.48 
Ca x PO4 product  2.94(0.9) 2.90(1.1) 0.83 
Albumin  37.3(5.9) 37.3(6.2) 0.94 
PTH  32.5(12.6,45.3) 31.5 (12.0,43.7) 0.98 
Aspirin 84 (40.6) 13 (33.3) 0.40 
Warfarin 8 (3.9) 3 (7.7) - 
ACEI/ARB 52 (25.1) 9 (23.1) 0.79 
Diuretic 45 (21.7) 5 (12.8) 0.20 
CCA 61 (29.5) 12 (30.8) 0.87 
α Adrenoceptor blocker 16 (7.7) 1 (2.6) - 
β Adrenoceptor blocker 89 (43.0) 17 (43.6) 0.95 
ESA 162(78.3) 34 (87.2) 0.20 
Vitamin D analogue 85 (41.1) 14 (35.9) 0.55 
Statin 80 (38.6) 13 (33.3) 0.53 
Ejection Fraction % 68.3(0.7) 45.6(13.3) <0.01 
LVMI (g/m2) 93.4(31.8) 131.6(45.4) <0.01 
EDV/BSA (ml/ m2) 70.1(23.2) 118.5(36.3) <0.01 
ESV/BSA (ml/ m2) 22.5(12.0) 67.1(25.0) <0.01 
LVH 120 (58.0) 37( 94.9) <0.01 
LVSD 24 (11.6) 21 (53.8) <0.01 
 
Table 3.9 Comparisons between patients with and without LV dilatation. 
Data are number with percentage in parentheses, mean ± standard deviation or median 
interquartile range for PTH. Tests of significance are t-test and Chi- square (parametric data) 
or Mann Whitney (non parametric data). 
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 Univariate Analyses Multivariate analyses 
 
Variable OR  95% CI p OR  95% CI P 
Ejection fraction (per %) 0.86 0.83,0.90 <0.01 0.87 0.83, 0.91 <0. 01 
UF volume (per litre) 1.73 1.18,2.54 <0.01 1.53 1.09, 2.17 0.01 
LVMI (per g/m2) 1.03 1.02,1.04 <0.01    
Mean PreSBP (per mmHg) 0.97 0.95,1.00 0.08    
Age (per year) 0.99 0.97, 1.02 0.77    
Sex (Male vs. Female) 0.75 0.36,1.57 0.44    
BMI (per kg/m2) 0.98 0.86,1.08 0.65    
HD duration (per year) 1.02 0.97, 1.08 0.45    
Ischaemic Heart Disease 0.98 0.41, 2.37 0.97    
Diabetes Mellitus 0.81 0.40,1.65 0.81    
Chronic Heart Failure 2.15 0.63, 7.36 0.22    
Cerebrovascular Disease 1.00 0.27, 3.74 0.99    
Peripheral Vascular Disease 0.57 0.12, 3.74 0.49    
Urea Reduction Ratio (per %) 1.56 0.76, 7.89 0.57    
Mean Post SBP (per mmHg) 1.02 0.99, 1.05 0.23    
Mean PreDBP (per mmHg) 1.04 1.00, 1.08 0.06    
Mean PostDBP (per mmHg) 0.97 0.93,1.01 0.19    
Mean Pre PP (per mmHg) 0.97 0.95,1.00 0.05    
Mean Post PP (per mmHg) 1.02 0.99-1.05 0.20    
Mean Haemoglobin (per g/dL) 0.86 0.65, 1.12 0.33    
Mean Adjusted Ca (per mmol/l) 3.48 0.48, 26.5 0.23    
Mean Serum PO4 (per mmol/l) 0.62 0.22, 1.75 0.36    
Mean Ca x PO4 (per mmol2/l2) 0.96 0.66, 1.40 0.83    
Mean Albumin (per g/dL) 1.00 0.94, 1.07 0.99    
Mean PTH (per pmol/l) 1.00 0.99, 1.02 0.98    
 
Table 3.10 Simple (left) followed by backward stepwise (conditional) 
multiple logistic regression analyses (R2=0.55) demonstrating independent 
predictors of presence of LV dilatation.   
Only variables found to be significant on univariate analyses were entered into the 
multivariate model.  Cardiac parameters were entered individually to generate the 
most predictive model. 
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3.4 DISCUSSION 
 
Uraemic cardiomyopathy describes a heterogeneous group of cardiac abnormalities 
that are very common in patients close to or receiving RRT (167;168). However, our 
understanding of its aetiology and thus identification of therapies to prevent, slow or 
reverse its development have proven difficult.  Our current understanding is derived 
from echocardiography which is inaccurate when estimating LV chamber size and 
wall thickness in ESRD patients. 
 
3.4.1 Development of uraemic cardiomyopathy 
The development of uraemic cardiomyopathy is believed to be initiated and 
perpetuated by elevated cardiac preload and afterload (see Table 3.11) (169;170). 
LVH develops as an adaptive response to maintain stroke volume and minimise 
ventricular wall stress in the face of volume and pressure overload which are 
common in advancing stages of CKD.  Both of these changes increase LV wall 
tension due to Laplace’s Law (170; 171): 
 
T = LV wall tension, P= intraventricular pressure, D= LV internal diameter  
 
Volume overload causes myocardial stretch, stimulating sarcomere proliferation in 
series and elongating pre-existing fibres to maintain stroke volume.  This manifests 
as eccentric ventricular remodelling and LV dilatation.  Wall tension rises increasing 
oxygen requirements of cardiomyocytes and subsequent risk of ischaemia (170;171).   
T  =   PD
4
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Table 3.11 Causes of increased preload and afterload in ESRD patients -
modified from (170) 
 
Systemic hypertension, on the other hand, increases cardiac afterload and stimulates 
sarcomere production in parallel resulting in LV wall thickening with preservation or 
reduction of chamber size.  The ventricle is remodelled in a uniform and concentric 
pattern.  
    
Thus, wall tension increases as intraventricular pressure (systemic hypertension, 
aortic stenosis) and intraventricular diameter (fluid overload) rise.  Adaptive 
responses are implemented to reduce wall stress (defined as T: cross sectional area of 
LV) redistributing work over a larger area and reducing energy consumption per 
muscle fibre. 
   
However, as the LV wall thickens, inadequate angiogenesis reduces capillary 
density, myocardial reserve and subsequently leads to myocyte ischaemia, death and 
reparative myocardial fibrosis.  This reduces contractile function per unit volume of 
myocardium and eventually causes symptomatic left ventricular failure.  Myocyte 
death is also facilitated by poor dialysis, poor nutrition and hyperparathyroidism, 
which are common in ESRD (134;171). 
Preload Afterload 
Intravascular volume expansion Systemic Hypertension 
Arteriovenous fistula Calcific Aortic Stenosis 
Anaemia Vascular calcification 
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Not all structural abnormalities have been attributed to these haemodynamic factors.  
Higher levels of interstitial myocardial fibrosis have been demonstrated in autopsy 
sections from dialysis patients when compared to hypertensive and diabetic patients 
(50).  Furthermore, in vivo studies have demonstrated a potential role of angiotensin 
II, aldosterone, PTH, catecholamines, and endothelin stimulating cardiac interstitial 
fibroblasts (61;172).   
 
3.4.2 Predictors of uraemic cardiomyopathy on CMR 
This study is the first to use CMR to define individual abnormalities of uraemic 
cardiomyopathy in a cohort of haemodialysis patient and use past clinical, blood and 
dialysis data, collected over 180 days prior to scanning, to assess the trends that 
predict presence of LVH, LVSD and LV dilatation. 
 
In ESRD patients, the presence of one myocardial abnormality is predictive of other 
features of uraemic cardiomyopathy.  Figure 3.1 demonstrated that abnormalities 
often occur in combination and correlation analyses for cardiac parameters 
demonstrated significant relationships between all LV measurements. In our 
regression analyses, only the most predictive models were presented after adding one 
cardiac abnormality.  However, when other cardiac abnormalities were included (e.g. 
ejection fraction for LVMI) similarly significant but less robust models were 
generated.   Given the close association of cardiac abnormalities in patients with 
uraemic cardiomyopathy and the processes described above, it is likely that different 
combinations of structural changes represent varying stages of the same 
adaptive/disease process. 
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In addition, this study demonstrates that clinical, blood and dialysis features 
previously proposed as predictors of uraemic cardiomyopathy detected by 
echocardiography, are not associated with LV abnormalities detected by CMR. 
 
3.4.2 Predictors of LVH 
LVH is the most common abnormality of uraemic cardiomyopathy and is estimated 
to be present in approx 67% of haemodialysis patients assessed by CMR.  A cross 
sectional study of patients with varying degrees of CKD demonstrated a progressive 
increase in the prevalence of LVH with deteriorating renal function (173).  LVH has 
been demonstrated as an independent predictor of heart failure, ventricular 
tachyarrhythmia and sudden cardiac death (47).   These data show that LVH assessed 
by CMR is common (63.8%) but is lower than previous echocardiography studies 
highlighting the tendency for echocardiography to overestimate LV mass in ESRD 
patients (132; 139).  These data also show that both LVMI and presence of LVH are 
associated with, and independently predicted by elevated end diastolic LV volume, 
pre-dialysis systolic blood pressure and Ca x PO4 product. 
 
3.4.2(a) Hypertension and LVH 
A number of different studies, using echocardiography, have demonstrated a 
significant association between LVH and hypertension: 
• Harnett at al studied haemodialysis patients with progressive LVH.  They 
demonstrated that age and pre-dialysis systolic blood pressure were associated with 
increased LV mass (174).   
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• Parfrey et al showed in 432 patients with a median of 3.3 months from starting 
haemodialysis, that presence of concentric LV hypertrophy was independently 
predicted by systolic blood pressure and female gender (47).   
 
Data from this thesis using CMR assessment support earlier studies suggesting that 
systolic hypertension acts as a major determinant of cardiac afterload and thus 
significantly predicts LVMI and presence of LVH. 
 
Previous studies have demonstrated that LVMI and dialysis BP measurements (pre- 
and post- HD) are usually only weakly (r=0,15-0.20) correlated (175). This is 
unsurprising given inaccuracies of blood pressure measurement at the time of 
dialysis. A number of studies have demonstrated that pre and post dialysis blood 
pressures provide misleading estimates and less reproducible measurements in 
haemodialysis patients. 
 
• In a comparative study between dialysis and 48 hour ambulatory BP measurements 
(ABPM),  Coomer et al demonstrated that predialysis BP overestimated mean 
intradialytic systolic BP by 10mmHg and post dialysis BP underestimated systolic 
measurements by 7mmg (176). 
• Peixoto et al investigated 21 haemodialysis patients who had pre- and post-HD 
measurements compared with 2 separate 48 hours ABPM monitoring readings.  
Their results showed that ABPM provided less variable and more reproducible 
results (177). 
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Despite these studies, ABPM monitoring remains unpopular because the 
methodology is not universally available, time consuming and uncomfortable for 
dialysis patients. In this study, ABPM was offered to patients, but many refused as 
they did not wish to wear the monitor overnight. 
 
The cause of hypertension in haemodialysis patients is multifactorial but is mostly 
due to volume overload (178).  Elevated intravascular volume stimulates higher 
cardiac output (due to Starling’s Law of the heart) and inappropriately increases 
systemic vascular resistance (believed to be caused by secretion of oubain like 
ATPase inhibitors which increase vascular smooth muscle intracellular Ca2+ 
concentration).  In addition, inappropriate activation of the sympathetic nervous 
system by uraemic metabolites, vascular stiffness due to calcification, 
vasoconstriction caused by abnormal endothelial function and erythropoietin 
administration may contribute to elevated BP in ESRD patients (175). 
 
3.4.2(b) Ca x PO4 product and LVH 
Elevated Ca x PO4 product is a risk factor for arterial calcification and consequently 
contributes to elevated blood pressure and the development of LVH (60;179).  It has 
been shown to be an independent predictor of cardiovascular and sudden death in 
patients with ESRD: 
• In the Dialysis Outcomes and Practice Patterns Study (DOPPS), all cause and 
cardiovascular mortality was directly and independently predicted by serum calcium, 
phosphate, PTH and Ca x PO4 product(180). 
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• In a study of 134 patients (only 80 of these were receiving haemodialysis) assessed 
twice by multi slice spiral CT, independent predictors of mortality included elevation 
of vascular calcification score (181). 
 
Other measurements and markers of vascular calcification, such as pulse wave 
velocity and electron beam CT, have demonstrated an association with LVH in 
ESRD patients. 
 
• Nitta et al investigated 49 haemodialysis patients using applanation tonometry to 
assess pulse wave velocity and abdominal CT to quantify aortic calcification index.  
LVMI was significantly correlated and independently predicted by both 
measurements (182). 
 
3.4.2(c)  End diastolic volume and LVH 
In our study, EDV/BSA was the strongest predictor of LVMI and LVH after 
multivariate analyses supporting an association between elevated LV mass and long-
term volume overload and ventricular stretch.  In addition, brain natriuretic peptide, 
whose production is stimulated by myocardial stretch, has been used to predict 
presence of LVH in ESRD patients with sensitivities ≥ 87% (183).  Unfortunately, 
we did not have samples available for measurement of BNP in this cohort.  
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3.4.2(d)  Anaemia and LVH 
Our study did not demonstrate a predictive role of haemoglobin concentration for 
LVMI.  The potential aetiological role of anaemia in development of LVH remains 
uncertain in ESRD patients.  In theory, haemodilution increases myocardial work to 
ensure adequate oxygenation of tissues resulting in hypervolaemia (±worsening 
hypertension) and increased cardiac preload.  Studies using echocardiography have 
demonstrated a strong predictive role of anaemia in LVH: 
 
• In a study of 51 dialysis patients studied by serial echocardiography, lower 
haemoglobin independently predicted LVMI.  However only 8 of these patients were 
receiving erythropoietin therapy (184). 
• Levin et al showed that left ventricular growth was independently predicted by 
haemoglobin concentration and systolic blood pressure in 246 dialysis patients (185). 
 
These earlier studies, however, were performed before the routine use of 
erythropoietin to correct anaemia in patients receiving renal replacement therapy.   
Erythropoietin receptors are present in myocardial tissues and in vivo studies have 
demonstrated that stimulation alters cellular turnover (186).  Studies demonstrating 
correction of moderate anaemia using erythropoietin stimulating agents have not 
shown significant reversal of LVH. 
 
• In a 2009 meta-analysis pooling data from 15 studies with 1731 erythropoietin 
treated patients, regression of LVH was observed only in patients treated with severe 
anaemia (Hb<10g/dL)  Patients with moderate anaemia (mean Hb≥10g/dL but <12 
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g/dL) had insignificant changes in LVMI.  These findings were consistent in dialysis 
and predialysis patients (187). 
 
The absence of significant association in our study is likely due to higher values and 
narrower range of haemoglobin in this cohort (mean haemoglobin = 11.3g/dl, 
standard deviation= 1.3) compared to other studies.  In addition, echocardiography 
overestimates LVMI at lower haematocrit and higher intravascular volumes (135).  
Thus any therapy that reduces haemodilution (e.g. correction of anaemia) could 
provide artefactual reduction in LVMI measured by echocardiography.  The use of 
CMR to assess change in LVMI after correction of anaemia in ESRD patients 
remains to be studied. 
 
3.4.3 Predictors of LVSD 
As in the general population, symptomatic heart failure predicts early mortality in 
ESRD patients and increasing severity, defined by the New York Heart Association 
(NYHA) classification, is associated with increased mortality: 
 
• In a study from the United Stated Renal Database System comparing 310456 
haemodialysis patients admitted to hospital for the first time with symptomatic heart 
failure, fluid overload or pulmonary oedema,  5- year survival rates were 12.5%, 
20.2% and 21.3% respectively (188). 
• Postorino et al demonstrated that NYHA classifications 1-4 were independently 
associated with increasingly poorer survival in ESRD patients (189).   
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Previous echocardiography studies have demonstrated differing prevalence of LVSD 
in ESRD patients (between 18-62%) (167;190).  This variability is presumably due, 
in part, to the difficulty obtaining accurate and reproducible images in patients with 
varying intraventricular cavity diameters.   However, data presented here are 
consistent with previous CMR studies in this patient cohort from our research group: 
 
• In a pilot study using CMR to assess myocardial structure in 134 ESRD patients, 
Mark et al demonstrated LVSD prevalence of 8.2%, although this included 
peritoneal dialysis and predialysis patients (139). 
• In a cross sectional study, LVSD was present in 15.6% of patients undergoing 
cardiovascular assessment for renal transplantation who underwent CMR (135; 191). 
 
LVSD is more common in ESRD patients compared to the general population and 
has historically been attributed to the accumulation of traditional cardiovascular risk 
factors (192) including ischaemic heart disease, hypertension, older age, and 
anaemia.  In addition, factors found only in ESRD patients have been shown to 
reduce LV function including chronic fluid overload, uraemia and calcific aortic 
stenosis (190).  
 
3.4.3(a) LVSD and fluid retention  
Our data show that lower LV ejection fraction and presence of LVSD are 
independently associated with higher ESV/BSA.  As suggested previously, this is 
most likely due to intravascular volume expansion, elevated diastolic LV filling, 
inadequate LV systolic emptying and subsequent decompensated heart failure.  
Independent predictors of LVSD also included mean dose of ultrafiltration consistent 
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with a recent study that demonstrated an association between elevated interdialytic 
weight gain and adverse outcome: 
 
• Data from a large (n=34107), retrospective study of haemodialysis patients 
investigated weight gain between dialysis sessions and outcome. Mortality was 
highest in patients with 3 month averaged interdialytic weight gain greater than 4kg 
and lowest in patients with gains less than 1kg.  The investigators concluded that 
higher fluid retention (especially >4kg) was associated with greater all-cause and 
cardiovascular mortality independent of other co-morbid conditions (193).   
 
It is impossible to determine whether elevated dose of ultrafiltration may be a cause 
or sequela of LVSD from the results presented above.  Dose of ultrafiltration is 
calculated from a patients “dry weight” and determined by the nephrologist on the 
basis of his/her clinical assessment.  However, this may not represent an accurate 
measure of patient’s ideal oedema free, normotensive weight.  More objective 
methods of assessing patients’ fluid status and thus dose of ultrafiltration, such as 
bioelectrical impendance analysis and radionuclide tagging are currently being 
investigated to determine their effect on myocardial function and patient outcome 
(194). 
 
3.4.3(b) LVSD and hypertension  
These data demonstrate a close relationship between blood pressure and LV systolic 
function: higher pre-HD SBP was significantly associated with lower LV ejection 
fraction.  This finding is in keeping with previous studies in the general population 
and ESRD patients: 
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• In the NHANES I follow up study in patients with congestive cardiac failure, 
hypertension was identified as an independent predictor of reduced LV ejection 
fraction and symptomatic chronic heart failure (195). 
• Harnett et al demonstrated hypertension as an independent predictor of congestive 
cardiac disease in patients with ESRD. Diastolic blood pressure predicted presence 
of de novo and recurrent congestive heart failure (192). 
 
3.4.3(c)  LVSD and ischaemic heart disease 
Consistent with other studies in the general population and ESRD patients, these data 
show that past history of symptomatic occlusive coronary disease independently 
predicted presence of LVSD.  The definition of ischaemic heart disease included 
patients with history of myocardial infarction, coronary artery intervention (surgical 
or percutaneous) or current symptoms of angina pectoris.  Mark et al previously 
showed that presence of LVSD is significantly associated with presence of 
subendocardial pattern of myocardial fibrosis highlighted by late gadolinium- 
diethylenetriamine- pentaacetic acid (Gd-DTPA) enhancement (LGE) on contrast 
CMR (139).  Subendocardial LGE represents areas of previous (commonly silent) 
myocardial infarction and based on these results it was postulated that LVSD in 
uraemic cardiomyopathy is mostly due to CAD and myocardial ischaemia/infarction.  
These data support the association of ischaemic heart disease and LVSD in ESRD 
patients. 
 
3.4.4 Predictors of LV dilatation 
LV dilatation, when assessed by echocardiography, is common in haemodialysis 
patients with a prevalence reported between 28-36% in most cohorts (134).  As 
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discussed previously, echocardiography provides inaccurate measurements of LV 
chamber size in fluid overloaded patients.  In contrast, CMR assessment of our 
cohort demonstrated prevalence of LV dilatation at 15.9% of patients and is 
consistent with other CMR studies within this patient group (135). LV dilatation has 
previously been shown to be an independent predictor of death in ESRD patients: 
  
• Parfrey et al demonstrated that presence of LV dilatation in patients assessed by 
echocardiography within a year of starting haemodialysis had a higher mortality after 
2 years on ESRD therapy (HR=1.86; p=0.02).  LV dilatation independently predicted 
death  of patients in this cohort (47). 
• Further analysis of these patients investigated LV geometry and outcome after 2 
years on ESRD.  The results separated the effect of LVH and LV dilatation on 
outcome.  In patients with normal cavity size and preserved systolic function, high 
LV mass and mass: volume ratios were independently associated with late mortality. 
Cavity volume did not have any effect on mortality.   In patients with elevated cavity 
size and preserved systolic function, high cavity size and low mass: volume ratios 
independently predicted death with LVMI having no effect on prognosis.  The 
authors concluded that the effect of mass: volume ratio on patients survival was 
dependent on LV cavity size (134). 
 
These data demonstrate that independent predictors of EDV/BSA and presence of 
LV dilatation were lower LV ejection fraction and higher mean doses of UF.  As 
demonstrated before, fluid retention and its subsequent effect on LV function plays a 
pivotal role in determining myocardial abnormalities and it is most likely that poor 
LV ejection fraction and higher mean UF doses are aetiological and perpetuating 
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agents of LV dilatation.  Thus, potential reversal of LV dilatation may involve 
attempts to improve LV function and more stringent adherence to fluid restriction in 
an attempt to break this cycle. 
 
Other factors have been identified as predictors of LV dilatation assessed by 
echocardiography: 
 
• In the two studies mentioned above, Foley et al demonstrated advancing age, male 
sex, low haemoglobin, serum calcium and albumin and high phosphate as 
independent risk factors for presence of LV dilatation (47;134).  
 
This CMR study did not demonstrate such associations presumably highlighting the 
inaccurate estimation of LV chamber size in ESRD patients by echocardiography.  In 
particular, the inclusion of haemoglobin and albumin are most likely the artefactual 
result of haemodilution, elevated intravascular volume, and imprecise measurement 
of chamber dimensions.   
 
3.4.5 Modifying uraemic cardiomyopathy 
Previous studies have identified potentially modifiable factors to reverse the 
abnormalities of uraemic cardiomyopathy and improve cardiovascular prognosis in 
ESRD patients.  Unfortunately, these studies have had limited success due in part to 
the many facets of cardiovascular disease in ESRD patients and inaccuracy of 
echocardiography when measuring cardiac chamber dimensions. 
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Based on the data presented in this thesis, regression of uraemic cardiomyopathy in 
ESRD should be directed at reducing cardiac preload and afterload.  The most 
amenable factors are: 
 
• Blood pressure control 
• Minimisation of fluid retention  
• Aggressive management of bone mineral disorders and vascular calcification  
 
Blood pressure control should be achieved in haemodialysis patients by maintenance 
of euvolaemia and anti-hypertensive medication.  A number of promising studies 
have illustrated a reduction of LV mass using these interventions: 
 
• In an early study, Wu et al investigated 39 patients on long term haemodialysis 
before and after treatment of blood pressure with regimens of ACE inhibitors, β- 
blockers, or calcium channel blocker.  This significantly reduced the prevalence of 
LVH and LVSD.  Responders, defined by a drop in mean arterial blood pressure ≥10 
mmHg, had most regression of LVH (196). 
• Studies that demonstrate improved BP control due to more frequent dialysis also 
demonstrate regression of LV mass.  Fagugli et al (197) compared the effect of short 
daily dialysis or standard thrice weekly dialysis on blood pressure management and 
LVMI in 12 patients over a year.  Blood pressures, LVMI and extracellular fluid 
were significantly lower in daily dialysis patients.  LVMI was measured by 
echocardiography. More recently, a randomised controlled study using CMR to 
determine changes in LVMI was performed by Culleton et al (20) comparing 
standard haemodialysis regimen (n=25) and frequent (5-6times/week) nocturnal 
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haemodialysis (n=26).  Results demonstrated a significant reduction in need for BP 
medication and LVMI.  However, in both of these studies, investigators were unable 
to determine whether regression of LV mass was independent of blood pressure 
control. 
 
Unfortunately there is a lack of studies that show a convincing improvement in 
myocardial function or LV dilatation in haemodialysis patients: 
 
• In a small study (n=30) assessing cardiac chamber sizes before and after renal 
transplantation using echocardiography, Peteiro et al showed a trend towards 
euvolaemia as demonstrated by reduction of LV ESV and EDV but no improvement 
in LV systolic function (198).  
 
Pharmacological intervention in dialysis patients may provide further survival 
benefit: 
 
• ACE I/ ARB.  Suzuki et al demonstrated a significant reduction in fatal and non fatal 
cardiovascular events in 360 hypertensive dialysis patients treated with ARBs (125).   
• Beta Blockers. In 114 dialysis patients with dilated cardiomyopathy, treatment with 
carvedilol significantly reduced cardiovascular deaths and hospital admissions 
compared to placebo (120). In addition, a retrospective cohort study showed that beta 
blockers reduced the risk of new onset heart failure in ESRD patients (199). 
 
Alterations in haemodialysis conditions may also improve myocardial function: 
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• Intradialytic hypotension and subsequent myocardial ischaemia, characterised by 
regional wall motion abnormalities (RWMA) on echocardiography, are recognised 
complications of haemodialysis therapy and are associated with LVSD and poorer 
survival (70).  However, biofeedback dialysis (whereby significant reductions in 
blood pressure are counteracted by reducing ultrafiltration rates) and cooled dialysis 
(35°C rather than 37°C) are associated with a significant reduction of new 
intradialytic RWMA.  The long term effect on prognosis of both of these 
interventions is awaited (72;73). 
 
Despite these studies, pharmacological treatment of heart failure remains 
underutilised in ESRD patients. Data from the USRDS estimated that less than 25% 
of patients with ESRD and heart failure are treated with beta blockers or 
ACEI/ARBs (200).  The use of beta blockers was higher in this cohort and is 
presumably a reflection of the extensive cardiovascular history and greater 
awareness of appropriate drug prescribing in these patients.   However, as more well 
controlled and randomised studies are performed, medical management may change 
in the future.  
 
3.4.6 Limitations of current study  
The current study has some limitations. Data from haemodialysis patients only has 
been presented.  This was due to the large amount of blood and dialysis data 
available for these patients from our electronic patient record.  One would hope that 
the data presented here could be extrapolated to peritoneal and pre-dialysis patients.  
In addition, these patients were referred, by a nephrologist, for cardiovascular 
assessment and may not represent a cross section of all dialysis patients due to 
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referral bias. Finally no record of vascular access for haemodialysis was presented. 
Arterio- venous fistulae has previously been associated with development of LVH 
due to increased cardiac preload. 
 
3.5 CONCLUSIONS 
In conclusion, pathophysiological changes associated with advancing kidney disease 
(hypertension, vascular calcification, expanded intravascular volume) are implicated 
in the development of the early features of uraemic cardiomyopathy.  These initially 
adaptive but subsequently pathological processes perpetuate the development of 
other cardiac abnormalities.  In this study the strongest predictor of each abnormality 
was another cardiac measurement. Prevention may have to be achieved by more 
aggressive management of the aetiological factors in earlier stages of chronic kidney 
disease since LV abnormalities are very common in predialysis patients.  Hopefully 
new guidelines that identify and allow treatment of cardiovascular risk factors in 
early chronic kidney disease (e.g. by aggressive blood pressure control) may reduce 
the development of uraemic cardiomyopathy.  
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Chapter 4 
 
A study identifying predictors of cardiovascular death in ESRD patients 
undergoing screening for renal transplantation 
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4.1 INTRODUCTION 
 
As discussed in the introduction, cardiovascular (CV) disease is the commonest 
cause of death in ESRD patients, including those on the renal transplant waiting list 
and those who have received a renal transplant.  Premature CV death may be the 
result of high prevalence of conventional risk factors (such as hypertension, 
smoking, dyslipidaemia and diabetes mellitus) but the relationship between these 
risk factors and CVD is much less clear than in the general population (1;5). For 
example, lower blood pressure and cholesterol are related to adverse outcome in 
patients on haemodialysis. In addition, a number of non-traditional and uraemia 
specific risk factors (such as endothelial dysfunction, oxidative stress, volume 
overload, hyperparathyroidism) have been associated with adverse CV outcome.   
 
Previous studies have assessed the effect of abnormal structure and function assessed 
by echocardiography on patient survival (47).  However, there have been no studies 
using CMR to identify these abnormalities, which provides a more accurate, 
reproducible, volume independent method of measuring cardiac function and 
dimensions. In addition, as has been shown previously in this thesis, these CMR 
measured cardiac abnormalities commonly occur in combination.   The Transplant 
Unit at the Western Infirmary, Glasgow has employed CMR for pre-transplant CV 
assessment since 2001.   
 
The aims of this study were to determine whether: 
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• The features of uraemic cardiomyopathy defined by CMR, namely left 
ventricular hypertrophy (LVH), left ventricular systolic dysfunction (LVSD), 
and left ventricular dilatation (LV dilatation), predicted CV death.   
• The accumulation of such cardiac abnormalities predicted CV death. 
• These features act independently of other established CV risk factors such as 
past clinical history. 
 
4.2  METHODS 
 
4.2.1 Patient recruitment 
Patients were recruited consecutively from the Western Infirmary, Glasgow as 
described in Chapter 2.  To achieve greater statistical power, 123 patients assessed 
by Dr Patrick Mark were added to those assessed to provide a larger cohort of 
patients.  However analyses were performed with blinding to patient outcome. 
 
4.2.2 Cardiovascular assessment 
All patients were recruited after referral from the transplant assessment team using 
criteria described in Chapter 2.  As part of the screening visit, ECG was recorded and 
classified as “abnormal” by the investigator if one of following criteria were present 
in standard limb leads or pre-cordial leads, except AVR or V1: 
 
• ST depression≥ 1mm or ST elevation≥ 1mm 
• T wave inversion 
• Left bundle branch block 
• LVH by Sokolow-Lyon criteria or Cornell index 
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• Pathological Q waves. 
  
CMR scans were acquired for assessment of LV mass and function and analysed as 
previously described.  Patients were classified as having LVH, LVSD or LV 
dilatation based on previously described normal values.  In addition the number of 
abnormalities was also recorded.  Serum haemoglobin, corrected calcium and 
phosphate were measured on the day of screening.   
 
4.2.3 Follow up 
Data on patient outcome, including cause of death, were obtained from the date of 
CMR to 30th September 2009 using the EPR of the Western Infirmary, Glasgow and 
Glasgow Royal infirmary Renal Units.  Deaths were categorised as “cardiovascular”, 
“malignancy”, “infective” and “unknown/other”.  Cause of death was reported by the 
attending nephrologist and recorded in the EPR.   
 
Deaths were classified as CV if primary cause on the EPR was reported as: 
• Myocardial ischaemia/infarction 
• Cardiac arrhythmia 
• Cardiac arrest (cause uncertain) 
• Cardiac failure 
• Sudden death at home- presumed cardiac 
• Cerebrovascular accident  
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4.2.4 Statistical methods 
Data are described as mean (±standard deviation) for normally distributed data or 
median (interquartile range) for non-normal data. Comparisons between patients who 
died and those that did not were performed by Student’s t test (for normal data), 
Mann-Whitney U test (for non-normal data), Chi squared test or Fisher’s exact test 
as appropriate.  
 
Survival data including survival time (mean± standard deviation) are shown as 
Kaplan-Meier curves (with statistical comparison using the log rank test). These data 
were also analysed by Cox multivariate survival analysis to assess the influence of 
multiple clinical and cardiac variables on death. A transplant censored survival 
analyses was performed to remove the beneficial effect of renal transplantation on 
outcome (201;202). Variables identified as significantly influential on outcome by 
Cox univariate analysis were entered into a backward stepwise regression model. 
Left ventricular abnormalities (LVH, LVSD and LV dilatation) or the “number of 
abnormalities present” were entered individually into the model due to significant 
interdependence between these variables. All analyses were performed using SPSS 
v15.0 (SPSS Inc, Illinois, USA).  
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4.3 RESULTS 
 
4.3.1 Patients demographics 
Patient demographics are shown in Table 4.1.  Between 1st January 2002 and 31st 
August 2009, 446 were recruited into the study.  Mean age was 53.0±11.8years.  
Two hundred and thirty nine (53.6%) were receiving thrice weekly maintenance 
haemodialysis, 62 (13.9%) were on peritoneal dialysis, 134 (30.0%) were pre-
dialysis (i.e. within 6 months of requiring renal replacement therapy), and 11 (2.5%) 
had failing renal transplants.  The total follow up time was 7.6 years (median 4.0 
years IQR 1.5, 5.7).   
 
One hundred and fifty six patients (35.0%) had normal cardiac structure and 
function.  Two hundred and seventy six patients (61.9%) had LVH, 85 (19.0%) had 
LVSD and 62 (13.9%) had LV Dilatation on CMR (Figure 4.1).  The accumulation 
of these abnormalities was examined, 194 (43.5%) had one abnormality and 96 
(21.5%) had 2 or 3 abnormalities.  LVH only was the commonest single abnormality 
present (n=183, 41% of all patients) with only 11 (2.5%) patients having LVSD 
alone.  Fifty nine (13.2%) patients had two abnormalities and 37 (8.3%) had all 
three. 
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Variable 
 
Total 
N=446 
% or ±SD 
Deaths 95 (21.3) 
Transplants 114 (25.6) 
Age (years) 53.0 (±11.8) 
Male (%) 297 (66.6) 
Body Mass Index (kg/m2) 26.1 (±5.1) 
    
Primary  Renal  Diabetic Nephropathy 98 (22.0) 
Diagnosis ADPCKD 50 (11.2) 
 Glomerulonephritis 88 (19.7) 
 Pyelonephritis 41 (9.2) 
  Renovascular disease 29 (6.5) 
 Unknown/Other 140 (31.4) 
Systolic BP (mmHg) 140.3 (±24.6) 
Diastolic BP (mmHg) 81.8 (±13.2) 
RRT time (years) 1.0 (2.1) 
RRT Haemodialysis 239 (53.6) 
 Peritoneal dialysis 62 (13.9) 
 Pre-dialysis 134 (30.0) 
 Failing Renal Transplant 11 (2.5) 
Diabetes mellitus 147 (32.9) 
Ischaemic Heart Disease 90 (20.2) 
Hypertension 412 (92.3) 
Cerebrovascular disease 41 (9.2) 
Peripheral vascular disease 42 (9.4) 
Smoking Never 219 (49.1) 
 Current 125 (28.0) 
 Ex 102 (22.9) 
Dylipidaemia 195 (43.7) 
Ischaemic ECG 151 (33.9) 
Ejection Fraction (%) 64.9 (±13.3) 
Myocardial mass/BSA  96.0 (±33.4) 
EDV/BSA (ml/ m2) 74.5 (±31.1) 
ESV/BSA (ml/ m2) 28.2 (23.0) 
LVSD (EF<55%) 85 (19.0) 
LVH  276 (61.9) 
LV dilatation 62  (13.9) 
Number of abnormalities 0 156 (35.0) 
 1 194 (43.5) 
 2 or 3 96 (21.5) 
    
Haemoglobin (g/dL) 11.5 (±1.7) 
Adjusted Calcium (mmmol/l) 2.38 (±0.3) 
Serum Phosphate (mmmol/l) 1.64 (±0.5) 
Calcium Phosphate Product (mmol2/l2) 3.88 (±1.2) 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4.1 Clinical, blood and cardiac information for patients.   
Data are number with percentage in parentheses or mean ± standard deviation except 
renal replacement time and CRP where median and interquartile range are used.   
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Figure 4.1  Distribution of abnormalities in patient cohort 
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4.3.2 Patient survival- all cause mortality 
There were 95 (21.3%) deaths during the follow up period.  Eighteen deaths 
occurred after transplantation.  Figure 4.2 shows the causes of death.  CV causes 
accounted for 53 (55.8%) deaths, with infective and malignant causes recorded for 
29 (30.5%) and 5 (5.3%) respectively.  The cause of death was unknown or due to 
other causes in 8 (8.4%) of cases. 
 
Comparisons between patients who were alive and dead at the end of the study are 
shown in Table 4.2.  Patients who died during the study were significantly older, and 
more likely to have a past medical history of diabetes mellitus, ischaemic heart 
disease and cerebrovascular disease.  In addition, patients who died had significantly 
poorer LV systolic function and more likely to have LV dilatation on CMR and an 
abnormal screening ECG. There were fewer transplants and a lower mean diastolic 
blood pressure in the group that died, but this did not reach statistical significance.  
Patients with 2 or more abnormalities were more likely to die during follow up. 
 
Transplant censored survival analyses were performed by removing transplant 
recipients from the study at the time of operation.  This was performed to account for 
the beneficial effect of renal transplantation on outcome. Patient survival was not 
significantly affected by the presence of LVH on CMR (Figure 4.3a).  However, 
presence of LVSD and LV dilatation were significantly associated with reduced 
mean patient survival (Figure 4.3b and 4.3c respectively).  Furthermore, presence of 
2 or more cardiac abnormalities was significantly associated with poorer survival 
compared to patients with normal hearts or 1 abnormality (figure 4.3d). Survival was 
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poorer in patients with 3 abnormalities compared to 2 (mean survival times 2 
abnormalities 6.4±2.0y vs. 3 abnormalities 4.8±3.1y; p=0.01, graph not shown). 
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Figure 4.2 Pie Chart showing causes of death.  Cardiovascular death is the 
commonest cause of death in this cohort. 
Cardiovascular
55.8%
Infective
30.5%
Malignancy
5.3%
Other/Unknown
8.4%
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Variable 
 
Alive 
N=351 
Dead 
N=95 
p 
Transplants 96 (27.4) 18 (18.9) 0.09 
Age (years) 52.1 (±11.9) 56.3 (±10.8) <0.01 
Male (%) 238 (67.7) 59(62.1) 0.30 
BMI (kg/m2) 26.1 (±4.9) 25.7 (±4.7) 0.25 
Primary Renal Diagnosis    
   Diabetic Nephropathy 73 (20.8) 25 (26.3) 0.36 
 ADPCKD 37 (10.5) 13 (13.7)  
 Glomerulonephritis 72 (20.5) 16 (16.8)  
 Pyelonephritis 37 (10.5) 4 (4.2)  
 Renovascular disease 23 (6.6) 6 (6.3)  
 Unknown/Other 109 (31.1) 31 (32.6)  
Systolic BP (mmHg) 141.1 (±24.8) 137.4 (24.1) 0.22 
Diastolic BP (mmHg) 82.5 (13.2) 80.8 (12.6) 0.09 
RRT Time (HD and PD only) 1.5 (4.3) 1.9 (4.4) 0.51 
RRT HD 190 (54.1) 49 (51.6)  
 PD 44 (12.5) 18 (18.9) 0.37 
 Predialysis 107 (30.5) 27 (28.4)  
 Failing Trans. 10 (2.8) 1 (1.1)  
Diabetes mellitus 105 (29.9) 42 (44.2) 0.03 
Ischaemic Heart Disease 61 (17.4) 29 (30.5) 0.01 
Hypertension 321 (91.5) 91 (95.8) 0.16 
Cerebrovascular disease 27 (7.7) 14 (14.7) 0.04 
Peripheral vascular disease 34 (9.7) 8 (8.4) 0.71 
Smoking Never 172 (49.0) 47 (49.5)  
 Current 99 (28.2) 26 (27.4) 0.99 
 Ex 80 (22.8) 22 (23.2)  
Dyslipidaemia 151 (43.0) 43 (45.3) 0.70 
Abnormal ECG 108 (30.8) 43 (45.3) <0.01 
CMR Ejection Fraction (%) 65.6(±12.5) 62.3(±15.3) 0.02 
Findings Myocardial mass/BSA 95.2 (±33.5) 97.2 (±33.1) 0.67 
 EDV/BSA (ml/ m2) 73.5 (±30.5) 78.4 (±33.5) 0.18 
 ESV/BSA (ml/ m2) 27.0(±21.2) 32.8(±28.5) 0.07 
 LVSD(EF<55%) 60 (17.1) 25 (26.3) 0.04 
 LVH 211 (60.1) 65 (68.4) 0.14 
 LV dilatation 43 (12.3) 19 (20) 0.05 
Number of abnormalities 0 127 (35.2) 29 (30.5)  
 1 155 (44.1) 39 (41.1) 0.02 
 2 or 3 69(19.7) 27(28.4)  
Haemoglobin (g/dL) 11.5 (±1.7) 11.3(±1.5) 0.24 
Adjusted Calcium (mmmol/l) 2.38 (±0.3) 2.37(±0.2) 0.87 
Serum Phosphate (mmmol/l) 1.66 (±0.5) 1.70(±0.5) 0.61 
Calcium Phosphate Product (mmol2/l2) 3.94 (±1.2) 1.70 (±0.5) 0.53 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
Table 4.2 Comparison between patients alive or dead at the end of the 
study.  
Data are number with percentage in parentheses or mean ± standard deviation except 
for RRT time where median and interquartile range and shown. Tests of significance 
are t-test and Chi-square except RRT time where Mann-Whitney U Test is 
performed. 
166 
 
Figure 4.3a Mean survival: No LVH (n=170) 6.5 ±2.5y vs. LVH (n=276) 6.3 
±2.7y; p=0.56.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure demonstrating no significant difference in survival between patients with and 
without LVH 
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Figure 4.3b Mean survival: No LVSD (n=361) 6.5 ±2.5y vs. LVSD (n=85) 5.6 
±3.2y; p=0.01 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure demonstrating association of LVSD with reduced patient survival. 
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Figure 4.3c Mean survival: No LV Dilatation (n=384) 6.5 ±2.5y vs. LV 
Dilatation (n=62) 5.7 ±2.9y; p=0.04.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure demonstrating association of LV dilatation with reduced patient survival. 
 
 
 
 
 
 
 
 
LV Dilatation 
No LV Dilatation 
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Figure 4.3d Mean survival for number of abnormalities:  None (n=156) 6.6 
±2.2y, 1 abnormality (n=94) 6.6 ±2.5y, 2or 3 abnormalities (n==97) 5.6 ±3.0y  
 
 
Figure demonstrating reduction in survival of patients with higher frequency of 
cardiac abnormalities 
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A Cox backward stepwise regression model was performed to indentify the most 
robust model for transplant censored patient survival (Table 4.3).  Increasing age, 
past history of ischaemic heart disease and presence of LVSD on CMR were 
significant independent predictors of death.  In Chapter 3, it was shown that 
combinations of myocardial abnormalities are often present.  To this end, the number 
of abnormalities was entered into the multivariate model, as opposed to the 
abnormality present.  Similarly, older age, clinical history of ischaemic heart disease 
and presence of 2 or 3 abnormalities independently predicted poorer survival. 
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Table 4.3 Results of univariate and multivariate Cox regression survival 
analyses of all patients screened; all-cause mortality is the dependable variable 
Hazard ratios (95% confidence intervals) are shown.  Alternative model with 
individual LV abnormalities entered is also shown. 
 
† Multivariate model when number of abnormalities replaced by LVSD and LV Dilatation 
Variable HR 95% CI p 
Age (per year) 1.05 1.13,3.27 <0.01 
Ischaemic Heart Disease 1.59 0.95,2.69 0.07 
LVSD (EF<55%) 2.10 1.23,3.43 <0.01 
LV dilatation   NS 
 
 Univariate Analyses Multivariate Analyses 
Variable HR 95% CI p HR 95% CI p 
Age (per year) 1.05 1.02, 1.07 <0.01 1.05 0.97, 1.07 <0.01 
Ischaemic Heart Disease 2.18 1.35,3.51 <0.01 1.63 1.07, 2.72 0.05 
No. of  0 1.00   1.00   
abnormalities 1 0.75 0.52, 1.50 0.75 1.01 0.57, 1.76 0.88 
 2 or 3 1.97 1.12,3.43 0.01 1.98 1.09, 3.58 0.02 
LVSD (EF<55%) 2.02 1.23,3.32 <0.01 †   
LV dilation 1.72 1.01, 2.96 0.05 †   
Abnormal ECG 1.99 1.27,3.11 <0.01    
BMI (per kg/m2) 0.98 0.94,1.02 0.99    
Systolic BP (per mmHg) 0.82 0.99,1.01 0.82    
Diastolic BP (per mmHg) 0.99 0.97,1.01 0.10    
RRT Time (per year) 1.03 0.91,1.18 0.62    
RRT HD 1.00      
 PD 1.83 1.02,3.30 0.06    
 Predialysis 1.17 0.67,1.97 0.55    
 Failing Trans. 0.46 0.06,3.36 0.44    
Diabetes mellitus 1.29 0.78,2.10 0.30    
Hypertension 1.27 0.47,3.50 0.64    
Cerebrovascular disease 1.72 0.80,3.67 0.16    
Peripheral vascular disease 0.75 0.29,1.92 0.55    
Smoking Never (ref) 1.00      
 Current 1.05 0.60,1.83 0.86    
 Ex 0.93 0.48,1.77 0.82    
Dyslipidaemia 1.33 0.88,2.09 0.21    
Ejection fraction (per %) 0.98 0.96, 1.03 0.87    
LVMI (per g/m2) 1.00 0.98,1.01 0.40    
EDV/BSA (per ml/ m2) 0.99 0.99, 1.06 0.27    
ESV/BSA (per ml/ m2) 1.03 0.99,1.05 0.12    
LVH  1.23 0.79, 2.05 0.32    
Haemoglobin (per g/dL) 0.94 0.78, 1.14 0.56    
Adjusted Calcium (per mmmol/l) 1.04 0.01, 4.50 0.99    
Serum Phosphate (per mmmol/l) 0.87 0.01, 7.04 0.89    
CaPO4 Product (per mmol2/l2) 1.04 0.40, 12.6 0.96    
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4.3.3 Patient Survival- cardiovascular mortality 
Similar survival analyses were performed to better define variables associated with 
transplant censored CV mortality only.  There were 53 CV deaths during the follow 
up period.  Six of these deaths occurred after renal transplantation and thus were 
censored at the time of transplantation. 
 
Table 4.4 shows comparison of patients who experienced CV death compared to 
those who died due to other causes or were alive at the end of the study.  As before, 
CV death was significantly more common in older patients and those with a history 
of ischaemic heart disease and diabetes mellitus.  In addition, patients who died from 
CV causes were more likely to have an abnormal screening ECG, and were more 
likely to demonstrate poorer LV function, LVH and LV dilatation on CMR.  CV 
death was significantly associated with 2 or more cardiac abnormalities.  There were 
no significant differences in the presence of other CV risk factors assessed 
(hypertension, cerebrovascular and peripheral vascular disease, dyslipidaemia and 
smoking history).  
 
Transplant censored survival analyses demonstrated significantly poorer CV survival 
when LVH, LVSD and LV dilatation were present on CMR at the time of 
recruitment into the study (Figure 4.4 a, b, c respectively).  Similarly, survival was 
significantly reduced when 2 or all 3 abnormalities were present.  Presence of a 
single abnormality did not significantly affect CV death (Figure 4.4d).  CV survival 
was poorer in patients with 3 abnormalities compared to 2 but this did not reach 
statistical significance (mean survival times 2 abnormalities 6.8±2.1y vs. 3 
abnormalities 5.8±2.8y; p=0.07, graph not shown). 
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Variable 
 
Alive/Non CV 
Death 
N=393 
CV Death 
N=53 
p 
Transplants 106 (27.0) 8 (15.1) 0.06 
Age (years) 52.5 (±11.9) 56.6 (±10.2) 0.02 
Male (%) 256 (65.1) 41(77.4) 0.08 
BMI (kg/m2) 25.9 (±4.9) 25.9 (±4.8) 0.92 
Primary Renal Diagnosis    
   Diabetic Nephropathy 84 (21.4) 14 (26.4) 0.12 
 ADPCKD 43 (10.9) 7 (13.2)  
 Glomerulonephritis 77 (19.6) 11 (20.8)  
 Pyelonephritis 41 (10.4) 0  
 Renovascular disease 26 (6.6) 3 (5.7)  
 Unknown/Other 122 (31.0) 18 (34.0)  
Systolic BP (mmHg) 140.8(±24.7) 137.0 (±24.3) 0.32 
Diastolic BP (mmHg) 82.1(±13.1) 79.6(±13.7) 0.21 
RRT Time (HD and PD only) 1.6(4.3) 1.4(4.5) 0.51 
RRT HD 211 (53.7) 38 (52.8)  
 PD 53 (13.5) 9 (17.0) 0.59 
 Predialysis 118 (30.0) 16 (32.0)  
 Failing Trans. 11 (2.8) 0  
Diabetes mellitus 117 (29.8) 30 (56.6) 0.04 
Ischaemic Heart Disease 70 (17.8) 20 (37.7) <0.01 
Hypertension 361 (91.9) 51 (96.2) 0.26 
Cerebrovascular disease 35 (8.9) 6 (11.3) 0.57 
Peripheral vascular disease 36 (9.2) 6 (11.3) 0.61 
Smoking Never 194 (49.4) 25 (47.2) 0.58 
 Current 112 (28.5) 13 (24.5)  
 Ex 87 (22.1) 15 (28.3)  
Dyslipidaemia 169 (43.0) 25 (47.2) 0.57 
Abnormal  ECG 124 (31.6) 27 (50.9) <0.01 
Ejection Fraction (%) 65.7 (±12.6) 58.7 (±16.4) <0.01 
Myocardial mass/BSA  95.3(±33.2) 101.5 (±4.7) 0.20 
EDV/BSA (ml/ m2) 73.4 (±30.4) 83.0(±32.7) 0.04 
ESV/BSA (ml/ m2) 26.9 (±21.1) 38.3 (±32.7) 0.02 
LVSD (EF<55%) 69 (17.6) 16 (30.2) <0.01 
LVH  236 (60.1) 40(75.5) <0.01 
LV dilatation 48 (12.2) 14 (26.4) <0.01 
Number of abnormalities 0 144 (36.6) 12 (22.6) <0.01 
 1 171 (43.5) 23 (43.4)  
 2 or 3 78 (19.8) 18 (33.9)  
Haemoglobin (g/dL) 11.5 (±1.7) 11.3(±1.6) 0.33 
Adjusted Calcium (mmmol/l) 2.37 (±0.2) 2.37 (±0.2) 0.78 
Serum Phosphate (mmmol/l) 1.67 (±0.5) 1.65 (±0.4) 0.80 
Calcium Phosphate Product (mmol2/l2) 3.97 (±1.2) 3.93(±1.1) 0.88 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4.4 Comparison between patients who experienced CV death and 
those who did not at the end of the study. 
Data are number with percentage in parentheses or mean ± standard deviation except for RRT time 
where median and interquartile range and shown. 
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Figure 4.4a Mean survival: No LVH 7.2±1.3y vs. LVH 6.8±2.1y; p=0.05. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure demonstrating reduction in CV survival of patients with LVH 
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Figure 4.4b Mean survival: No LVSD 7.2 ±1.3y vs. LVSD 6.1±2.8y; p<0.001 
 
Figure demonstrating reduction in CV survival of patients with LVSD 
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Figure 4.4c Mean survival: No LV Dilatation 7.1±1.6y vs. LV Dilatation 
6.2±2.6y; p=0.003 
 
 
Figure demonstrating reduction in CV survival of patients with LV dilatation 
LV dilatation 
No LV dilatation 
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Figure 4.4d Mean survival for number of abnormalities:  None= 7.3±1.3y, 1 
abnormality = 7.1±1.7y, 2 or 3 abnormalities= 6.4±2.5y; p=0.002. 
 
 
Figure demonstrating reduction in CV survival of patients with higher frequency of 
cardiac abnormalities 
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As before, a Cox backward stepwise regression model was performed to identify 
factors associated with transplant censored CV survival (Table 4.4).  Increasing age, 
past history of ischaemic heart disease and presence of LV dilatation on CMR were 
significant independent predictors of CV death.  When entering number of 
abnormalities into the multivariate model, older age and presence of 2 or 3 
abnormalities independently predicted CV death. 
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Table 4.4  Results of univariate and multivariate Cox regression survival 
analyses of all patients screened; CV mortality is the dependable variable. 
 
Hazard ratios (95% confidence intervals) are shown.  Alternative model with individual 
LV abnormalities (**) entered are also shown 
 
 
 Univariate Analyses Multivariate Analyses 
Variable HR 95% CI p HR 95% CI p 
Age (per year) 1.05 1.02,1.08 <0.01 1.06 1.03,1.09 <0.01 
No. of  0 1.00   1.00   
abnormalities 1 1.43 0.64,3.18 0.387 1.46 0.65, 3.26 0.36 
 2 or 3 3.39 1.53,7.51 <0.01 3.80 1.71, 8.41 <0.01 
Ischaemic Heart Disease 2.18 1.19,3.99 0.01    
LVSD (EF<55%) 2.77 1.51,5.10 <0.01 **   
LV dilatation 2.51 1.32,4.78 <0.01 **   
Ejection Fraction (per %) 0.96 0.95, 0.98 <0.01    
Abnormal ECG 2.00 1.12,3.56 0.02    
ESV/BSA (per ml/ m2) 1.04 1.01, 1.06 <0.01    
LVH  2.00 0.99,4.03 0.05    
BMI (per kg/m2) 1.02 0.96, 1.08 0.53    
Systolic BP (per mmHg) 1.00 0.98, 1.02 0.72    
Diastolic BP (per mmHg) 0.99 0.96, 1.02 0.57    
RRT Time (per year) 0.99 0.92,1.05 0.66    
RRT HD 1.00      
 PD 1.26 0.57, 2.81 0.56    
 Predialysis 1.07 0.55, 2.09 0.85    
 Failing Trans. 0.98 0.46, 2.07 0.97    
Diabetes mellitus 0.94 0.52, 1.71 0.84    
Hypertension 1.39 0.34, 5.76 0.65    
Cerebrovascular disease 1.36 0.54, 3.45 0.51    
Peripheral vascular disease 1.70 0.67, 4.31 0.27    
Smoking Never (ref) 1.00      
 Current 1.06 0.53, 2.15 0.87    
 Ex 1.07 0.53, 2.16 0.86    
Dyslipidaemia 1.40 0.78, 2.51 0.26    
LVMI (per g/m2) 1.01 0.97, 1.02 0.34    
EDV/BSA (per ml/ m2) 1.98 0.96, 2.08 0.71    
LV dilatation       
Haemoglobin (per g/dL) 0.77 0.56, 1.07 0.11    
Adjusted Calcium (per mmmol/l) 0.45 0.08, 2.67 0.38    
Serum Phosphate (per mmmol/l) 0.69 0.30,1.59 0.38    
CaPO4 Product (per mmol2/l2) 0.89 0.62, 1.27 0.51    
 
 
  
  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
**  Multivariate model when number of abnormalities replaced by LVSD and LV Dilatation 
 
 
 
Variable HR 95% CI p 
Age (per year) 1.05 1.02, 1.08 0.001 
Ischaemic Heart Disease 1.89 1.01, 3.46 0.04 
LVSD (EF<55%)   NS 
LV dilatation 2.46 1.27, 4.78 0.008 
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4.5 DISCUSSION 
 
The determinants of uraemic cardiomyopathy were described in Chapter 3.  The 
development of LV abnormalities was described as a process initiated and 
perpetuated by elevated cardiac preload and afterload which are very common in 
ESRD patients due to fluid overload, vascular calcification and systemic 
hypertension.  Furthermore, due to these persistent cardiac stressors it was very 
common for ESRD patients to have more than one LV abnormality presumably 
representing different stages in the patho-physiological process.   The rationale of 
therapeutic intervention would be to disrupt this process thus halting and/or 
reversing abnormalities and improving CV outcome in ESRD patients. 
 
The aim of this study was to investigate the effect of myocardial abnormalities 
detected by CMR on CV survival in ESRD patients.  Although, similar studies have 
demonstrated reduced survival in ESRD patients with LVH, LVSD and LV 
dilatation detected by echocardiography, no such long term outcome data are 
available for measurements recorded by CMR.   
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4.5.1 Uraemic cardiomyopathy and outcome 
Examining the cohort as a whole, there were only 95 deaths (21.3%) deaths over a 
median follow up time of 4.0 (IQR 4.2) years.  This mortality rate was lower 
compared to other studies investigating outcome in all ESRD patients where rates 
between 30-50% have been observed over a similar follow up time.  However, the 
patients of this cohort were referred for CV assessment as part of their preparation 
for renal transplantation and thus were deemed fit enough by their referring 
nephrologist to undergo renal transplantation.  Other studies in the pre-transplant 
group have demonstrated similar rates of death on follow up (203).  As in other 
studies, transplant censored survival was assessed for all cause and CV mortality to 
remove the beneficial bias conferred by renal transplantation from the analyses 
(134;167).   
 
4.5.2 LVH and outcome 
These data demonstrate that presence of LVH and elevated LVMI were not 
significantly associated with higher all cause mortality. In addition, presence of LVH 
was not associated with reduced survival times and did not independently predict all 
cause mortality on Cox proportional survival analyses.  Although, presence of LVH 
was significantly associated with a higher CV mortality and significant reduction in 
CV survival, multivariate Cox survival analyses did not demonstrate LVH as 
independent predictors of CV death.  
 
This result was unexpected given previous published data demonstrating elevated 
LV mass and presence of LVH as significant predictors of all cause and CV 
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mortality in ESRD patients (47;48).   There are a number of reasons for these 
discrepancies of results. 
 
Previous studies have used M Mode echocardiography to assess LV mass and 
chamber size.  LVH has been reported to be present in 50-80% of patients with 
ESRD.  The methodological inconsistencies of echocardiography, particularly at 
higher LVMI (>120g/m2) have been highlighted previously.  Parfrey et al (47) 
performed a large prospective trial in 432 patients initiating dialysis therapy and their 
echocardiography results compared to these data are shown in Table 4.5. 
 
 Parfrey et al (%) 
Echocardiography 
These Data (%) 
CMR 
Normal 16 35 
LVH 41 (concentric) 61.9 
LVSD 15 19 
LV Dilatation 28 
(preserved LV function) 
13.9 
7.6% with preserved LV 
function 
 
Table 4.5  Comparison between Parfrey et al and these data. 
 
These differences highlight the importance of hydration status on timing of cardiac 
scanning.  When echocardiography is used, identification of chamber borders can be 
inaccurate especially in fluid overloaded patients, and errors in calculation of 
chamber size and LV mass magnified due to the computations performed. As a 
result, there is a greater likelihood for patients to be incorrectly classified as having 
LVH (when LV mass is overestimated) or LV dilatation (when end diastolic 
chamber size is overestimated). CMR data presented here demonstrate a much larger 
proportion of patients with normal cardiac structure and fewer patients with LV 
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dilatation compared to echocardiography data.   It should be noted that no formal 
distinction between eccentric and concentric LVH was made.  
 
Serial echocardiography has provided some insight into the effect of worsening 
cardiac changes and patient outcome.  Paoletti et al demonstrated that progression of 
LVH is a much stronger predictor of sudden cardiac death than the absolute value of 
LVMI at inception echocardiogram (89).  It is most likely that these studies included 
ESRD subjects with chronic fluid overload and in the future, repeat CMR of patients 
in this cohort may help to support this hypothesis. 
 
In summary, although presence of LVH has a statistically significant effect on CV 
survival in this study, it did not have as great an effect as has previously been 
demonstrated in echocardiography studies. 
 
4.5.3 LVSD and outcome   
From previous late gadolinium enhanced CMR studies of ESRD patients, LVSD has 
been significantly associated with (usually silent) ischaemic heart disease. As 
described in Chapter 3, micro- and macrovascular coronary disease, which are very 
common in ESRD patients, are significant causes of myocardial ischaemia and 
subsequent LVSD.   
 
These data confirm previous echocardiography studies demonstrating a significantly 
poorer survival (all cause and cardiovascular) in patients with impaired LV function.  
The determinants of LVSD have previously been described in Chapter 3.  
Interestingly presence of LVSD was a significant predictor of all cause, but not 
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cardiovascular, mortality independent of a past clinical history of ischaemic heart 
disease (Tables 4.3 and 4.4) and is most likely due to: 
• Presence of LVSD also being associated with higher risk of non cardiac causes of 
death.  This has been demonstrated before (188;204), and is due to the close 
association of LVSD with other co-morbidities including peripheral and 
cerebrovascular disease and diabetes mellitus in the absence of clinically apparent 
ischaemic heart disease (139). 
• A close association between clinical history of ischaemic heart disease and LVSD in 
patients who died from CV causes thus removing independent associations on 
multivariate Cox survival modelling.  
 
Nonetheless, these data demonstrate a significantly poorer survival, including CV 
survival, in patients with LVSD on CMR. 
 
4.5.4 LV dilatation and outcome 
From these data, presence of LV dilatation was associated with significantly reduced 
all cause and CV survival.  Presence of LV dilatation also independently predicted 
CV death adjusted for age and past history of ischaemic heart disease. As has been 
discussed previously in this thesis, LV dilatation is independently associated with 
LVSD and chronic fluid overload (represented by elevated mean doses of 
ultrafiltration in haemodialysis patients) in the absence of an adequate compensatory 
increase in LV mass.  LV dilatation has previously been independently associated 
with poorer prognosis in ESRD patients (134).  In particular, in patients with 
established LV dilatation and preserved systolic function, survival has been shown to 
be worse in patients with higher LV cavity volumes and inadequate compensatory 
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increase in LV mass.    Moreover, isolated LV dilatation was not recorded in any 
patients from this cohort, and it is likely that LV dilatation is a marker of significant 
global LV disease thus explaining poor CV outcome in patients who develop this 
abnormality. 
 
4.5.5 Accumulation of myocardial abnormalities and outcome 
Unsurprisingly, patients who had two or more cardiac abnormalities had poorer all 
cause and CV survival. In addition, number of cardiac features independently 
predicted all cause and CV mortality in ESRD patients.  The presence and number of 
cardiac abnormalities were not entered simultaneously into the Cox survival model 
due to their close association.  Survival (from all and CV causes) was also worst in 
patients with all 3 abnormalities compared to those with a combination of two (LVH 
and LVSD, LVH and LV dilatation or LVSD and LV dilatation).   
 
Presence of one abnormality did not have a significant effect on Kaplan Meier or 
Cox multivariate survival analyses.  LVH accounted for 94% of patients with one 
abnormality and this reflects our earlier finding that LVH did not have as significant 
an influence on survival of ESRD patients as previously demonstrated.  It would be 
interesting in the future to repeat this analysis using more patients with isolated 
LVSD.  
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4.5.6 Potential targets for intervention  
The main aim of this study was to determine whether features of uraemic 
cardiomyopathy measured by CMR had an effect on patient CV outcome.  In 
addition, by identifying poor prognostic features it allows targeting of potential 
therapeutic interventions. 
 
As discussed in Chapter 3, it is likely that the development of cardiac abnormalities 
is progressive and accounts for the common finding of more than one abnormality in 
ESRD patients. Thus to reverse these abnormalities and improve CV prognosis, 
interventions should be aimed at reducing cardiac preload and afterload (i.e. 
hypertension, fluid overload, vascular calcification) that propel the 
pathophysiological process.   Early studies, investigating the effect of 
pharmacological and dialysis interventions on myocardial structure and function 
have been described in Chapter 3. 
 
Myocardial structure has been shown to change even in milder stages of CKD and 
continue to progress as renal function deteriorates (170; 173). Given that the 
prognosis in this study was not significantly different between patients with normal 
hearts and one abnormality, aggressively targeting patients at an early stage to 
prevent progression to more than one structural change may be beneficial.  It is 
essential that measures employed to prevent development or reverse LVH, LVSD 
and LV dilatation in ESRD patients be employed early.   Furthermore, slowing or 
regressing these abnormalities has not been convincingly achieved using adequately 
powered, randomised controlled studies and it is still not known whether 
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intervention will improve CV outcome.  This study will hopefully provide data to 
power such studies in the future. 
 
4.5.7 Limitations of current study 
There were differences, particularly in mortality rates between these and previously 
published data.  As stated previously, this is most likely due to recruitment from the 
pre-transplant population.  However, it is likely that these results are relevant to 
other CKD 5 patients with more significant co-morbidities. 
 
4.6 CONCLUSIONS 
In conclusion, LVSD and LV dilatation detected by CMR are associated with higher 
all cause and CV mortality in ESRD patients.  Although LVH significantly reduces 
cardiovascular survival, this is not to the extent suggested by echocardiography 
studies in this patient group.  Although presence of one cardiac abnormality did not 
significantly affect survival, accumulation of two or more cardiac abnormalities was 
associated with a significantly poorer prognosis.  These findings suggest that 
measures should be assessed to aggressively reverse these changes and improve 
cardiovascular outcome in ESRD patients. 
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Chapter 5 
 
A study of determinants of mortality in ESRD patients with LVH: the role of 
left atrial volume. 
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5.1 INTRODUCTION 
 
As previously mentioned, echocardiography studies have identified abnormalities in 
left ventricular structure and function, termed “uraemic cardiomyopathy”, that 
independently confer a poorer prognosis in ESRD patients (47).  
 
Of these, left ventricular hypertrophy is present in approximately 67% of patients 
with ESRD and the most common manifestation of uraemic cardiomyopathy. 
Moreover, it is an independent risk factor for sudden cardiac death, heart failure, and 
cardiac arrhythmias in both the general population and patients receiving 
haemodialysis. The presence of LVH alone has a variable prognosis. Furthermore, 
reversal of LVH in ESRD patients has proven difficult and attempts have been made 
to identify additional cardiac abnormalities that predict death and are amenable to 
intervention (53;205;206).  
 
The strengths of CMR over echocardiography to assess LV mass in ESRD have been 
described in Chapter 1.  In addition, elevated left atrial (LA) volume (corrected for 
body surface area (BSA) or height) is an independent predictor of mortality in the 
general population, and in hypertensive and ESRD patients, when measured by 
echocardiography (207;208). Causes of increased left atrial volume (LAV) in ESRD, 
include mitral valve disease, fluid overload and impaired left ventricular diastolic 
relaxation and filling (called LV diastolic dysfunction) (209).  LAV can be reliably 
and reproducibly measured on echocardiography and CMR using the biplane area-
length method described in Chapter 2 (155;156).   
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The aim of this prospective study was to accurately identify a cohort of ESRD 
patients with LVH on CMR and to identify additional features that would confer 
poorer survival.  Given the findings from previous studies, LAV was included in the 
analyses.  
 
5.2 METHODS 
 
5.2.1 Patients 
ESRD patients were recruited from the renal transplant assessment clinic from the 
Western Infirmary as described in Chapter 2.  Haemodialysis data, including doses 
of ultrafiltration, were recorded at 30 day intervals up to 180 days prior to CMR.  
Only patients with evidence of LVH on CMR were entered into the study.  All 
patients were in sinus cardiac rhythm at the time of scanning. 
 
To ensure that only non valvular causes of LA dilatation were assessed, patients with 
grade II to IV mitral valve regurgitation (i.e. greater than mild) on colour Doppler 
echocardiography were excluded from the study.  Severity of mitral valve 
incompetence was assessed using American Heart Association/ American College of 
Cardiology criteria of (210): 
• Colour Doppler jet area. 
• Vena contracta diameter (defined as point in a fluid stream where the diameter of the 
stream is the least). 
 
To obtain a large cohort of patients and achieve greater statistical power, previous 
CMR scans (n=46) performed by Dr Patrick Mark were added to current studies.  
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These scans, however, were analysed separately by the investigator (RKP) who was 
blinded to patients’ characteristics and outcome.   
 
5.2.2 CMR acquisition and analyses 
CMR scans were acquired as part of assessment of LV mass and function and 
analysed as previously described.  In addition, LAV was measured using the bi-plane 
area length method for ellipsoid bodies which was previously described in Chapter 2. 
 
5.2.3 Mitral valve inflow Doppler velocity measurement 
Echocardiography was performed by an experienced echocardiographer (Tony 
Cunningham, Clinical Research Iniative, Western Infirmary, Glasgow).  Diastolic 
function was assessed using pulsed-wave Doppler (211;212) from apical four 
chamber views to measure the ratio of early (E) to late (A) mitral inflow peak flow 
velocity (E/A ratio). 
 
5.2.4 Follow up 
Patient follow up data were collected from the date of CMR scan to the 30th 
September 2009 from the electronic patient records of the Western Infirmary, 
Glasgow and Glasgow Royal Infirmary Renal units.  Death from all causes was the 
study end point. 
 
5.2.5 Statistical methods 
Data are described as mean and standard deviation (for normally distributed data) or 
median (interquartile range) for non-normal data. Comparisons were made between 
those patients with high or low LAV by student’s t test (for normal data), Mann-
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Whitney U test (for non-normal data) and Chi squared test or Fisher’s exact test.  
Survival data including survival time (mean± standard deviation) are shown as 
Kaplan-Meier graphs (with statistical comparison using the log rank test). These data 
were also analysed by Cox multivariate survival analysis to assess the influence of 
multiple clinical and cardiac variables on outcome. This study included transplant 
censored survival analyses. Variables identified as significantly influential on 
outcome by univariate analysis were entered into a backward stepwise regression 
model. All analyses were performed using SPSS v15.0 (SPSS Inc, Illinois, USA).  
 
5.3 RESULTS 
 
5.3.1 Patient demographics 
From 312 ESRD patients assessed for renal transplantation with CMR, 201 patients 
with LVH were identified. Median follow up and transplant censored follow up were 
3.62 years (IQR 1.2- 5.2 years) and 1.69 years (IQR 1.0-3.9 years) respectively. The 
mean age of patients was 51.6 (± 11.8) years; 72.1 % were male. Seventy one 
patients received a renal transplant during the period of study.  Table 5.1 shows the 
mode of renal replacement therapy, past medical history and cardiac drug history.   
 
5.3.2 Cardiac parameters 
Examining the whole cohort (Table 5.1), the mean heart rate during MRI was 77 
beats per minute (±26). Mean ejection fraction was 63.1% (±14.4), LVMI was 
117.3g/m2 (±31.1), EDV/BSA was 86.3 ml/m2 (±31.4) and ESV/BSA was 34.1 
ml/m2 (±25.3). Fifty (24.9%) patients had LVSD and 49 (24.4%) had LV dilatation. 
Doppler mitral valve inflow velocity measurement showed a mean peak E wave 
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velocity of 0.74 cm/s (±0.2), mean peak A wave of 0.75 cm/s (±0.2) and E:A ratio of 
1.04 (±0.5). Median LAV/BSA was 30.4 ml/m 2 (IQR 26.2, 34.1) and distribution of 
corrected LAV measurements is shown in Figure 5.1.   
 
5.3.3 Left atrial volume 
 
5.3.3 (a) Correlates 
There were no significant correlations between LAV and patient age, dialysis 
vintage, LV ejection fraction, LVMI, EDV>BSA, mean dose of ultrafiltration during 
haemodialysis, or E:A ratio. 
 
5.3.3 (b) Comparison dependent on median LAV 
To further identify determinants and consequences of elevated LAV, patients were 
divided into high LAV (≥ median LAV/BSA; n=100) or low LAV (LAV\BSA 
<median; n=101) groups (Table 5.2). There was a significantly higher mortality in 
the high LAV group (low LAV 18 deaths vs.  high LAV 36  deaths; p<0.01). High 
LAV was significantly associated with treatment with higher doses of ultrafiltration 
during haemodialysis.  Low LAV was significantly associated with male sex.  There 
were no significant differences in age, number of patients transplanted, BSA and 
type of renal replacement therapy or duration between high and low LAV groups. 
Furthermore, there were no significant differences in number of patients with 
diabetes mellitus, smoking history and cardiovascular (namely ischaemic heart 
disease, cerebrovascular and peripheral vascular diseases and chronic heart failure) 
history. On comparison of cardiac medications, there were no other significant 
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differences between the low and high LAV groups except for statin usage which was 
higher in the high LAV group. 
 
5.3.3 (c) Predictors of LAV≥ median 
To further identify predictors of elevated LAV, logistic regression analyses were 
performed with LAV/BSA≥ median as the outcome variable.  Female sex and mean 
dose of ultrafiltration during haemodialysis were significant, independent predictors 
(R2=0.27) of high LAV on CMR after logistic regression analyses.  
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Figure 5.1 Distribution of LAV/BSA in patient cohort 
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Table 5.1  Clinical and cardiac information for patients.   
Data are number with percentage in parentheses or mean ± standard deviation. 
Variable 
 
Total 
N=201 
 
Deaths 54 (26.9) 
Transplants 71 (35.3) 
Age (years) 51.6 (±11.8) 
Male (%) 145 (72.1) 
Body Surface Area (m2) 1.76 (±0.2) 
Left Atrial volume (ml) 56.3 (±9.7) 
Systolic BP (mmHg) 136.9 (±24.6) 
Diastolic BP (mmHg) 80.9 (±12.9) 
RRT Haemodialysis 108 (53.7) 
 Peritoneal dialysis 52 (25.9) 
 Predialysis 41 (20.4) 
Mean Ultrafiltration (HD only) 2.3 (±0.9) 
Diabetes mellitus 121 (60.2) 
Ischaemic Heart Disease 54 (26.9) 
Heart failure 12 (6.0) 
Cerebrovascular disease 12 (6.0) 
Peripheral vascular disease 16 (8.0) 
Smoking Never 107 (53.2) 
 Current 54 (26.9) 
 Ex 40 (19.9) 
Epo receptor Agonist 151 (75.1) 
β Adrenoceptor Blocker 87 (43.3) 
Aspirin 83 (41.3) 
Warfarin 7 (3.5) 
ACEI/ARB 54 (26.9) 
Diuretic 60 (29.6) 
Calcium Channel Blocker 58 (28.9) 
α Adrenoceptor Blocker 21 (10.4) 
Statin 83 (41.3) 
Heart Rate  76.8 (±26.1) 
Ejection Fraction (%) 63.1 (±14.4) 
Myocardial mass/BSA  117.3 (±31.1) 
EDV/BSA (ml/ m2) 86.3 (±31.4) 
ESV/BSA (ml/ m2) 34.1 (±25.3) 
LVSD on MRI (EF<55%) 50 (24.9) 
LV dilatation 49 (24.4) 
Peak E wave (cm/s) 0.74 (±0.2) 
Peak A wave (cm/s) 0.75 (±0.2) 
E:A ratio 1.04 (±0.4) 
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Variable 
 
Low LAV 
N=101 
High LAV 
N=100 
p 
Deaths 18(17.1) 36 (36) <0.01 
Transplants 40(39.6) 31(31) 0.20 
Age (years) 50.4(±12.6) 52.8(±10.9) 0.14 
Male (%) 82(81.2) 63(63) <0.01 
LA volume (ml) 50.4(±6.8) 62.3(±8.4) <0.01 
Systolic BP (mmHg) 135.6 (±26.2) 138.4 (±22.8) 0.51 
Diastolic BP (mmHg) 82.2 (±13.5) 79.3 (±12.1) 0.20 
RRT HD 56(55.4) 52(52)  
 PD 23 (22.8) 29(29) 0.58 
 CKD 5 22(21.8) 19(19)  
Mean Ultrafiltration (HD only) 2.2(±0.9) 2.8 (±1.2) 0.01 
Diabetes mellitus 61(60.4) 60 (60)  0.95 
Ischemic Heart Disease 24(23.8) 30(30)  0.41 
Heart failure 6 (5.9) 6(6)  0.96 
Cerebrovascular disease 6(5.9) 6(6)  0.96 
Peripheral vascular disease 6(5.9) 10(10)  0.27 
Smoking Never 56(55.4) 51 (51)  
 Current 23 (22.8) 31 (31) 0.40 
 Ex 22 (21.8) 18 (18)  
Epo receptor Agonist 72 (71.2) 79 (79) 0.10 
β Adrenoceptor Blocker 45 (44.6) 42 (42) 0.81 
Aspirin 38 (37.6) 45(45) 0.23 
Warfarin 4 (4.0) 3 (3) 0.67 
ACEI/ARB 28 (27.7) 26 (26) 0.85 
Diuretic 31(30.7) 29 (29) 0.87 
Calcium Channel Blocker 33 (32.7) 25(25) 0.26 
α Adrenoceptor Blocker 13(12.9) 8 (8) 0.28 
Statin 35 (34.7) 48 (48) 0.05 
Heart Rate  76.3(±26.1) 77.4(±26.1)  0.31  
Ejection Fraction (%) 63.4(±13.9)  62.8(±15.0)  0.77 
Myocardial mass/BSA  115.7 (±29.8)  119.0 (±32.5)  0.44 
EDV/BSA (ml/ m2) 86.9 (±30.5) 85.8 (±32.4) 0.81 
ESV/BSA (ml/ m2) 33.7(±25.0) 34.5 (±25.7) 0.82 
LVSD on MRI (EF<55%) 23 (22.8) 27(27)  0.50  
LV dilatation 23 (22.8)  26(26)  0.59  
Peak E wave (cm/s) 0.77 (±0.2) 0.71 (±0.2) 0.29 
Peak A wave (cm/s) 0.76 (±0.3) 0.72 (±0.2) 0.32 
E:A ratio 1.06 (±0.4) 1.02± (0.4) 0.72 
 
Table 5.2 Comparison between patients according to median LAV/BSA (low < 
median, high ≥ median).  
Data are number with percentage in parentheses or mean ± standard deviation. Tests of 
significance are t-test and Chi-square. 
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Table 5.3 Simple (left) followed by backward stepwise (conditional) 
multiple logistic regression analyses (R2=0.27) demonstrating independent 
predictors of presence LAV≥ median.   
Only variables found to be significant on univariate analyses were entered into the 
multivariate model.   
 
  
 Univariate Analyses Multivariate analyses 
 
Variable OR  95% CI p OR  95% CI P 
Mean ultrafiltration(per L) 1.64 1.09,2.46 0.02 1.68 1.09,2.57 0.02 
Male Sex 0.40 0.21,0.75 0.01 0.35 0.19,0.76 0.04 
Age (per year) 1.01 0.99, 1.04 0.14    
Duration on RRT (per year) 1.12 0.88, 1.42 0.34    
RRT Predialysis 1.00      
 Haemodialysis 1.46 0.64, 3.32 0.37    
 Peritoneal Dialysis 1.08 0.52,3.32 0.84    
LV ejection fraction (per %) 0.98 0.98, 1.02 0.77    
LVMI (per g/m2) 1.00 0.99, 1.01 0.44    
EDV/BSA (per ml/m2) 0.99 0.99, 1.01 0.82    
ESV/BSA (per ml/m2) 1.00 0.99,1.01 0.82    
LVSD 1.25 0.66, 2.38 0.48    
LV Dilation 1.19 0.63, 2.27 0.59    
Diabetes Mellitus 1.16 0.55, 2.45 0.70    
Ischaemic Heart Disease 2.49 0.90, 6.91 0.08    
Chronic Heart Failure 0.94 0.22, 5.15 0.94    
Peripheral Vascular Disease 2.19 0.50, 9.71 0.30    
Hypercholesterolaemia 1.66 0.81,3.41 0.17    
Smoking Never 1.00      
 Current 2.24 0.99, 5.05 0.05    
 Ex smoker 0.99 0.41,2.41 0.99    
Ischaemic ECG 1.04 0.51,2.14 0.91    
E:A ratio 0.81 0.25, 2.59 0.72    
 
199 
 
5.3.4 Survival Analyses 
There were 54 (26.9%) deaths over a 6.65 year follow up period. Eleven of these 
deaths occurred after renal transplantation.  
 
5.3.4 (a) Factors associated with death 
Clinical and cardiac factors were compared between patients who were alive and 
dead at the end of the study (Table 5.4).  Renal transplantation and male sex were 
significantly associated with lower mortality.  In addition, LA volumes (corrected 
for BSA) were significantly higher in the group that died compared to those that 
survived.  Similarly, LVSD on CMR and past history of ischaemic heart disease 
were significantly associated with a higher number of deaths.   Patients who 
survived were more likely to have never smoked but less likely to have stopped 
smoking compared to those that died.  When drug usage was compared, patients 
that died were more likely to be receiving aspirin therapy.  
 
5.3.4 (b) Clinical indicators of outcome 
The effect of left atrial and ventricular abnormalities on patient survival was 
investigated (Figure 5.2). Left atrial volume above the median was significantly 
associated with a poorer prognosis (Figure 5.2a, low LAV 5.6±2.1years vs.  high 
LAV 4.7±2.6 years; p=0.01). Similarly, LVSD (n=50) was associated with a 
significant reduction in mean survival time (Figure 5.2b, no LVSD (n=151) 5.4±1.8 
years vs.  LVSD (n=50) 4.4±3.9years; p=0.01).  Left ventricular dilatation was 
associated with a non-significant reduction in patient survival (Figure 5.2c, no LV 
dilatation (n=152) 5.2±1.9 years vs.  LV dilatation (n=49) 4.7±3.7 years; p=0.18).  
Past history of ischaemic heart disease conferred a significant reduction in survival 
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(Figure 5.2d, no IHD (n=147) 5.3±2.3 years vs. IHD (n=54) 4.5±2.5years; p=0.02).  
Patient sex did not have a significant impact on patient survival (male 5.3±2.4 years 
vs. female 4.7±2.5 years; p= 0.11; graph not shown). 
 
Given the survival benefits of renal transplantation, a transplant censored survival 
analyses was performed (Figure 5.3). As before, left atrial volume ≥median (Figure 
5.3a) and LVSD (Figure 5.3b) were significantly associated with reduction in 
transplant censored patient survival (low LAV 5.5±2.7years vs.  high LAV 4.5±2.9 
years; p=0.01;  no LVSD 5.3±2.7 years vs. LVSD 4.1±3.2years; p=0.02). Similarly, 
left ventricular dilatation was also associated with a non-significant effect on patient 
prognosis (Figure 5.3c, no LV dilatation 5.2±2.8 years vs.  LV Dilatation 4.3±3.0 
years; p=0.07).  Ischaemic heart disease did not significantly affect transplant 
censored survival (Figure 5.3d). 
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Variable 
 
Alive 
N=147 
Dead 
N=54 
p 
    
Transplants 60 (40.8) 11 (20.4) 0.01 
Age (years) 51.1(±11.4) 52.9(±12.8) 0.34 
Male (%) 112 (76.2) 33 (61.1) 0.04 
LA volume (ml/m2) 29.8 (16.2, 32.5) 33.0 (26.9,42.8) <0.01 
Systolic BP (mmHg) 137.1 (±26.7) 135.6(±17.3) 0.89 
Diastolic BP (mmHg) 81.0(±13.9) 80.4(±9.5) 0.79 
RRT HD 79 (53.7) 29 (53.7) 0.17 
 PD 34 (23.1) 33.3 (18)  
 CKD 5 34 (23.1) 7 (13.0)  
Mean Ultrafiltration (HD only) 2.49 (±1.1) 2.6(±1.1) 0.74 
Diabetes mellitus 91 (61.9) 30 (55.6) 0.42 
Ischaemic Heart Disease 32 (21.8) 22(40.7) 0.01 
Heart failure 8 (5.6) 4 (7.4) 0.74 
Cerebrovascular disease 6(4.2) 6 (11.1) 0.07 
Peripheral vascular disease 10 (7.0) 6 (11.1) 0.35 
Smoking Never 83 (56.5) 24 (44.4) 0.04 
 Current 41 (27.9) 13 (24.1)  
 Ex 23 (15.6) 17 (31.5)  
Epo receptor Agonist 110 (77.5) 41 (80.4) 0.66 
β Adrenoceptor Blocker 65 (45.8) 22 (43.1) 0.75 
Aspirin 55 (38.7) 28 (54.9) 0.05 
ACEI/ARB 39 (27.5) 15 (29.4) 0.79 
Diuretic 43 (30.3) 17 (33.3) 0.69 
Calcium Channel Blocker 44 (31.0) 14 (27.5) 0.64 
α Adrenoceptor Blocker 14 (9.9) 7 (13.7) 0.45 
Statin 58 (40.8) 25 (49.0) 0.31 
Heart Rate  75.2 (±20.1) 77.1(±22.9) 0.88 
Ejection Fraction (%) 63.3(±13.5) 61.6(±16.7) 0.39 
Myocardial mass/BSA  117.3 (±31.3) 117.2(±16.7) 0.97 
EDV/BSA (ml/ m2) 84.2(±30.6) 92.3(±30.9) 0.11 
ESV/BSA (ml/ m2) 32.4(±22.8) 38.8(±30.8) 0.12 
LVSD on MRI (EF<55%) 32 (21.8) 18 (33.3) 0.05 
LV dilatation 32 (21.8) 17 (31.5) 0.16 
Peak E wave (cm/s) 0.74 (±0.36) 0.74 (±0.2) 0.97 
Peak A wave (cm/s) 0.74 (±0.2) 0.75 (±0.42) 0.97 
E:A ratio 1.03 (±0.3) 1.06 (±0.4) 0.34 
 
Figure 5.4 Comparison of patients alive and dead at the end of the study 
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Figure 5.2 Kaplan Meier survival  curves according to (a) LAV median, (b) 
LVSD  
(a) 
  
(b) 
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Figure 5.2 Kaplan Meier survival  curves according to, (c) LV dilatation and 
(d) past history of ischaemic heart disease 
(c) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(d) 
No LV Dilatation 
LV Dilatation 
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Figure 5.3 Kaplan Meier transplant censored survival curves according  to 
(a) LAV median, (b) LVSD 
 
 
 
 
 
 
 
 
 
 
 
 
(b) 
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Figure 5.3 Kaplan Meier transplant censored survival curves  according  to 
c) LV dilatation and (d) past history of ischaemic heart disease 
(c) 
 
(d) 
No LV Dilatation 
LV Dilatation 
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5.3.4 (c)  Predictors of death 
 Table 5.5 shows univariate and multivariate Cox survival analyses for patient 
clinical and cardiac characteristics. As before, we initially performed non-transplant 
censored analyses. Univariate analyses showed that LVSD, LAV/BSA (absolute 
value or categorised according to the median) and past history of ischaemic heart 
disease were significantly associated with death. Advancing age increased risk of 
death but this did not reach statistical significance. Multivariate analysis (Table 5.5) 
was performed only entering one measurement of LAV (LAV ≥median or 
LAV/BSA). Independent predictors of mortality were LVSD, LAV/BSA or LAV 
≥median and past history of ischaemic heart disease.  
 
Transplant censored Cox survival analyses was also performed (Table 5.6). The 
factors significantly associated with death were LVSD and left atrial volume 
(corrected for BSA or categorised according to median LAV).   Older age was also 
associated with death, but did not reach statistical significance (p=0.06).  Independent 
predictors of death were LVSD and LAV/BSA. 
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** Entering LAV/BSA instead of LAV/BSA≥ median 
LV Systolic Dysfunction   HR 1.81  95% CI 1.02-3.23   p=0.04 
LAV/BSA (per ml/m2)  HR 1.07  95% CI 1.03-1.12   p<0.01 
Ischaemic Heart Disease  HR 2.23  95% CI 1.27-3.92  p<0.01 
 
Table 5.5 Results of univariate and multivariate Cox regression survival 
analyses of all patients with LVH  
All-cause mortality is the dependable variable. Hazard ratios (95% confidence 
intervals) are shown. 
 
 Univariate Analyses Multivariate Analyses 
Variable HR 95% CI p HR 95% CI p 
LV Systolic Dysfunction 1.98 1.12-3.50 0.02 1.86 1.05-3.28 0.03 
LAV/BSA greater/=median 2.09 1.18-3.67 0.01 2.04 1.16-3.62 0.01 
Ischaemic Heart Disease 1.88 1.09-3.23 0.02 2.02 1.13-3.52 0.01 
Mean Dose of Ultrafiltration 1.01 0.63-1.63 0.96    
LAV/BSA (per ml/m2)** 1.07 1.03-1.12 <0.01 **   
Ejection Fraction (per %) 0.98 0.97-1.00 0.10    
LVMI (per g/m2) 1.00 0.99-1.01 0.59    
LV Dilatation 1.48 0.83-2.63 0.18    
Systolic BP (per mmHg) 1.00 0.98-1.02 0.94    
Diastolic BP (per mmHg) 0.99 0.95-1.03 0.76    
Age (per year) 1.02 0.99-1.05 0.08    
BSA (m2) 0.28 0.08-1.10 0.10    
Male Sex 0.64 0.37-1.10 0.11    
Diabetes Mellitus 0.83 0.48-1.41 0.48    
Heart Failure 1.08 0.39-2.98 0.88    
Cerebrovascular Disease 1.97 0.84-4.62 0.12    
Peripheral Vascular Disease 1.22 0.52-2.84 0.65    
Smoking Never (ref) 1.00      
 Current 1.26 0.64-2.48 0.49    
 Ex smoker 1.91 0.89-3.55 0.08    
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** Entering LAV/BSA instead of LAV/BSA≥ median 
 
LV Systolic Dysfunction   HR 2.00 95% CI 1.06-3.76 p=0.03 
LAV/BSA (per ml/m2)  HR 1.08 95% CI 1.03-1.18 p<0.01 
 
Table 5.6 Results of univariate and multivariate Cox regression transplant 
censored patient survival analyses of all patients with LVH.  
Results of univariate and multivariate Cox regression survival analyses of all patients 
with LVH; all-cause mortality is the dependable variable. Hazard ratios (95% 
confidence intervals) are shown 
 
 Univariate Analyses Multivariate Analyses 
Variable HR 95% CI p HR 95% CI p 
LV Systolic Dysfunction 2.12 1.13-3.97 0.02 1.90 1.01-3.58 0.05 
LAV/BSA  greater /= median 2.24 1.16-4.30 0.01 2.21 1.15-4.27 0.02 
LAV/BSA (per ml/m2)** 1.08 1.03-1.13 <0.01 **   
Mean Dose of Ultrafiltration 1.27 0.72-2.23 0.41    
Ejection Fraction (per %) 0.98 0.96-1.00 0.11    
Systolic BP (per mmHg) 1.01 0.99-1.04 0.28    
Diastolic BP (per mmHg) 0.98 0.93-1.02 0.27    
LVMI (per g/m2) 1.00 0.99-1.01 0.63    
LV Dilatation 1.77 0.95-3.32 0.08    
Age (per year) 1.02 0.99-1.05 0.06    
BSA (m2) 0.25 0.06-1.21 0.12    
Male Sex 1.30 0.67-2.44 0.46    
Diabetes Mellitus 0.91 0.50-1.70 0.77    
Ischaemic Heart Disease 1.51 0.77-2.97 0.23    
Heart Failure 1.50 0.54-4.27 0.43    
Cerebrovascular Disease 2.29 0.90-5.86 0.12    
Peripheral Vascular Disease 2.04 0.86-4.84 0.11    
Smoking Never (ref) 1.00      
 Current 1.49 0.72-3.08 0.28    
 Ex smoker 1.84 0.89-3.79 0.09    
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5.4 DISCUSSION 
As has been stated before, LVH develops early in chronic kidney disease, with a 
roughly reciprocal relationship existing between renal function and LV mass (173).  
Most echocardiography studies indicate LVH as the commonest abnormality of 
uraemic cardiomyopathy, being prevalent in 70-80% of patients who commence 
dialysis. This figure may be an overestimate due to inaccurate measurement and 
calculation of LV mass using echocardiography. Nevertheless, CMR has also 
estimated LVH to be present in approximately 60-67% of ESRD patients confirming 
these early echocardiography findings (142).  In addition, presence and progression 
of LVH are associated with poorer outcome and is an independent risk factor for 
cardiac tachyarrhythmias, sudden cardiac death and symptomatic heart failure in 
ESRD patients (89).   
 
Whether regression of LVH in ESRD is possible, as has been demonstrated in the 
general population, remains controversial (213).  By the identification and 
intervention of specific variables (such as intravascular volume, hypertension, 
calcium and/or phosphate), a number of small studies have demonstrated a 
significant reduction in LVMI.  However, application of these data into clinical 
practice is limited due to lack of adequate controls and randomisation, small sample 
sizes and use of echocardiography.  A greater body of evidence demonstrates 
persistence or worsening of LVH despite more intensive dialysis or better blood 
pressure and fluid control (214). 
 
Thus, to improve cardiovascular survival in ESRD patients with LVH, alternative 
targets have been sought which may be amenable to intervention.  In this way, well 
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controlled, adequately powered and randomised studies could be performed to better 
tailor therapeutic strategies. 
 
Bearing this in mind, the following study was performed using CMR to assess 
cardiac morphology and performance.  To identify independent prognostic factors of 
ESRD patients with LVH, clinical history and other cardiac abnormalities were 
included in the survival analyses.  Ultimately, the strength of this study lies with the 
use of CMR to most accurately identify a cohort of patients with LVH for 
subsequent analyses.  Left atrial volume was also measured and included in the 
prognostic modelling.   
 
5.4.1 Left atrial volume   
The left atrium performs three functions during the cardiac cycle (209) and its size 
changes accordingly: 
1. Isovolumetric contraction and LV systole: receive and store blood from the 
pulmonary circulation. 
2. Early Diastole: transfer blood into the left ventricle after mitral valve opening 
via a pressure gradient (this is represented by the “E wave” on mitral valve 
colour Doppler. 
3. Late Diastole: atrial contraction augments LV stroke volume by 20% (this is 
represented by the “A wave” in mitral valve colour Doppler. 
 
5.4.1(a) Measurement of LA volume 
In practice and in this study, maximum LAV (just before mitral valve opening) is 
routinely measured.  This can accurately and reproducibly be performed using 2D 
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echocardiography and accordingly, the American Society of Echocardiography has 
recommended quantification of LA volume using biplane 2D echocardiography 
using the area-length method.  Similarly, CMR accurately estimates of LA volume 
using similar cine images from vertical and horizontal log axis views (156;210). 
 
5.4.1(b) Determinants of LA size 
Body size is a major determinant of LA volume, but a correction can be performed 
using body surface area.  Gender differences in LA volume are usually accounted for 
by variation in body size. Furthermore, age related LA enlargement and impaired 
diastolic conduit function have been reported (209).  As in ventricular remodelling, 
the atria enlarge in response to excessive pressure and volume: 
 
• Pressure overload: LA enlargement has been demonstrated in patients with mitral 
valve stenosis and LV dysfunction (i.e. increased LA afterload).   
• Volume overload: conditions with chronic volume overload, (valvular regurgitation, 
arterio-venous fistulae) and high cardiac output states (anaemia) are also associated 
with LA enlargement. 
 
However, in the absence of an atrial or valvular disorder, LA volume usually reflects 
ventricular filling pressures.  As ventricular relaxation and compliance are reduced 
during diastole, LA pressure rises to maintain LV filling and is accompanied by 
increased atrial wall tension, chamber dilatation and myocyte stretch.  Thus, LA 
volume may be representative of the magnitude of LV diastolic dysfunction (see 
below).  The value of LAV has been shown to represent the average effects of 
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chronic LV diastolic dysfunction (and hence haemodynamic control) rather than the 
immediate effect at the time of the study (215). 
 
In this study, elevated left atrial volume (above median) was less common in male 
patients.  Furthermore, female sex was an independent predictor of high LAV (≥ 
median) on CMR however neither sex nor BSA had any effect on survival in these 
analyses.  Previous studies have shown removal of sex related difference in LAV 
when corrected for body size (see above). These previous studies had a higher 
proportion of females in the study cohort (between 50-67%) compared to this study 
(27.9%) which may have affected this analysis.  
 
There was no significant difference in cardiovascular disease history between both 
groups (above or below median LAV) and heart rate, LV ejection fraction, LVMI 
and LV chamber size (at end diastole and systole) were similar in both groups.  
Similarly, E:A ratio was not significantly different between groups. This suggests 
that LA size was not a marker of delayed diastolic filling time or impaired LV 
systolic emptying.  However, mean dose of ultrafiltration was significantly 
associated with high LAV and a significant predictor of LAV in haemodialysis 
patients. As discussed before, mean dose of ultrafiltration is a crude marker of fluid 
overload and patients with large interdialytic fluid gains most likely receive higher 
doses. Unfortunately, no other assessments of fluid status, such as radionuclide 
tagging or bio-impedance analyses, were available for this cohort especially those 
patients not receiving haemodialysis.  However, these findings confirm previous 
studies, in the general population, that demonstrate a significant relationship between 
elevated LAV and chronic fluid overload. 
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5.4.2 Left ventricular diastolic dysfunction in ESRD patients 
LV diastolic dysfunction can be defined as an abnormality of diastolic relaxation, 
filling or compliance that impairs ventricular diastolic filling.   Diastolic function can 
be assessed using Doppler echocardiography to measure rate of LV pressure decline 
(isovolumetric relaxation time: IVRT) or rate and extent of LV filling (commonly 
using mitral inflow early (E) and late (A) ratios or more recently tissue Doppler 
myocardial velocity, strain and strain rate.).  More invasive studies using cardiac 
catheterisation and angiography can be used to obtain cardiac cycle pressure-volume 
loops. 
 
Expanded intravascular volume and LV hypertrophy/interstitial fibrosis are common 
in ESRD patients and predispose to development of LV diastolic dysfunction.  Most 
studies have used Doppler echocardiography to quantify diastolic dysfunction in 
ESRD patients: 
 
• Josephs et al demonstrated significantly impaired early diastolic filling in 100 
haemodialysis patients using Doppler E:A ratio as a marker of diastolic function.  In 
particular, older (>60 years) haemodialysis patients were at higher risk of diastolic 
dysfunction and diastolic function was significantly correlated with dialysis 
adequacy and higher blood pressure (216). 
 
• Similarly in 25 CAPD patients, Huting et al demonstrated impaired LV diastolic 
dysfunction especially in patients with more severe LVH, using trans-mitral inflow 
velocities and colour tissue Doppler measurements (217). 
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• Using more invasive cardiac pressure measurements, Wizeman et al demonstrated 
elevated LV end diastolic pressure in 29 haemodialysis patient compared to healthy 
controls.  Most patients had preserved systolic function and the authors concluded 
that reduced LV compliance and subsequent impaired diastolic filling predisposed 
patients to symptoms of congestive cardiac disease (218). 
 
The data presented in this chapter do not support a role of diastolic dysfunction in 
LA enlargement within this patient group since there were no significant difference 
in E:A ratios between high and low LAV groups.   
 
5.4.3 Left atrial volume and outcome 
A number of studies in the general population have demonstrated the predictive role 
of elevated LA volume for adverse cardiovascular outcome.  Of these, two of the 
largest are described below: 
• Data from the Cardiovascular Health Study looking at M-Mode echocardiographic 
measurements and outcome in 5888 patients demonstrated higher left atrial size as an 
independent predictor of all cause mortality, stroke and coronary artery disease 
(219).   
• In a sub analyses from the Framingham Heart Study (n=3099), Gajewski et al 
demonstrated that LA enlargement predicted higher rates of stroke and death in men, 
however the effect was attenuated when corrected for LV mass (220) .   
 
In ESRD patients, two studies have demonstrated a prognostic role of LAV: 
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• Tripepi et al used echocardiography to measure cardiac parameters and related them 
to patient outcome.  LAV was predicted by LVMI, LVEF, E:A ratio and 
antihypertensive therapy.  In addition, elevated LAV corrected for height 
independently predicted death in this patient population (207).  There was no 
difference in the results presented in this chapter when LAV was corrected for height 
as opposed to BSA. 
• In a subsequent study from the same group, patients underwent repeat 
echocardiography.  Rise in LAV/height between scans was predictive of fatal and 
non-fatal cardiac events compared to patients whose LAV/height remained the same.  
Similarly, a 1ml/m2 increase in LAV/height was associated with a 12% increase in 
relative risk of a cardiovascular event (221). 
 
5.4.4 Prognostic findings 
From these data female sex, higher LAV corrected for BSA, past history of 
ischaemic heart disease, and LVSD on CMR were significantly associated with death 
during the follow up period.  Aspirin use was higher in those patients who died, 
presumably due to the higher proportion of patients with a cardiac history in this 
patient group.   
 
In the survival analysis, elevated LAV and LVSD were significantly associated with 
poorer survival (transplant and non transplant censored; Figure 5.2 and 5.3).  
Multivariate analysis showed that elevated LAV/BSA (represented as an absolute 
value or divided according to the median) and LVSD independently predicted death 
(even when censored for renal transplantation) in ESRD patients with LVH. Past 
history of ischaemic heart disease was a significant, independent predictor of non 
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transplant censored mortality and significantly reduced non transplant censored 
survival. Presence of LV dilatation did not have a statistically significant effect on 
survival.  These data confirm the findings of previous studies investigating LAV and 
survival.  However this study differs in two aspects: 
 
• Previously, all ESRD patients were included in analyses.  This study only includes 
patients with pre-existing features of LVH.   
• This cohort has been examined using CMR to provide an accurate assessment of LV 
mass whereas the previous studies have used echocardiography.  One should note, 
however, that there is no difference in assessment of LAV between both methods. 
 
5.4.4 (a) Left atrial volume and survival 
In the present study, LAV was not significantly correlated with LV mass, suggesting 
that elevated LA volume is not solely due to impaired atrial emptying into a large, 
poorly compliant LV.  LAV was not associated with diastolic dysfunction in our 
population as measured by E:A ratio, however, measurement of other markers of LV 
diastolic dysfunction, such as pulmonary venous flow velocity or LV tissue Doppler 
would have been useful to confirm these mitral valve studies.  In addition, E:A ratio 
is a limited marker for diastolic function at greater LA pressures due to a tendency 
back to normal values (also known as “pseudonormalisation”). 
 
Thus, based on these results in ESRD patients with LVH, left atrial enlargement is 
largely caused by chronic fluid overload, and the associated expansion in 
intravascular volume.  This hypothesis is supported by the finding that dose of 
ultrafiltration (acting as a crude marker of fluid retention) independently predicted 
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LAV in haemodialysis patients.  Reduction of LA volume has been achieved in 
patients with mitral valve disease and atrial fibrillation (222;223); however its effect 
on overall prognosis remains unknown. Whether tight control of fluid-volume status 
in patients with ESRD patients similarly reduces LA volume and mortality requires 
controlled clinical trials in the future. 
 
5.4.4.(b) Left ventricular systolic dysfunction and survival 
Left ventricular systolic dysfunction has been associated with (often asymptomatic) 
ischaemic heart disease and, in turn, with poorer survival (139). This is presumably 
due to occlusive large vessel disease and inadequate growth of penetrating epicardial 
vessels in response to cardiac myocyte hypertrophy. Ventricular action potential 
propagation and recovery are impaired in the presence of LVH and LVSD increasing 
the risk of ventricular re-entrant tachyarrhythmias (51;224). The potential benefits of 
improving systolic function on prognosis of patients with ESRD, has been 
demonstrated in a number of small studies using pharmacological approaches or 
modification of dialysis regimens (20;124).  However, these interventions are not 
commonly used in ESRD patients due to poor tolerance of patients or the opinions of 
the treating nephrologist.  Hopefully, as more robust data becomes available medical 
practice may change in ESRD patients with myocardial dysfunction. 
 
5.4.4 (c) Ischaemic heart disease and survival 
As has been shown before, a clinical history of CV disease also reduced survival, 
since non-transplant censored multivariate Cox survival analyses identified past 
history of ischaemic heart disease as a significant, independent predictor of death.  
Clinical history of ischaemic heart disease did not, however, significantly, affect 
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transplant censored survival.  These differences between transplant and non- 
transplant censored survival can be explained by the disproportionately high number 
of patients with ischaemic heart disease who subsequently underwent renal 
transplantation (IHD 53.7% vs. No IHD 28.6%) in this cohort.  As a result of 
transplant censoring, there was not a statistically significant difference in survival 
despite Kaplan-Meier analyses demonstrated separating survival curves (Figure 5.2).  
This is presumably due to fewer patients in the IHD group.  
 
5.4.5 Limitations 
As before, patients recruited to this study were being assessed for renal 
transplantation and may not be representative of all ESRD subjects.  However, since 
these patients are considered healthy enough to be considered for transplantation, it 
is likely that these results would be relevant to other patients with more significant 
co-morbidities.  In addition, limited information was obtained regarding ventricular 
diastolic function in this cohort and hopefully, as more detailed methods (e.g. tissue 
Doppler) are utilised, these data will become available. 
 
5.5 CONCLUSIONS 
In conclusion, in ESRD patients with LVH, elevated LAV and presence of LVSD 
are independent predictors of death and may provide novel factors that may be 
amenable to modification to improve cardiovascular prognosis.  Elevated LAV is 
due, in part, to fluid overload which may be a useful target in the future. 
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Chapter 6 
 
A study of Microvolt T Wave Alternans in ESRD patients 
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6.1 INTRODUCTION 
As has been discussed in Chapter 1, patients with end stage renal disease (ESRD), 
including those receiving or close to requiring dialysis, have a significantly increased 
risk of premature cardiovascular death.  In contrast to the general population, where 
myocardial ischaemia and infarction (MI) are the leading cause of cardiovascular 
death, ESRD patients are significantly more likely to develop cardiac (commonly 
ventricular) tachyarrhythmias and sudden cardiac death (SCD).  Factors associated 
with SCD include myocardial structural abnormalities of uraemic cardiomyopathy 
and accelerated coronary artery disease.  In addition, factors such as large electrolyte 
fluctuations, bone mineral disease, uraemia, autonomic dysfunction and 
inflammation have also been implicated in the development of SCD. However, 
despite elucidation of potential risk factors for ventricular tachyarrhythmias (VTA), 
identification of high risk ESRD patients and primary prevention of SCD has proven 
difficult. Furthermore, treatment of traditional cardiovascular risk factors (eg 
dyslipidemia) has shown little survival benefit (26;81). 
 
A similar problem exists in patients with symptomatic heart failure and impaired LV 
systolic function.  Results from MADIT II and SCD- Heart Failure Trial show 
significant survival benefit using implantable cardioverter defibrillators (ICD) for 
primary prevention of SCD in patients with ischaemic and non-ischaemic 
cardiomyopathy (82; 83). However many of these ICDs remain unused and current 
estimates suggest that to prevent one SCD, 18 devices require to be inserted.  
Additional electrophysiological tests have been evaluated to better identify higher 
risk patients who would benefit from ICD insertion. 
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Microvolt T Wave Alternans (MTWA; HearTwave II system, Cambridge Heart, 
Bedford, Massachusetts) is a novel, non-invasive technique of assessing VTA risk in 
patients. The principles of MTWA have been discussed in Chapter 1.  MTWA 
measures beat-to-beat variations in standard 12-lead ECG T-wave morphology, 
indicating unstable ventricular repolarisation. Several large prospective trials have 
demonstrated that MTWA analysis is superior or comparable to other more invasive 
electrophysiological methods of independently predicting (negatively and positively) 
patients at risk of VTA or SCD.  These studies included patients with ischaemic 
heart disease, biventricular cardiac failure and implantable cardiac defibrillators.  In 
patients with symptomatic ischaemic cardiomyopathy, the prevalence of abnormal 
MTWA result varies between 64 and 72% (105;161;225).  Furthermore, in diabetic 
patients with no symptoms of cardiovascular disease, abnormal result has been found 
in 25.4% of patients which is significantly higher when compared to normal healthy 
controls (5.7% ) (111;226).   No such studies have been performed in ESRD patients. 
 
In this study, two hundred patients with ESRD and 30 control patients with 
hypertensive LVH were assessed using MTWA.  The aims of this study were to: 
• Determine prevalence of abnormal MTWA in ESRD patients compared to patients 
with hypertensive LVH and normal renal function. 
• Determine associations between features of uraemic cardiomyopathy and MTWA 
result. 
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6.2 METHODS 
 
6.2.1 Patients 
ESRD patients already established on or within 6 months of requiring renal 
replacement therapy (RRT) were consecutively assessed.  In addition, hypertensive 
patients with evidence of LVH on echocardiography or ECG and normal renal 
function (measured within 6 months of recruitment) were also entered into the study 
as controls (termed LVH patients). 
 
 All patients underwent cardiovascular risk factor assessment including history, 
clinical examination, ECG as well as routine haematological, biochemical and lipid 
profile.  CMR was performed to measure left ventricular (LV) mass and function 
followed by MTWA testing.  Patients with contraindication to CMR (e.g. presence 
of permanent pacemaker or ferromagnetic implants, severe claustrophobia, 
pregnancy) were not entered into the study.  Furthermore, patients with atrial 
fibrillation were excluded as irregular R-R intervals confound frequency analysis 
during MTWA testing. 
 
6.2.2 CMR acquisition and analyses 
CMR scans were acquired for assessment of LV mass and function and analysed as 
described in Chapter 2.  Patients were classified as having LVH, LVSD or LV 
dilatation based on previously described normal values. 
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6.2.3 MTWA testing 
Preparation, acquisition, analyses and classification of MTWA testing have been 
described in detail in Chapter 2.  Based on previously published studies, we further 
classified results as “abnormal” for positive and indeterminate test results and 
negative tests as “negative”.  If initially an indeterminate result was obtained, 
immediate retesting was attempted. The reason for indeterminate test was also 
provided by the analysis software (227).  
 
6.2.4 Statistical analyses 
Statistical analyses were performed using SPSS version 15.0 (SPSS Inc. Illinois, 
USA). Data are described as mean±standard deviation.  Data were compared by chi-
squared or Fisher’s test for categorical data and paired t-test for continuous data. 
Simple followed by multivariate logistic regression analyses were performed to 
identify individual predictors of abnormal MTWA result.  BNP underwent 
logarithmic transformation to allow parametric statistical comparison. Survival data 
including survival time (mean± standard deviation) are shown as Kaplan-Meier 
graphs (with statistical comparison using the log rank test). 
 
6.3 RESULTS 
 
6.3.1 Patient demographics 
Two hundred ESRD patients and 30 LVH patients were assessed.   Table 6.1 shows 
the clinical and cardiac data for ESRD and LVH patients.   
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6.3.2 Comparison between ESRD and LVH patients 
There were no statistically significant differences between age, sex, BMI, and 
systolic blood pressures between each group.  Interestingly, diastolic blood pressure 
was significantly higher in the LVH group compared the ESRD group.  As one 
would expect, there was a significantly higher frequency of traditional 
cardiovascular risk factors in ESRD patients compared to patients with LVH.  This 
difference is also reflected in the medications these patients were taking.   
 
LV systolic function was preserved in both groups.  Cardiac data demonstrated a 
lower ejection fraction and higher LVMI and LV chamber size in the ESRD group 
compared to LVH patients, although these did not reach statistical significance.  
Presence of LVH was high in both groups and despite LVH patients being recruited 
based on previous echocardiography and ECG, only 18 (60%) had LVH on CMR.  
LVSD and LV dilatation was also more common in ESRD patients, but similarly this 
did not reach statistical significance. 
 
Microvolt T wave alternans result was negative for 85 (42.5%), positive for 44 
(22%) and indeterminate in 71 (35.5%) in ESRD patients.  In the LVH group of 
patients, MTWA was negative in 22 (73.3%), positive in 3 (10%) and indeterminate 
in 5 (16.7%) of patients (Figure 6.1).  On comparison, abnormal MTWA result was 
significantly more common in ESRD compared to LVH patients (ESRD 57.5% vs. 
LVH 26.7%; p=0.002; Table 6.1). 
 
Reasons for indeterminate tests in ESRD patients (Figure 6.2) were failure to achieve 
heart rate between 105 and 110bpm for ≥1min (50.7% of all indeterminate results), 
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excessive ventricular ectopy during exercise (23.9%), a noisy recording (21.1%) and 
rapid rise through target heart rate of 105-110bpm or unsustained MTWA (≤1 min; 
4.2%).  In LVH patients, 5 indeterminate tests were due to failure to achieve heart 
rate rise (2 patients) and to noisy recording (3 patients). 
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Table 6.1 Clinical, drug and cardiac data for patients.   
Comparisons between ESRD and LVH patients are shown.. Data are number with 
percentage in parentheses or mean ± standard deviation except for RRT time where median 
and interquartile range are shown .   
 
Variable 
 
ESRD 
N=200 
LVH Only 
N=30 
 
p 
MTWA abnormal  115(57.5) 8 (26.7) <0.01 
Age (years) 56.3(±12.7) 53.1 (±10.7) 0.21 
Male (%) 142 (71) 25 (83.3) 0.16 
BMI (kg/m2) 26.5(4.7) 27.1(4.9) 0.19 
Systolic BP (mmHg) 146 (±24.1) 152 (±22.5) 0.17 
Diastolic BP (mmHg) 82 (±14.2) 89(±11.1) 0.01 
Renal Replacement Therapy    
 HD 118 (59.0) -  
 PD 17 (8.5) -  
 CKD 5 65 (32.5) -  
RRT Time 1.14 (2.1) -  
Primary Renal Disease    
Diabetic Nephropathy 46 (23.0) -  
APCKD 20 (10.0) -  
Glomerulonephritis 42 (21.0) -  
Renovascular Disease 16 (8.0) -  
Chronic Pyelonephritis 20(10.0) -  
Other 26 (13.0) -  
Unknown 30 (15.0) -  
Clinical History    
Diabetes mellitus 54 (27.0) 0 <0.01 
Ischemic Heart Disease 49 (24.5) 2(9.5) <0.01 
Heart failure 15 (7.5) 1 (3.3) 0.70 
Cerebrovascular disease 26 (13) 1(3.3) 0.22 
Peripheral vascular disease 35 (17.5) 0 0.01 
Dyslipidaemia 117 (58.5) 10 (33.3) 0.01 
Smoking Never 89 (44.5) 19 (61.9) 0.08 
 Current 54 (27.0) 3 (10)  
 Ex 57 (28.5) 8 (26.7)  
    
Drug History    
Epo receptor Agonist 162 (81.0) 0 <0.01 
β Adrenoceptor Blocker 92 (46.0) 10 (33.3) 0.15 
Aspirin 102 (51.0) 3 (10) 0.01 
Warfarin 13 (6.5) 0 0.23 
Clopidogrel 17 (8.5) 0 0.16 
ACEI/ARB 91 (45.5) 12 (40.0) 0.51 
Diuretic 58 (29) 6 (20.0) 0.54 
Nitrate 15 (7.5) 8(26.7) <0.01 
Calcium Channel Blocker 76 (38.0) 8(26.7) 0.19 
α Adrenoceptor Blocker 24 (12.0) 1 (3.3) 0.09 
Statin 125 (62.5) 9(30.0) <0.01 
CMR Results    
Ejection Fraction (%) 61.9 (±15.3) 65.8(±11.5) 0.19 
Myocardial mass/BSA 93.3 (±38.2) 82.0(±32.9) 0.13 
EDV/BSA (ml/ m2) 68.9(±35.6) 67.1(±13.7) 0.79 
ESV/BSA (ml/ m2) 28.7(±26.2) 23.5(±12.4) 0.08 
LVH on MRI 124 (62.0) 18 (60.0) 0.87 
LVSD on MRI (EF<55%) 45 (22.5) 4 (13.8) 0.34 
LV dilation 19 (9.5) 2 (6.9) 0.65 
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Figure 6.1 Comparison of MTWA result of ESRD and LVH patients. Data 
labels are percentage in each patient group. 
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Figure 6.2 Cause of Indeterminate MTWA result in ESRD patients only.  
HR= heart rate, VE= ventricular ectopics 
 
50.7%
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Inufficient rise in HR Excessive VEs
Noisy recording Rapid rise/unsustained MTWA
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6.3.3 Factors associated with abnormal MTWA result 
In the ESRD group, abnormal MTWA (Table 6.2) result was significantly associated 
with older age and receiving haemodialysis as RRT.  Furthermore, those patients 
with current or past cardiovascular morbidity were more likely to have an abnormal 
MTWA result. There was a significant association between an abnormal result and 
diabetic nephropathy or renovascular disease as primary renal disorder, past medical 
history of diabetes mellitus, ischaemic heart, cerebrovascular or peripheral vascular 
disease, and dyslipidaemia. In addition, abnormal result was significantly associated 
with statin therapy. 
 
To assess the effect of blood parameters on MTWA result, venepuncture was 
performed 10- 15 minutes before testing (Table 6.2).  There was no significant 
difference between measured serum cations (namely potassium and calcium), 
haemoglobin, fibrinogen, inorganic phosphate, PTH, inflammatory markers, and 
troponin I between both groups. Random plasma glucose and glycosylated 
haemoglobin were significantly higher in patients with an abnormal MTWA result, 
presumably as a result of higher proportion of diabetic patients in this group.   Brain 
natriuretic peptide was also significantly higher in the abnormal MTWA group.  
Total plasma cholesterol was significantly lower in patients with an abnormal 
MTWA result.   
 
The associations between LV structural abnormalities of uraemic cardiomyopathy 
and MTWA result were assessed (Table 6.3).  Abnormal MTWA result was 
significantly associated with abnormalities of uraemic cardiomyopathy: higher LV 
mass, lower ejection fraction and higher EDV/BSA and ESV/BSA.  In addition, 
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there were significantly higher proportions of patients with LVH and LV dilatation 
in the abnormal MTWA group.   More patients had LVSD in the abnormal MTWA 
group but this did not achieve sufficient statistical significance (p=0.08). 
 
6.3.4 Variables associated with abnormal MTWA result in ESRD patients 
Logistic regression analyses were performed to determine variables independently 
associated with abnormal MTWA result in ESRD patients only (Table 6.4).  In our 
model (R2=0.40), entering only factors found to be significant after univariate 
analyses, increasing age and past clinical history of coronary, peripheral vascular and 
cerebrovascular diseases were independently associated with abnormal MTWA 
result.  In addition, increasing LVMI (or presence of LVH) was independently 
associated with abnormal MTWA result.  Presence of LV dilatation was associated 
with abnormal result but did not achieve statistical significance. 
 
6.3.5 Effect of abnormal MTWA result on patient outcome 
There were 16 deaths during a median follow up of 1.9 years (IQR 1.5, 2.6 years).  
Abnormal MTWA was associated with a higher number of deaths compared to 
negative MTWA result (12 deaths vs. 4 deaths; p=0.15) although this did not reach 
statistical significance.  Furthermore, abnormal MTWA result was associated with a 
trend toward reduced survival compared to negative MTWA (Figure 6.3). 
231 
 
 
 
 
Table 6.2 Comparisons of clinical and blood results between patients are shown 
based on MTWA result.  
Data are number with percentage in parentheses and  mean ± standard deviation except for ESR, CRP, 
PTH and BNP where median and interquartile range are shown 
Variable 
 
MTWA  
Negative 
N=85 (42.5) 
MTWA 
Abnormal 
N=115 (57.5) 
p 
Age (years) 52.4(12.8) 59.1(12.0) <0.01 
Male (%) 59 (69.4) 83(72.2) 0.67 
BMI (kg/m2) 26.9 (4.8) 26.2(4.6) 0.29 
BSA (m2) 1.89(0.2) 1.87 (0.2) 0.45 
Systolic BP (mmHg) 144 (23.2) 147 (24.8) 0.29 
Diastolic BP (mmHg) 83(12.9) 82 (15.2) 0.52 
Renal Replacement Therapy 1.17 (1.7) 1.1 (2.4) 0.67 
 HD 41 (48.2) 77( 67.0) <0.01 
 PD 11 (12.9) 6 (5.2) 0.09 
 Predialysis 33 (38.8) 32 (27.8) 0.10 
RRT Time (years) 1.2 (0.6,2,4) 1.2 (0.6, 2.4) 0.97 
Primary Renal Disease    
Diabetic Nephropathy 13 (15.3) 33 (28.7) 0.02 
APCKD 12 (14.1) 8(7.0) 0.10 
Glomerulonephritis 23 (27.1) 19 (16.5) 0.07 
Renovascular Disease 3(3.5) 13 (11.3) 0.05 
Chronic Pyelonephritis 11 (12.9) 9 (7.8) 0.23 
Other 9 (10.6) 17 (14.8) 0.38 
Unknown 14 (16.5) 16 (13.9) 0.62 
Diabetes mellitus 16 (18.8) 38 (33.0) 0.03 
Ischaemic Heart Disease 8 (9.4) 41 (35.7) <0.01 
Hypertension 73 (85.9) 105 (91.3) 0.23 
Heart failure 4 (4.7) 11 (9.6)  
Cerebrovascular disease 3 (3.5) 23 (20) <0.01 
Peripheral vascular disease 4 (4.7) 31 (27) <0.01 
Dyslipidaemia 42 (49.4) 75(65.2) 0.03 
Smoking Never 45 (52.9) 44 (38.3) 0.12 
 Current 20 (23.5) 34 (29.6)  
 Ex 20 (23.5) 37 (32.2)  
Epo receptor Agonist 64 (75.3) 98 (85.2) 0.08 
β Adrenoceptor Blocker 26 (30.6) 46(40) 0.10 
Aspirin 41 (48.2) 61 (53.0) 0.50 
ACEI/ARB 41 (47.1) 51 (44.3) 0.25 
Diuretic 29 (34.1) 29 (25.2) 0.17 
Nitrate 3 (3.5) 12 (10.4) 0.07 
Calcium Channel Blocker 28 (32.9) 48 (41.7) 0.21 
α Adrenoceptor Blocker 12 (14.1) 12 (10.4) 0.43 
Statin 46 (54.1) 79 (68.7) 0.04 
Haemoglobin (g/dL) 11.4 (1.8) 11.4 (1.8) 0.96 
Fibrinogen (g/L) 4.34 (1.1) 4.25 (1.0) 0.58 
ESR (mm/h) 28 (9.5,49.0) 31(14.5, 44.0) 0.74 
CRP (mg/L) 4.9(2.0, 9.9) 5.3 (3, 14) 0.08 
Adjusted Ca2+(mmol/L) 2.39 (0.4) 2.40 (0.2) 0.87 
PO4 (mmol/L) 1.69 (0.5) 1.56 (0.5) 0.08 
PTH (pmol/L) 27.1(14.7, 50.7) 28.6(15.2,46.4) 0.99 
Glucose (mmol/L) 5.3 (2.4) 5.9 (2.7) 0.02 
HbA1c (%) 5.2 (1.0) 5.4 (1.5) 0.03 
Potassium (mmol/L) 4.7(0.7) 4.7 (0.8) 0.76 
BNP (ng/L) 174(45, 340) 335 (129,1340) <0.01 
LogBNP 2.21(±0.6) 2.61(0.7) <0.01 
Cholesterol (mmol/L) 4.61 (1.3) 4.23 (1.1) 0.04 
Triglyceride (mmol/L) 1.7 (0.9) 1.6 (0.9) 0.46 
HDL- Chol (mmol/L) 1.4 (0.8) 1.4(0.8) 0.28 
LDL- Chol (mmol/L) 2.4(1.3) 2.2 (1.3) 0.14 
Troponin I (µg/L) 0.01 (0.05) 0.03( 0.07) 0.23 
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Variable 
 
MTWA  
Negative 
N=85 (42.5) 
 
MTWA 
Abnormal 
N=115 (57.5) 
 
p 
Ejection Fraction (%) 65.1 (11.4) 59.5 (17.3) 0.01 
Myocardial mass/BSA 84.9 (33.1) 99.7 (40.6) <0.01 
EDV/BSA (ml/ m2) 60.6 (22.6) 75.2 (41.8) <0.01 
ESV/BSA (ml/ m2) 22.4 (14.2) 33.5 (31.7) <0.01 
SV/BSA (ml/m2) 38.2 (13.5) 41.6 (21.9) 0.21 
LVH on MRI 46 (54.1) 78 (67.8) 0.05 
LVSD on MRI (EF<55%) 14 (16.5) 31 (27.0) 0.08 
LV dilation 2 (2.4) 17 (14.8) <0.01 
 
Table 6.3 Comparisons of CMR data between patients are shown based on 
MTWA result.  
Data are number with percentage in parentheses or mean ± standard deviation. 
Tests of significance are t-test and Chi-square. 
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Table 6.4 Simple (left) followed by backward stepwise (conditional) 
multiple logistic regression analyses (R2=0.40) demonstrating independent 
predictors of abnormal MTWA result.   
Only variables found to be significant on univariate analyses were entered into the 
multivariate model.  †LVMI or LVH were entered individually in the model. 
 Univariate Analyses Multivariate analyses 
 
Variable OR  95% CI p OR  95% CI P 
       
Age (per year) 1.04 1.02,1.07 <0.01 1.04 1.01,1.07 0.01 
Ischaemic Heart Disease 6.19 2.74,13.94 <0.01 3.24 1.31,8.02 0.01 
Cerebrovascular Disease 6.83 1.98,23.60 <0.01 5.81 1.56,12.87 <0.01 
Peripheral Vascular Disease 7.47 2.53,22.11 <0.01 5.34 1.68,16.96 <0.01 
LVH 1.79 1.01,3.18 0.05 †2.01 1.01,4.03 0.05 
LV Dilation 7.20 1.62,32.07 0.01 4.34 0.98,21.90 0.06 
Log BNP 2.66 1.45,4.87 <0.01    
Glucose (per mmol/L) 1.10 1.02,1.19 0.01    
Ejection fraction (per %) 0.98 0.95,0.98 0.01    
LVMI (per g/m2) 1.01 1.00,1.02 0.01 † 1.02 1.01,1.02 0.02 
LVSD 1.87 0.93,3.79 0.08    
Diabetes Mellitus 2.12 1.09,4.15 0.03    
Hypercholesterolemia 1.92 1.08,3.40 0.03    
Renal Replacement Therapy       
 Predialysis 1.00      
 PD 0.57 0.19,1.70 0.31    
 HD 1.93 1.05,3.59 0.04    
RRT Time (per year) 1.10 0.91,1.33 0.30    
Sex (Male vs. Female) 1.06 0.59,1.90 0.84    
BMI (per kg/m2) 0.97 0.92,1.03 0.36    
Systolic BP (per mmHg) 1.01 0.99, 1.02 0.07    
Diastolic BP (mmHg) 0.97 0.95, 1.00 0.06    
Pulse Pressure 1.02 0.99,1.03 0.07    
Chronic Heart Failure 2.14 0.65,6.97 0.21    
Smoking Never 1.00      
 Current 1.73 0.88,3.47 0.12    
 Ex 0.70 0.95,3.75 0.09    
Haemoglobin (per g/dL) 1.02 0.86,1.18 0.96    
Fibrinogen (per g/L) 0.92 0.70,1.23 0.58    
ESR (per mm/h) 0.99 0.98,1.01 0.83    
CRP (per mg/L) 1.01 0.99,1.02 0.62    
Adjusted Ca2+( per mmol/L) 1.08 0.41,2.85 0.86    
PO4 (per mmol/L) 0.60 0.34,1.07 0.08    
PTH (per pmol/L) 0.99 0.98,1.01 0.42    
HbA1c (per %) 0.99 0.98,1.01 0.48    
Potassium (per mmol/L) 0.94 0.63,1.40 0.76    
BNP (per ng/L) 1.02 1.01,1.04 <0.01    
Cholesterol (per mmol/L) 0.60 0.32,1.17 0.13    
Triglyceride (per mmol/L) 1.12 0.69,1.81 0.67    
HDL- Chol (per mmol/L) 1.34 0.70,2.57 0.38    
LDL- Chol (per mmol/L) 1.17 0.63,2.16 0.62    
Troponin I (per µg/L) 12.15 0.02,32.8 0.26    
EDV/BSA (ml/ m2) 1.00 0.98,1.02 0.64    
ESV/BSA (ml/ m2) 1.02 0.98,1.04 0.21    
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Figure 6.3 Kaplan Meier survival curve of ESRD patients based on MTWA 
result based on (a) abnormal/negative classification and (b) automated result 
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6.4 DISCUSSION 
 
As has been discussed in Chapter 1, premature cardiovascular death is the 
commonest cause of death in patients with ESRD including those receiving or within 
6 months of requiring renal replacement therapy. According to the USRDS (4; 228), 
the commonest causes of death in ESRD and dialysis patients are cardiac arrhythmia 
and cardiac arrest accounting for between 60-65% of cardiac and 20-25% of all 
deaths.   
 
Findings from the “Deutsche Diabetes Dialyse Studies (4D)”   and  “A Study to 
Evaluate the Use of Rosuvastatin in Subjects on Regular Hemodialysis: An 
Assessment of Survival and Cardiovascular Events (AURORA)” trial  have 
highlighted significant differences in cardiovascular disease between dialysis 
patients and the general population (25;26). 
 
• The 4D study was a prospective randomised controlled trail investigating the effect 
of atorvastatin therapy on cardiovascular outcome in 1225 type 2 diabetic 
haemodialysis patients.  Although LDL cholesterol was reduced, there was no 
statistical significant reduction of the composite primary endpoint (death from all 
cardiac causes, fatal stroke, non fatal MI, or non fatal stroke).  Post hoc analyses, 
however, revealed that adjudicated deaths due to coronary artery disease only 
accounted for 9% of deaths and sudden death accounted for 26% of all cause 
mortality (25).  
• In the AURORA trial, a prospective randomised  study investigating therapy with 
rosuvastatin in 2776 haemodialysis patients, LDL cholesterol was reduced by 43% in 
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the therapy arm but there was no significant effect on primary outcome (adjudicated 
death from cardiovascular causes, non fatal MI, non fatal stroke).  In the rosuvastatin 
treated group, death from cardiovascular cause occurred at a rate of 7.2 events/100 
patient-years compared to 7.3 events/100 patient–years in the placebo group 
(p=0.97) and death from definite coronary heart disease was not significantly 
different (26).  
 
Both of these studies, in combination with previous interventional studies, suggest 
that in non-ESRD population, coronary atherosclerosis causes myocardial 
ischaemia/infarction which may lead to sudden cardiac death.  However in ESRD 
patients, sudden cardiac death is not as greatly influenced by coronary artery disease 
compared to the general population.  Alternatively, these data may suggest that 
CAD in ESRD patients does not respond to statin treatment. 
 
 
6.4.1  Factors associated with sudden cardiac death in ESRD 
The presence of stable VTAs on ambulatory ECG monitoring has been shown to 
increases risk of SCD in the general population (99).  Ventricular tachyarrhythmia 
development is commonly due to the interaction of abnormal myocardial substrate 
and aetiological triggers which interfere with normal, uniform cardiac action 
potential propagation and myocardial repolarisation.  In the general population, 
transient myocardial ischaemia or areas of post MI scarring commonly produce areas 
of slowed ventricular action potential conduction, non-uniform 
depolarisation/repolarisation, and increase risk of re-entry and VTA.  In patients with 
preserved LV function, these arrhythmias have only a small haemodynamic effect.  
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However, if patients have compromised myocardial function, haemodynamic effects 
may be great and may lead to degeneration of depolarisation wavefront and 
ventricular fibrillation.  ESRD patients are at risk of unique factors that affect 
substrate (myocardium) and triggers that have been discussed in more detail in 
Chapter 1.  Briefly these features include: 
 
1. Changes in myocardial structure and function (substrate):  
Including features of uraemic cardiomyopathy, accelerated coronary artery 
disease and fluid overload induced myocardial stretching. 
 
2. Changes in myocardial environment (trigger): 
Including fluctuations/imbalances in extracellular electrolyte concentrations, 
uraemia, anaemia, inflammation and autonomic imbalance. 
 
6.4.2 Reducing risk of sudden cardiac death in ESRD patients 
Ideally, reduction of sudden cardiac death in ESRD patients should be achieved by 
identification of individuals at high risk and implementation of therapy shown to 
reduce cardiac events with randomised prospective trials.  Unfortunately, studies in 
this area have provided limited data due to under powering, absence of sufficient 
controls, or the retrospective nature of their design.  However, a number of 
promising studies have identified therapeutic agents that may reduce VTA and SCD 
in ESRD patients. 
• Beta adrenergic  receptor blockers   
In a small prospective study, Cici et al randomised 144 haemodialysis patients with 
dilated cardiomyopathy to receive carvedilol or placebo.  Prevalence of 
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cardiovascular death after 2 years was 29.3% in the carvedilol group compared to 
67.9% in the placebo group.  In addition, there was a trend to reduced SCD 
(carvedilol 3.4% vs placebo 10.6%) but did not achieve statistical significance due to 
inadequate numbers (120).  Further studies are required to determine whether β 
blockers similarly reduce SCD in ESRD patients with normal LV function and 
structure. 
 
In post MI studies (CAPRICORN and COPERNICUS), patients with mild to 
moderate CKD also showed marked reduction in cardiovascular death when treated 
with carvedilol compared to placebo suggesting that blockade of sympathetic 
nervous system at early stages of CKD may provide some benefit (229;230). 
 
• Renin angiotensin system blockers 
There are no studies to prospectively evaluate the role of ACE inhibitors or 
angiotensin receptor blockers (ARBs) in ESRD patients with SCD as a primary 
outcome.  In addition, no interventional studies have been performed in ESRD 
patients with reduced LV function.  Small observational studies have demonstrated a 
significant reduction in mortality, independent of blood pressure reduction in dialysis 
patients treated with ACE inhibitors (231).  However, a prospective trial with 
fosinopril found no difference in fatal and non fatal cardiovascular events between 
treatment and placebo group.  A small prospective study of candersartan showed a 
reduction in cardiac arrhythmias and cardiovascular events in haemodialysis patients.  
However, this result was not statistically significant due to small event numbers 
(123;125). 
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Nonetheless, ACEI/ARBs are attractive therapies, if tolerated, due to their multiple 
effects demonstrated in non renal populations (i.e. effects on neurohumoral 
activation, vascular haemodynamics, myocardial architecture, vascular inflammation 
and oxidative stress).   
 
• Aldosterone receptor blockers 
In patients with severe symptomatic heart failure, spiranolactone has been shown to 
significantly reduce cardiovascular death and SCD (RALES study) (232).  In 
addition, aldosterone may contribute to myocyte hypertrophy and fibrosis in ESRD 
patients and earlier stages of CKD (233) and is an attractive target for intervention.  
Most clinicians will not prescribe these agents to dialysis patients due to risk of 
hyperkalaemia.  In a recent prospective study of spiranolactone in 30 haemodialysis 
patients, no patients developed serum K+> 6.0mmol/l and only two patients required 
alteration in dialysate suggesting that this recognised side effect can be 
accommodated if necessary. Unfortunately this study demonstrated no effect on 
LVMI measured by CMR after 9 months of spiranolactone therapy (234). 
 
• Implantable cardioverter defibrillators (ICD).  
In patients with reduced LV ejection fraction, secondary prevention with ICD 
insertion has been associated with reduced mortality (82). Studies which have 
investigated beneficial effects of ICD in dialysis patients have already been 
discussed in Chapter 1. 
 
In addition, some investigators believe that the survival benefit afforded by primary 
ICD insertion patients may be negated in patients with significant co-morbid 
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conditions such as ESRD.  For example, in a retrospective study of 585 patients 
(235) who received ICDs, survival in dialysis patients was significantly reduced 
compared to patients with normal renal function patients, despite receiving dialysis 
being a significant predictor of ICD discharge (HR 2.30 95% CI 1.20-4.50).  
 
In secondary prevention of VTA, data from the USRDS have demonstrated a 
significant (42%) reduction in mortality in dialysis patients who receive ICDs (128).  
Unfortunately, this study also reported that only 8% of dialysis patients who met 
criteria for ICD insertion as secondary prevention of SCD had a device fitted. 
Underutilisation of ICDs may be due to recent data reporting higher complication 
rates (bleeding, infection) in dialysis patients and problems when dialysis access and 
insertion site are ipselateral (such as subclavian vein stenosis and occlusion) (130). 
 
Intervention in ESRD patients, particularly for primary prevention of SCD, remains 
controversial necessitating more studies. Similar to the therapeutic approach of 
patients with heart failure, intervention should be directed and intensified to well 
characterised groups of ESRD patients that have been identified as higher risk of 
VTA and SCD.   
 
6.4.3 ESRD patients at high risk of sudden cardiac death- role of MTWA 
A large number of studies have demonstrated strong negative and positive predictive 
power (similar to invasive electrophysiological testing) of MTWA test results for all 
cause mortality in ischaemic and non-ischaemic cardiomyopathy (105;106).  Based 
on these initial findings, MTWA was considered an ideal method of identifying 
those patients with reduced LV function (ejection fraction<30-35%) who would have 
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survival benefit from primary ICD implantation.  Two more recent prospective 
studies (MASTER and TWA SCD-HeFT) have suggested reduced specificity and 
sensitivity of MTWA for risk stratifying heart failure patients (109;110).  These 
studies used cardiac arrhythmia, ICD discharge or sudden cardiac death as a 
composite end point compared to all cause or cardiovascular mortality used in 
previous studies.  Further investigations are currently underway to elucidate the 
setting in which MTWA would be useful for predicting VTA in heart failure patients 
and other patients at risk of SCD.  
 
To this end, this study was performed in ESRD patients using MTWA testing to 
assess the prevalence of and significant associations with an abnormal MTWA 
result.  CMR measurements were obtained in subjects to assess relationship with 
features of uraemic cardiomyopathy. 
 
These data show that abnormal MTWA test results are common (57.5%) in ESRD 
patients and this prevalence is similar to previous heart failure studies (236). 
However, the patients in our cohort had preserved LV function (ejection fraction 
61.9±15.3%) suggesting that the aetiology of cardiac arrhythmias differs between 
ESRD patients and patients with ischaemic and non ischaemic cardiomyopathy. On 
comparison of these results with diabetics and healthy athletes, abnormal MTWA 
result was more common in ESRD patients (111).   
 
6.4.4 Comparison between ESRD and hypertensive LVH 
Patients with hypertensive LVH and normal renal function were used as controls in 
this study. Hypertensive LVH differs from uraemic cardiomyopathy both in extent 
242 
 
and pattern of sarcomere expansion and interstitial fibrosis (49;51).  This control 
group was used to provide an indication of the additional risk afforded by uraemic 
cardiomyopathy and the abnormal myocardial environment in ESRD patients.  These 
data show that prevalence of abnormal MTWA was significantly higher in ESRD 
patients compared to hypertensive LVH patients despite similar LV size and function 
between both groups. 
 
An earlier study comparing MTWA results between patients with hypertrophic 
cardiomyopathy and hypertensive LVH patients found a much higher prevalence of 
positive test result (31%) in LVH patients compared to data presented in this chapter.  
However different MTWA exercise protocols (only HR up to 110 bpm were 
performed) and older classification criteria (indeterminate tests were not reported) 
were employed in this study (237). 
 
Abnormal MTWA result has been associated with repolarisation alternans, which is 
defined as discordant and alternating action potential duration between neighbouring 
cardiomyocytes. Biopsy proven cellular changes (myocyte hypertrophy) and 
arrangement (disarray) in conjunction with myocardial fibrosis have been associated 
with abnormal MTWA result and may contribute with repolarisation alternans (103).  
Endomyocardial biopsies have demonstrated increasing myocardial fibrosis and 
more heterogeneous histology with worsening CKD (51).  One would expect with 
higher inter-myocyte deposition of collagen (usually type 1), and greater changes in 
tissue arrangement, there would be greater fluctuations in AP 
depolarisation/repolarisation, leading to non- uniform depolarisation and increasing 
risk of abnormal MTWA result and SCD.  
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However, there are some limitations in this comparison.  Prior to recruitment, 
hypertensive patients were eligible for inclusion based on prior ECG or 
echocardiographical evidence of LVH.  Unfortunately, CMR results showed that 
only 18 (60%) of patients had LVH using previously defined cut offs for LVMI 
(154). Furthermore there were no significant differences between myocardial 
abnormalities of both groups since this study was powered only to determine a 
difference in MTWA result. On examination of the data, however, ESRD patients 
had more extreme cardiac abnormalities (represented by higher LVMI, greater 
variability in LV chamber size, and reduced ejection fraction) and a greater number 
of cardiovascular risk factors compared to LVH patients.  
 
6.4.5 Implications for an indeterminate MTWA test 
The rate of indeterminate tests was high (35.5%) and a large proportion (51%) of 
these patients were unable to achieve adequate HR elevation reflecting poor exercise 
tolerance of ESRD patients.  A proportion of these patients were able to attempt a 
repeat test but this did not affect final MTWA result.  Poor exercise tolerance in 
ESRD patients has been demonstrated by other studies and is due to high levels of 
co-morbidity including peripheral vascular disease, diabetic peripheral neuropathy 
and pulmonary oedema (238).   In heart failure patients, pharmacological attempts to 
elevate heart rate have been used, however ethical approval for this approach was not 
obtained.  Nonetheless, an indeterminate result has been demonstrated as a 
significant independent predictor of death (both arrhythmic and non-arrhythmic) in 
heart failure patients in a small prospective trial (227) and the relevance in ESRD 
patients remains to be assessed.  
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6.4.6 MTWA and uraemic cardiomyopathy 
This study also demonstrates a strong association between the features of uraemic 
cardiomyopathy (LVH, LVSD and LV dilatation) and abnormal MTWA result (table 
6.3).  In patients with other cardiomyopathies (such as dilated or hypertrophic), 
abnormal MTWA result rate is high (between 65-78%) and it follows that non 
uniform repolarisation is associated with atypical myocardial cytoarchitecture (e.g. 
LVH, myocardial fibrosis) (105).  Unfortunately, due to the association between 
gadolinium based contrast agents and nephrogenic systemic fibrosis (NSF), further 
assessment of myocardial fibrosis could not be performed (239).   
 
6.4.7 Factors associated with abnormal MTWA 
ESRD patients with an abnormal test were significantly older, which is similar to 
findings of previous studies in patients with ischaemic and non ischaemic 
cardiomyopathy (225).  Diabetic patients with ESRD had a significantly higher rate 
of abnormal test result and this most likely represents the additional, and initially 
silent, cardiovascular morbidity that diabetics have compared to non-diabetic ESRD 
patients. In addition, presence of abnormal MTWA result was significantly higher in 
ESRD patients with history of macrovascular atheromatous disease, namely 
coronary, peripheral and cerebrovascular, which is reflected in their medical therapy- 
abnormal result was associated with greater statin usage.  Interestingly, there was no 
difference in aspirin, beta adrenergic blocker and ACE inhibitor or angiotensin 
receptor blocker therapy between both groups supporting the evidence that these 
drugs may be under utilised in high cardiovascular risk patients.  To further identify 
factors independently associated with abnormal test, multivariate logistic regression 
analysis was performed using abnormal MTWA result at the outcome variable.  This 
245 
 
confirmed older age, past clinical history of macrovascular diseases, and features of 
uraemic cardiomyopathy (higher LVMI and presence of LV dilatation) as 
independent predictors of abnormal MTWA result.  Interestingly, abnormal MTWA 
was independently predicted by clinical history of peripheral and cerebrovascular 
atheromatous disease.  These results suggest that in the absence of CMR evidence of 
uraemic cardiomyopathy or ischaemic heart disease, interference of cardiomyocyte 
repolarisation occurs in patients with previous stroke or lower limb vascular 
insufficiency.  It is likely that in these patients, cardiac small vessel disease and 
clinically silent myocardial ischaemia are present. 
  
At this stage of the study, a trend toward reduced survival in the patients with 
abnormal MTWA result was demonstrated (Figure 6.3). These results are 
unsurprising given that major predictors of CV death in ESRD patients include past 
medical history of CV disease and myocardial structural changes (Chapter 4).  Given 
that abnormal MTWA result was more common in patients with established CV 
disease, additional information for predicting SCD seems unlikely.  However, as 
more data on patient outcome for this cohort becomes available, the predictive value 
of MTWA for SCD in ESRD patients can hopefully be fully established.  
 
6.4.8 Limitations of current study 
As before this study was limited by the recruitment of patients undergoing pre-
transplant CV assessment.  Furthermore, although control patients had 
echocardiographical or ECG evidence of LVH, only 60% had CMR proven LVH.  
This study was powered to compare differences between MTWA results only based 
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on pilot data and previously published studies.  As a result there was a discrepancy 
between the numbers of patients in each group. 
 
6.5 CONCLUSIONS 
In conclusion, this study demonstrates a strong association between the myocardial 
abnormalities of uraemic cardiomyopathy and abnormal MTWA result, implicating 
abnormal ventricular repolarisation with high risk of SCD in ESRD patients.  
Similarly, a history of macrovascular atheromatous disease is significantly associated 
with an abnormal MTWA result.  The potential role that MWTA may have to 
independently predict development of cardiac arrhythmia and SCD remains to be 
assessed.  
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Chapter 7 
 
A study of 31P Magnetic resonance spectroscopy in uraemic and hypertensive 
cardiomyopathy 
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7.1 INTRODUCTION 
As discussed in Chapter 1, uraemic cardiomyopathy is characterised by 
abnormalities of myocardial structure, namely LVH, LVSD and LV dilatation, which 
are associated with elevated risk of CV morbidity and mortality.  In patients with 
heart failure, abnormal cardiac structure is associated with alteration in 
cardiomyocyte metabolism (147).  Changes occur in metabolic substrate transport 
and usage, oxidative phosphorylation, and high energy phosphate metabolism.  The 
latter is particularly important since reduced creatine kinase activity results in 
decreased free ATP concentration, reduced transfer of energy (in the form of high 
energy phosphate bonds) from cardiomyocyte mitochondria to myofibrils, and 
elevation of cytoplasmic ADP concentration.  31P-MRS allows non-invasive 
measurement of relative concentrations of phosphorus containing compounds 
including ATP, PCr and 2, 3-DPG and thus the assessment of high energy phosphate 
(HEP) metabolism. Previously, only small studies have been performed in ESRD 
patients and patients with hypertensive LVH.  In addition, the relationships between 
HEP metabolism and features of uraemic cardiomyopathy have not been 
investigated. 
 
The aims of this study were to: 
• Compare HEP metabolism in a cohort of ESRD patients and hypertensive LVH 
patients with normal renal function to determine the additional detrimental effects of 
uraemia. 
• Determine associations between uraemic cardiomyopathy and HEP metabolism. 
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7.2 METHODS 
 
7.2.1 Patients 
As before, ESRD patients were recruited from subjects being assessed for renal 
transplantation as discussed in Chapter 2.  In addition, 30 hypertensive patients with 
ECG or echocardiographic evidence of LVH and normal renal function (within 6 
months of recruitment) were assessed (termed LVH patients).  Each patient provided 
cardiovascular history, examination, ECG, and blood for biochemical and 
haematological profile.  Patients with contraindication to MRI (see Chapter 2) were 
excluded.  Since only the effect of uraemia was to be assessed, patients with past or 
current history of ischaemic heart disease or heart failure were excluded from the 
study.   
 
7.2.2 CMR acquisition and analyses 
CMR scans were acquired for assessment of LV mass and function and analysed as 
described in Chapter 2.  Patients were classified as having LVH, LVSD or LV 
dilatation based on previously described normal values. 
 
7.2.3 31P MRS acquisition 
Resting 31P MRS was performed in all patients as described in Chapter 2.  Care was 
taken to ensure spectra were acquired from areas of uniform LV contraction (ie not 
from regions of poor wall motion).  Areas under the curve for 2,3-DPG, PCr, and β-
ATP were measured, and a blood corrected PCr: βATP ratio (PCr: ATP) calculated 
(156). 
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7.2.4 Statistical analyses 
Statistical analyses were performed using SPSS version 15.0 (SPSS Inc. Illinois, 
USA). Data are described as mean± standard deviation.  Data were compared by chi 
squared or Fisher’s test for categorical data and paired t-test for continuous data.  
Correlations between PCr: ATP and cardiac measurements were evaluated by 
Pearson’s and Spearman’s correlation coefficient as appropriate.  
 
Twenty anonymised spectra were used for reproducibility studies.  Intra-observer 
variability of PCr: ATP was determined by a single observer (RKP) assessing each 
scan twice (at least 7 days apart) followed by calculation of the differences between 
each scan.  Inter-observer variability was determined by two independent observers 
(RKP and T Steedman, Clinical Research Initiative, Western Infirmary, Glasgow) 
analysing the same scans.  The level of difference for PCr: ATP was measured for all 
scans and the consistency of ratios assessed using the intra-class correlation 
coefficient (ICC) 
 
7.3 RESULTS 
 
7.3.1 Patient demographics 
Clinical, drug and blood data for ESRD (n=53) and LVH (n=30) patients are shown 
in Table 7.1. Despite excluding patients with symptomatic ischaemic heart disease, 
there was higher burden of CV disease in ESRD compared to LVH patients; there 
was a higher number of ESRD patients with a past history of diabetes mellitus, 
peripheral and cerebrovascular disease, dyslipidaemia, and current or previous 
history of smoking compared to patients with LVH.  Furthermore, use of aspirin, β 
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blockers, statins and calcium channel blockers was more common in ESRD patients.  
Diastolic blood pressure was higher in LVH patients compared to ESRD patients 
probably reflecting wider pulse pressure and increased vascular stiffness in ESRD.   
There were no significant differences in age, sex, systolic blood pressure and use of 
warfarin or diuretic therapy between both patient groups. Comparison of blood 
results between ESRD and a population with normal renal function was as expected 
(in ESRD patients haemoglobin was lower, inflammatory markers were elevated, 
biochemical features of secondary hyperparathyroidism were present and serum 
potassium was higher.)  Glucose was also higher in the ESRD compared to LVH 
patients due to the higher proportion of diabetic patients in this cohort.  Serum 
cholesterol was significantly higher in the LVH group, however the use of statins 
was lower in these patients compared to ESRD subjects.  Brain natriuretic peptide 
levels were significantly higher in the ESRD group compared to the LVH group, 
most likely due to chronic fluid overload, myocardial dysfunction and subsequent 
elevated ventricular wall tension. 
 
7.3.2 Cardiac data 
Table 7.2 shows CMR results for ESRD and LVH patients.    There were no 
significant differences in LV systolic function (which was preserved), LV mass or 
chamber size.  Despite echocardiography or ECG evidence of LVH, only 18 (60%) 
of hypertensive patients had LVH on CMR assessment, based on previously 
published values.  LV systolic dysfunction and dilatation were more common in the 
ESRD group compared to the LVH group, however, LVSD did not reach statistical 
significance due to small sample size. 
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7.3.3 Reproducibility of measurement of cardiac 31P magnetic resonance 
spectroscopy 
To assess reproducibility, twenty anonymised spectra were re-analysed.  The intra-
observer variability of measurements of PCr: ATP, assessed by absolute difference 
of ratios was 0.17±0.24, and there was no significance between analyses (p=0.78).  
The inter-observer variation was determined by comparing mean corrected PCr: ATP 
for all scans measured by each observer: RKP= 1.28±0.43, TS= 1.21±0.41; p=0.56.  
Intra-class correlation coefficient was 0.89. 
 
7.3.4 Comparison of 31P-MRS results   
Table 7.2 shows comparison of 31P-MRS results between ESRD and LVH patients.  
There were no significant differences between PCr, β-ATP and 2,3- DPG values.  
However, mean PCr: ATP ratios (uncorrected and corrected for blood 
contamination) were significantly lower in ESRD patients compared to LVH patients 
(corrected PCr: ATP ESRD 1.3±0.5 vs. LVH 1.6±0.4 p=0.007, Figure 7.1).  In the 
ESRD group, there was no significant difference between diabetic and non diabetic 
patients (PCr: ATP diabetic 1.4±0.7 vs non diabetic 1.3±0.4; p=0.66, data not 
shown).   Only 18 (60%) of hypertensive patients with echocardiographic/ECG 
evidence of LVH met CMR criteria for LVH.  PCr: ATP was significantly lower in 
ESRD patients compared to hypertensive patients with CMR evidence of LVH 
(ESRD n=53 corrected PCr: ATP 1.3±0.5 vs. LVH on CMR n=16 :1.7±0.3 p=0.03) 
 
7.3.5 PCr: ATP and uraemic cardiomyopathy 
In the ESRD group, PCr: ATP was significantly lower in patients with LV systolic 
dysfunction (no LVSD 2.0±0.5 vs LVSD 1.2±0.2; p=0.05) and LV dilatation (no LV 
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dilatation 1.79±0.4 vs LV dilatation 0.98±0.8; p=0.01).  LVH was not associated 
with significant difference in PCr:  ATP. 
 
7.3.6 Correlations of PCr: ATP in ESRD patients 
There was a weak but significant correlation between corrected PCr: ATP and LV 
ejection fraction (Pearson’s R= 0.31; p=0.03).  BSA corrected end systolic volume 
was negatively correlated with corrected PCr: ATP (Pearson’s R= -0.27, p= 0.06), 
but this did not reach statistical significance (Table 7.3).  There were no other 
significant correlations between PCr: ATP and clinical, blood and cardiac data 
(including, LVMI, haemoglobin and bone biochemistry). 
 
7.3.7 Determinants of PCr: ATP in ESRD patients 
Multivariable linear regression analysis was performed to create the most robust 
predictive model for PCr: ATP (Table 7.3).  Factors considered in the model were 
those identified as significant (or close) correlates with PCr: ATP.  Using backward 
stepwise regression, the most significant model (highest R2=0.27) demonstrated LV 
ejection fraction as the only significant variable that was independently associated 
with PCr: ATP. 
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Variable 
 
ESRD 
N=53 
LVH Only 
N=30 
p 
Age (years) 54.7(±12.6) 54.6 (±10.6) 0.98 
Male (%) 33(63.3) 24 (80.0) 0.09 
BMI (kg/m2) 26.2(±5.2) 27.1(±3.6) 0.41 
Systolic BP (mmHg) 142 (±23) 139 (±17) 0.53 
Diastolic BP (mmHg) 81 (±14) 87 (±9) 0.03 
RRT HD 37 (69.8) -  
 PD 0 -  
 CKD 5 16(30.2) -  
RRT Time(years) 1.26 (1.9) -  
Primary Renal Disease    
Diabetic Nephropathy 22 (41.5) -  
APCKD 5(9.4) -  
Glomerulonephritis 6(11.3) -  
Renovascular Disease 4(7.5) -  
Chronic Pyelonephritis 5(9.4) -  
Other/Uknown 11(20.8) -  
Diabetes mellitus 14 (26.4) 0 <0.01 
Hypertension 39 (73.6) 30 (100) 0.08 
Cerebrovascular disease 11 (20.8) 1 (3.3)  
Peripheral vascular disease 12 (14.5) 0  
Dyslipidaemia 25 (47.1) 9(30) <0.01 
Smoking Never 22 (41.5) 19 (63.3) 0.06 
 Current 17 (32.1) 3(10)  
 Ex 14 (26.4) 8 (26.7)  
Epo receptor Agonist 46(86.8) 0  
β Adrenoceptor Blocker 25 (47.2) 10 (33.3) <0.01 
Aspirin 35 (66.0) 3 (10) <0.01 
Warfarin 3(5.7) 0 0.63 
Clopidogrel 3(5.7) 0  
ACEI/ARB 30 (56.6) 12 (40.0) 0.08 
Diuretic 13(24.5) 6 (20.0) 0.11 
Nitrate 0 8(26.7)  
Calcium Channel Blocker 26 (49.1) 8(26.7) 0.02 
α Adrenoceptor Blocker 6 (11.3) 1 (3.3)  
Statin 30 (56.6) 9(30.0) 0.03 
Haemoglobin (g/dL) 11.8(±2.2) 14.8(±1.4) <0.01 
Fibrinogen (g/L) 4.1(±1.0) 3.2(±0.5) <0.01 
ESR (mm/s) 29 (14, 56) 8(2, 10) <0.01 
CRP (mg/L) 5.0(3.3, 13.3) 1.1 (0.7, 4.3) <0.01 
Adjusted Ca2 +(mmol/L) 2.33(±0.2) 2.41 (±0.1) <0.01 
PO4 (mmol/L) 1.52(±0.4) 1.05 (±0.1) <0.01 
PTH (pmol/L) 19.3(11.6, 45.1) 5.6(4.6, 7.5) <0.01 
Glucose (mmol/L) 9.1(±1.8) 5.2(±3.3) <0.01 
HbA1c (%) 6.9(±2.8) 5.4(±0.9) 0.02 
Potassium (mmol/L) 4.8(±0.3) 4.1(±0.3) <0.01 
BNP (ng/L) 228(134, 557) 27 (13, 43) <0.01 
Cholesterol (mmol/L) 4.3(±1.2) 5.4(±1.2) <0.01 
Triglyceride (mmol/L) 1.9(±0.8) 2.0(±1.1) 0.68 
HDL- Chol (mmol/L) 1.2(±0.6) 1.4(±0.4) 0.14 
LDL- Chol (mmol/L) 2.4(±0.4) 2.8(±0.8) 0.21 
 
Table 7.1 Comparisons of clinical and blood results between ESRD and LVH 
patients.  
Data are number with percentage in parentheses and mean ± standard deviation 
except for ESR, CRP, PTH and BNP where median and interquartiles are shown.  
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Variable 
 
ESRD 
N=53 
LVH Only 
N=30 
P 
Ejection Fraction (%) 66.4(±12.4) 65.5(±11.2) 0.75 
Myocardial mass/BSA 87.5(±30.4) 82.4(±32.6) 0.48 
EDV/BSA (ml/ m2) 63.8(±24.9) 65.7(±14.1) 0.70 
ESV/BSA (ml/ m2) 22.4(±15.8) 23.2(±12.1) 0.81 
LVH on MRI 33(62.2) 18 (60) 0.72 
LVSD on MRI (EF<55%) 8(22.9) 1(3.3) 0.07 
LV dilatation 22 (41.5) 1(3.3) <0.01 
PCr  7.7(±3.8) 8.3(±3.6) 0.48 
β-ATP 6.5(±3.1) 5.3(±2.6) 0.10 
2,3-DPG 1.1(±0.8) 1.2(±0.9) 0.55 
Uncorrected PCr: βATP 1.9(±0.8) 2.4(±0.7) <0.01 
Corrected PCr: βATP 1.3(±0.5) 1.6(±0.4) <0.01 
 
Table 7.2 Comparisons of cardiac and 31P MRS results between ESRD and 
LVH patients.  
Data are number with percentage in parentheses and mean ± standard deviation.   
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Figure 7.1 Bar chart showing mean (± standard deviation) of corrected PCr: 
ATP for ESRD (n=53) and LVH patients (n=30) 
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Table 7.3 Correlation between PCr:ATP and clinical, blood and cardiac 
parameter (left) and multivariate linear regression (right) entering only 
significant correlates into the (backward stepwise) model (adjusted R2=0.27). 
    p 95% CI 
   Constant 
0.35 
 
0.27 
 
-0.28-0.98
 r p B β  β 
LV Ejection fraction (per %) 0.31 0.03 0.10 0.27 0.04 0.21-0.42 
ESV/BSA (per ml/m2) -0.27 0.06     
LDL- Cholesterol (per mmol/l) 0.35 0.20     
Serum Cholesterol (per mmol/l) 0.30 0.24     
ESR (per mm/s) 0.59 0.07     
Male Sex  -0.17 0.22     
BMI (per kg/m2) -0.05 0.75     
Haemodialysis (ref predialysis) 0.08 0.54     
Systolic Blood Pressure (per mmHg) 0.06 0.66    
Diastolic Blood Pressure (per mmHg) 0.16 0.25    
Haemoglobin (per g/dL) 0.15 0.56    
Fibrinogen (per g/L) -0.36 0.20    
CRP (per mg/L) 0.02 0.94    
Serum Calcium (per mmol/l) 0.21 0.88    
Serum Phosphate (per mmol/l) -0.43 0.86    
Ca x PO4 Product(per mmol2/l2) -0.12 0.93    
Parathyroid Hormone (per pmol/l) -0.06 0.66    
Glucose (per mmol/l) -0.21 0.17    
Serum Potassium (per mmol/l) -0.05 0.74    
Triglyceride (per mmom/l) 0.25 0.11    
HDL-  Cholesterol (per mmol/l) 0.09 0.55    
BNP (ng/L) -0.33 0.13    
LVMI (per g/m2) -0.96 0.34    
EDV/BSA (per ml/m2) -0.08 0.56    
Diabetes Mellitus  0.03 0.81    
Cerebrovascular Disease  -0.05 0.74    
Peripheral vascular disease -0.03 0.82    
Smoker 0.04 0.79    
Β Blocker 0.08 0.58    
Aspirin -0.05 0.72    
Erythropoietin  -0.27 0.16    
ACE Inhibitor/ARB 0.15 0.21    
Calcium Channel Antagonist 0.18 0.16    
Statin -0.13 0.33    
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7.4 DISCUSSION 
 
31Phosphorus magnetic resonance spectroscopy has been used in vivo to study LV 
high energy phosphate (HEP) metabolism in human hearts (145;146).  As stated in 
Chapter 1, inherited and acquired cardiomyopathies are not only associated with 
abnormal cardiac structure but also reduced PCr: ATP in areas of apparently normal 
LV contraction.  These results suggest that although echocardiography or CMR may 
demonstrate “normal” myocardial contraction, biochemical abnormalities are present 
which may precede development of systolic dysfunction by reducing metabolic 
activity and/or efficiency (147).  The clinical relevance of HEP metabolism has been 
demonstrated in heart failure patients, where reduced myocardial PCr: ATP has been 
significantly associated with lower LVEF and NYHA symptom severity.  
Furthermore, in dilated cardiomyopathy patients, lower PCr: ATP is significantly 
associated with reduced survival and is a better predictor of survival than LVEF or 
NYHA class (144). 
 
As shown in Chapter 4, features of uraemic cardiomyopathy are associated with 
poorer survival and are independent predictors of adverse CV outcome.  In ESRD 
patients, presence of wall motion abnormalities are rare at rest (240), indicating that 
global, uniform LV “disease” is a more common cause of reduced LV ejection 
fraction. 
 
In this current study, HEP metabolism was investigated in a cohort of ESRD 
patients.  Patients with known ischaemic heart disease were excluded to assess the 
effect of uraemia and small vessel ischaemia (Table 8.1).  Acquisition voxels were 
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placed on visibly functioning myocardium to ensure that PCr: ATP was measured 
from viable cardiac tissue and not scar/fibrotic tissue.  As a control group, patients 
with LVH due to hypertension were assessed to allow the effect of additional 
abnormalities (LVSD and LV dilatation) and uraemia to be determined in ESRD 
patients.   
 
7.4.1  Reduced PCr:ATP in uraemic cardiomyopathy 
The biochemical changes that accompany reduced PCr:ATP are not completely 
understood and derived mostly from animal studies.   Lowered PCr:ATP indicates 
that in the resting state there are reduced myocardial energy reserves and in animal 
models for cardiac hypertrophy (e.g. spontaneously hypertensive rat) a reduction in 
PCr:ATP has been demonstrated  (241;242).   In clinical and experimental models of 
cardiac failure, reduced PCr:ATP ratio have been attributed to reduced levels of 
creatine kinase activity.  However, in animal models of uraemic cardiomyopathy 
changes in creatine kinase activity (243) and cyptoplasmic creatine concentration 
have not been convincingly demonstrated (244). 
 
Impaired ATP synthesis (e.g. from oxidative phosphorylation) or increased 
utilisation (excitation- contraction coupling) may reduce PCr by the buffering 
creatine kinase system.  Furthermore, the subsequent elevation in free cyptoplasmic 
ADP may affect cardiac function adversely, since high ADP concentration inhibit 
myosin ATPase activity thus exacerbating contractile dysfunction.  These 
experimental finding are consistent with the results of this study.  In ESRD patients, 
not only were features of uraemic cardiomyopathy (LVSD and LV dilatation), 
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significantly associated with reduced PCr:ATP ratio but LV ejection fraction was the 
only variable that was independently associated with PCr:ATP measurements.  
 
7.4.2 Comparison of PCr: ATP result 
The values obtained for ESRD and LVH patients are comparable to previous studies 
(149;245).  These results show that despite similar LV mass, function and chamber 
size, PCr: ATP ratios were significantly lower in ESRD patients compared to LVH 
patients.  As one would expect, there were significantly more ESRD patients with 
LVSD and LV dilatation using established criteria. Only 60% of hypertensive 
patients with LVH on echocardiography had evidence on CMR, highlighting greater 
accuracy of LV mass measurement using CMR.  PCr:ATP ratio was similarly lower 
in ESRD patients compared to hypertensive patients with LVH on CMR.  Consistent 
with a previous smaller study which compared HEP metabolism between diabetic 
and non diabetic uraemic patients (149), there was no significant difference in PCr: 
ATP between diabetic and non diabetic ESRD patients. 
 
The differences between PCr:ATP in ESRD and LVH patients are most likely due to 
alteration of: 
• Composition of myocardial interstitial tissue  
• Cardiomyocte metabolic function. 
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7.4.3 Alteration in intercellular composition- myocardial fibrosis. 
 
Left ventricular hypertrophy is characterised by changes in tissue architecture 
including myocardial fibrosis and expansion of sacrcomere volume and density.  In 
patients with systemic hypertension and ESRD, myocardial fibrosis is a consequence 
of accumulation of collagen, mostly type 1 fibres, within the cardiac interstitium, and 
around the intermyocyte arterial tree.  This accumulation is due to a combination of 
excessive collagen production by fibroblasts accompanied with reduced or unstable 
degradation of older fibres by extracellular metalloproteinases (50; 51).   
 
Initially in patients with hypertension and CKD, factors such as pressure overload, 
oxidative stress, inflammation and production of pro- fibrotic cytokines (namely 
TGF-β and cardiotrophin-1) stimulate collagen fibre production.  Both in vitro and in 
vivo studies using the spontaneously hypertensive rat (SHR), have demonstrated that 
chronic pressure overload stimulates procollagen gene expression and collagen 
protein synthesis resulting in deposition of collagen fibres within the cardiac 
interstitium (51).  Post-mortem and endomyocardial biopsy studies of hypertensive 
and ESRD patients have demonstrated similar patterns of collagen deposition 
reflecting lines of excessive wall stress and  increasing collagen density proportional 
to wall thickness (246;247).  Angiotensin II is a potent stimulator of cardiac fibrosis 
in humans with hypertension via stimulation of the angiotensin II receptor- 1 and is 
facilitated by locally produced factors produced by cardiomyocytes (e.g. ostepontin, 
endothelin-1).  Studies assessing regression of fibrosis using ACE inhibitors or AII 
receptor blockers have demonstrated some improvement in patients with no renal 
impairment but little effect in ESRD individuals (248;249). 
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Myocardial fibrosis is also stimulated by other factors in advanced stages of renal 
disease.  Parathyroid hormone stimulates rat cardiac fibroblast proliferation in vitro.  
In 5/6 nephrectomised rats (acting as an animal model of uraemic cardiomyopathy), 
interstitial fibroblasts express higher levels of proliferation markers (eg proliferating 
cell nuclear antigen), platelet derived growth factor, integrin β1 and laminin 
compared to experimental models of genetic hypertension (61;250).   
 
In patients with hypertensive heart disease, the degree of myocardial fibrosis has 
previously been assessed using endomyocardial biopsy, MRI with gadolinium 
enhancement, and serum markers for collagen type 1 deposition (251).  In patients 
with advancing stages of CKD, the degree of LVH and indicators of diastolic 
dysfunction increase at a similar rate and this may be due, in part, to higher levels of 
myocardial fibrosis.  Patients with worsening degrees of CKD have consistently 
demonstrated higher levels of inter-myocyte fibrosis (252). Furthermore, in patients 
with dilated cardiomyopathy, dialysed patients have been shown to have more severe 
and disorganised myocardial fibrosis on endomyocardial biopsies compared to their 
non dialysed counterparts (253).  Taken together, interstitial cardiac fibrosis is likely 
to contribute to CMR and echocardiographical features of uraemic cardiomyopathy. 
 
Thus it is likely that a greater degree of inter-myocyte fibrosis within the tissue of 
interest is a significant contributing factor to reduced PCr:ATP ratio in ESRD 
patients compared to LVH ones.  Reduction of measured HEP metabolism may be a 
consequence of: 
• Impeded nutrient/metabolic substrate (e.g. glucose, oxygen) transfer to cardiac 
myocytes as a result of intervening collagen. 
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• Reduced cardiomyocyte volume per acquisition voxel due to presence of fibrosis 
which may not interfere with macroscopic contracting tissue. 
 
7.4.4 Alteration of cardiomyocyte function 
Several animal model and clinical studies have demonstrated abnormalities of 
cardiomyocyte metabolism in uraemia. 
 
7.4.4a Abnormal cyptoplasmic calcium cycling within cardiomyocytes. 
Since intracellular Ca2+ plays a central role in excitation-contraction coupling of 
cardiomyocytes, alterations of intracellular handling may contribute to contractile 
failure. In experimental rat models of uraemic cardiomyopathy (5/6 nephrectomy), 
elevating extracellular perfusing Ca2+ did not have an effect on uraemic hearts (n=8) 
compared to the positively inotropic response of sham operated controls (n=8), 
despite similar changes in heart rate (244). This was also associated with a reduced 
PCr:ATP in the uraemic cardiomyopathy group compared to controls. The authors 
concluded that disordered myocardial calcium usage may contribute to cardiac 
metabolic derangements.  Furthermore, the same group performed isolated 
ventricular myocyte studies from similar rat groups.  Using steady state field 
stimulation to investigate intracellular Ca2+ concentration changes during cell 
contraction, significant slowing of return to diastolic intracellular Ca2+ levels 
compared to controls was demonstrated in myocytes from uraemic hearts (254).  
This effect has been abolished by inhibiting the Na+/Ca2+ exchanger suggesting that 
membrane bound transporters play a pivotal role in controlling intracellular Ca2+ 
concentrations and relaxation during diastole in myocytes from uraemic hearts (255). 
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Similarly, in an isolated rat cardiac myocyte system investigating Ca2+ cycling and 
contractile function, treatment of these cells with uraemic patient sera (n=6) resulted 
in prolongation of cell relaxation and calcium mediated recovery compared to sera 
from healthy controls (256). Thus, uraemia is associated with abnormal Ca2+ cycling 
which may significantly affect excitation coupling and relaxation of cardiac tissue 
and utilisation of ATP during the cardiac cycle. 
 
7.4.4b Microvascular disease and myocardial ischaemia 
Development of cardiac hypertrophy is commonly due to an adaptive response to 
pressure and volume overload.  However, a mismatch of energy demand (from 
hypertrophied myocytes) and supply (due to inadequate angiogenesis) may 
contribute to the development of cardiac failure (257).  
 
Myocardial ATP production is primarily achieved by oxidative phosphorylation and 
the creatine kinase reaction acts as a cardiac energy buffer/reserve providing ATP 
rapidly to the sites of need.  Cardiomyocyte ATP production is directly related to 
myocardial oxygen consumption, and any reduction in oxygen supply has a profound 
effect on cardiac energetics and the PCr:ATP ratio.  In this study, there was no 
significant difference in cardiac parameters between ESRD and LVH groups even 
when patients with symptomatic CAD were excluded.  Furthermore, care was taken 
not to acquire spectra from areas of obvious wall motion abnormality.  Nonetheless, 
it is likely that microvascular disease due to inadequate angiogenesis, myocardial 
ischaemia and subsequent reduction of mitochondrial oxidative phosphorylation may 
be an important cause of reduced PCr:ATP ratio in uraemic hearts.  As stated before, 
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silent myocardial ischaemia is common in ESRD patients and often associated with 
CMR features of LVSD (139).   
 
The cause of inadequate angiogenesis in ESRD is not due to hypertension alone and 
appears to be specific to the heart.  In 5/6 nephrectomised rats, the density of cardiac 
capillaries is less than sham operated controls and the SHR model for hypertension 
(258).   Similarly studies have shown lower cardiac capillary density in uraemic 
patients compared to subjects with LVH due to hypertension and healthy controls 
(257). However, this inadequate angiogenesis was not found in other muscles (e.g. 
psoas).  The cause of this uraemia specific effect is not clear but may be related to 
centrally acting sympathetic stimulation and locally derived endothelial factors since 
in experimental models, cardiac capillary density could be improved by monoxidine 
and endothelin receptor blockers (49;257;259).   These effects could not be 
reproduced with calcium channel blocking agents or ACE inhibitors. 
 
Other alterations of cardiac metabolism occur during low oxygen supply.  Changes 
in metabolic substrate usage of cardiomyocytes from fatty acids to glucose have been 
described in hypoxic conditions.  Interestingly, experimental rat models of uraemic 
cardiomyopathy have demonstrated reduction in expression of membrane glucose 
transporter, Glut 4, possibly further hindering substrate availability for oxidative 
phosphorylation (49). 
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7.4.5 Limitations of current studies 
This small study was limited by noisy signal during MRS acquisition.  This was 
minimised by ensuring the magnetic field was homogenised completely.  As before, 
only 60% of patients labelled as “LVH” had evidence on CMR.  However this did 
not alter the findings that cardiac energy metabolism was lower in ESRD patients 
and patients with LVH when CMR confirmed cases were compared.   An interesting 
additional control group would have been healthy individuals, however ethical 
approval was not obtained for this part of the study. 
7.5 CONCLUSIONS 
This study shows that despite similar myocardial mass, ESRD patients have lower 
HEP metabolism compared to LVH patients.  This may be due to greater myocardial 
fibrosis or altered myocyte metabolic function in ESRD patients. Lower PCr: βATP 
ratio is associated with features of uraemic cardiomyopathy  
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Chapter 8 
 
A study of changes in left ventricular mass after renal transplantation 
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8.1 INTRODUCTION 
 
As discussed in Chapter 1, left ventricular hypertrophy (LVH) is the most common 
myocardial abnormality in patients with ESRD, a component of uraemic 
cardiomyopathy, and an independent risk factor for sudden cardiac death, heart 
failure, and cardiac arrhythmias in the general population and dialysis patients 
(1;205).  Furthermore, successful renal transplantation (RT) is associated with lower 
cardiovascular morbidity and mortality compared to patients who remain on the 
transplant waiting list (201;202) and has been associated with significant 
echocardiographic regression of LVH (260;261). 
 
The inaccuracies of echocardiographic estimation of left ventricular mass (LV mass) 
in patients with ESRD, as previously discussed, are due to geometric assumptions 
made during calculation of LV mass and limited visualisation of chamber borders.  
To this end, cardiac magnetic resonance (CMR) imaging has been used to provide a 
more detailed, volume independent, measurement of cardiac structure in this patient 
population. 
 
The aim of this study was to compare changes in LV structure and function between 
patients who undergo RT and those who remain on the transplant waiting list 
receiving maintenance haemodialysis (HD). 
269 
 
8.2 METHODS 
 
8.2.1 Patients 
The subjects from this study were obtained from a larger project investigating 
outcomes in patients undergoing cardiovascular assessment for renal transplantation.  
Patients were recruited from the renal transplant assessment clinic from the Western 
Infirmary as described in Chapter 2.  This study recruited 25 patients accepted onto 
the transplant waiting list who were later successfully transplanted (defined as serum 
creatinine <150 µmol/litre at the time of second scanning), and another 25 patients 
accepted for transplantation, who remained on the waiting list.    
 
8.2.2  CMR acquisition 
Initial CMR scans were acquired as part of assessment of LV function and analysed 
as previously described.  Patients were invited for repeat CMR scan as part of the 
study.  Definitions of  LVH, LVSD and LV dilatation have been presented in 
Chapter 2. 
 
8.2.3 Data collection 
Mean haemoglobin and blood pressures were calculated from monthly 
measurements 3 months before and after CMR scanning. Blood pressure 
measurements taken immediately before the start of haemodialysis were recorded. 
 
8.2.8 Statistical analyses  
Statistical analyses were performed using SPSS version 15.0 (SPSS Inc. Illinois, 
USA).  Data are expressed as mean ± standard deviation or median and interquartile 
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range.  Comparisons were made between those patients who received a transplant 
and those who remained on the waiting list by student’s t test (for normal data) or 
Mann-Whitney U test (for non-normal data).  Time between scans for both groups 
was calculated from the difference between dates of CMRs.  Due to inter-patient 
variation in time between CMR scans, changes were expressed as percentage change 
per year (%/y).  
 
8.3 RESULTS 
 
8.3.1 Patient demographics 
Fifty patients were studied.  The mean time between the CMR studies was 2.8±1.1 
years for those patients who were transplanted and 2.4 ±1.2years for those remaining 
on the waiting list.  No patients had cardiac events (myocardial infarction, acute 
coronary syndrome, cardiac arrhythmias) between scans.   
 
The demographic data are presented in Table 8.1.  This shows that patients who 
received a transplant were younger at the time of first scan (45.9± 14.4 years vs 52.7 
± 10.4 years; p=0.06) compared to those who remained on the transplant waiting list.  
However, there was no significant difference in the number of patients who were 
male, who had diabetes mellitus, a past history of ischaemic heart disease, 
hypertension, heart failure, or in the smoking status (although there was a trend 
towards non-smokers in the transplanted group).   At the time of first scan, there was 
no significant difference in duration on renal replacement therapy between both 
groups (not transplanted 2.3±2.6 years vs. transplanted 3.0±3.0years; p=0.47).  The 
distribution of cardio active drugs was not significantly different between the groups.  
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The only noted change was that one patient was on erythropoietin following 
transplantation, compared to 80% of those who remained on the waiting list.  All 
transplant recipients were receiving low dose maintenance glucocorticoid therapy, a 
purine synthesis inhibitor, and a calcineurin inhibitor as part of their 
immunosuppressive regimen. 
 
Systolic blood pressure was higher after transplantation and during transplant 
assessment (performed on a non-dialysis day).  However, there was no significant 
difference in systolic or diastolic blood pressure between those transplanted or those 
remaining on the waiting list; nor was there a change in the number of anti-
hypertensive agents taken.  Haemoglobin was well controlled on dialysis, and there 
was no significant difference between groups after transplantation. 
 
8.3.2 Cardiac structure and function 
Table 8.2 shows cardiac measurements for both CMR scans.  There was no 
difference in any of the cardiac parameters measured (Table 8.2) – ejection fraction, 
left ventricular mass index (Figure 8.1), BSA corrected end-diastolic and end-
systolic volumes before transplantation or on follow-up scans.    
 
There was a small reduction in left ventricular mass index (-3.6% per annum) in 
dialysis patients and a small increase associated with transplantation (+2.8% per 
annum).  However, none of the measured cardiac parameters achieved statistical 
significance (Figure 8.1).  The proportion of patients with left ventricular 
hypertrophy was 68% in both groups and did not change significantly on follow-up.   
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  Not Transplanted 
N=25 
Transplanted 
N=25 
p 
Age 52.7 (±10.4) 45.9(±14.4) 0.06 
Male 15 (62.5) 20 (80) 0.18 
Diabetes Mellitus 4 (16) 5(20) 0.11 
Past history IHD 6 (24) 4(16) 0.48 
Hypertension 24 (96) 22 (88) 0.29 
Heart Failure 3 (12) 1(4) 0.29 
Smoking status 
Never 
Yes 
Ex 
 
8 (32) 
11 (44) 
6(24) 
 
16(64) 
6(24) 
3(12) 
 
 
0.08 
Number on haemodialysis 12(48) 10 (44) 0.41 
Time on RRT prior to CMR1(y) 2.31 (±2.6) 3.01(±3.0) 0.47 
Drug History    
ESA   
                        
 
CMR 1  
CMR 2 
20(80) 
20 (80) 
18 (72) 
1 (4) 
0.51 
<0.01 
Beta Blocker   CMR1 
CMR2 
8(32) 
19(76) 
 
11(44) 
15(60) 
0.38 
 
Aspirin 
 
CMR1 
CMR2 
6(24) 
10 (40) 
 
9(36) 
9(36) 
0.36 
0.77 
ACE-I/AIIRA 
 
CMR1 
CMR2 
7 (28) 
8(32) 
 
6(26) 
9(36) 
0.75 
0.77 
Calcium channel 
antagonist 
CMR1 
CMR2 
2 (8) 
4 (16) 
 
7 (28) 
6(24) 
0.06 
0.48 
Other clinical data 
 
   
Mean SBP  CMR1  
CMR2 
139 (±17.2) 
145 (±20.5) 
 
135 (±20.1) 
147(±17.4) 
0.40 
0.31 
Mean DBP CMR1  
CMR2 
81 (±12.3) 
77 (±13.2) 
 
78(±11.5) 
81(±13.1) 
0.41 
0.35 
Mean BMI (kg/m2) CMR1 
CMR2 
26.4(±4.0) 
26.8 (±4.1) 
 
26.1(±5.2) 
27.0(±5.7) 
0.79 
0.92 
Mean Hb (g/dL) CMR1  
CMR2 
12.1 (±1.8) 
13.0 (±7.0) 
 
11.9(±1.9) 
12.8 (±2.3) 
0.61 
0.89 
Mean Haematocrit CMR1  
CMR2 
0.38 (±0.05) 
0.37(±0.05) 
 
0.37(±0.06) 
0.39(±0.06) 
0.22 
0.26 
 
Table 8.1 Comparison of demographic, clinical and drug data for patients. 
CMR1= first CMR; CMR2= second CMR. Data are number with percentage in 
parentheses or mean ± standard deviation 
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  Not Transplanted 
N=25 
Transplanted 
N=25 
p 
Mean Time between CMRs (y) 2.4(±1.1) 2.8 (±1.2) 0.14 
Mean Time Transplant to 
CMR2 (y) 
 1.8 (±0.9)  
Ejection Fraction % CMR1 
CMR2 
64.2 (±12.2) 
64.7 (±11.5) 
66.3(±11.5) 
67.1 (±12.2) 
0.56 
0.52 
 
LVMI (g/m2) CMR1 
CMR2 
90.5 (75.1, 113.5) 
87.4 (69.3, 112.1) 
94.7 (77.2, 108.7) 
99.1 (79.1, 119.9) 
0.96 
0.27 
 
EDV/BSA (ml/ m2) CMR1 
CMR2 
74.6(±31.4) 
59.2 (±18.9) 
69.3(±18.9) 
62.3 (±18.6) 
0.51 
0.59 
 
ESV/BSA (ml/ m2) CMR1 
CMR2 
28.8 (±23.3) 
21.9(±17.4) 
24.3±(±20.6) 
25.4(±20.7) 
0.55 
0.51 
 
% change ejection fraction/year + 2.1 (±11.9) - 0.4 (±5.3) 0.34 
% change LVMI/year - 3.6 ( ±16.7) + 2.8 (9.1) 0.10 
% change EDV/year - 3.4  (±31.5) + 0.1(±19.5) 0.64 
% change ESV/year + 3.0 (±55.5) + 15.2 (±65.2) 0.48 
 
LVH  CMR1 
CMR2 
17 (68) 
15 (60) 
17 (68) 
19 (76) 
1.00 
0.23 
LVSD CMR1 
CMR2 
5 (20) 
2 (8) 
3(12) 
2 (8) 
 
LV dilatation CMR1 
CMR2 
5(20) 
1 (4) 
4 (16) 
0 
 
 
Table 8.2 Comparisons of cardiac MRI results for baseline (CMR1) and 
second scan (CMR2).   
Data are mean ± standard deviation in parentheses except for LVMI on MRI where 
median and interquartile range is shown. 
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Figure 8.1 Bar graphs demonstrating (a) mean percentage change of ejection 
fraction per year (with 95% confidence intervals; p=0.34). (b) mean percentage 
change of LVMI per year (with 95% CI; p=0.10) 
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8.4 DISCUSSION 
 
The incidence of patients commencing renal replacement therapy is increasing (262).  
Renal transplantation remains the treatment of choice for patients with ESRD due to 
improved morbidity and significant increase in life expectancy.  This has been 
shown in a number of studies: 
 
• In a longitudinal study comparing survival between transplanted and wait-listed 
patients between 1991 and 1997, Wolfe et al demonstrated an increased risk of death 
in the immediate 2 weeks following transplantation (RR 2.88).  However, there was 
a significant reduction in mortality after 18 months (RR 0.32, 95% CI 0.30-0.35, 
p<0.01) in transplant recipients compared to patients that remained on the renal 
transplant waiting list (201). 
• A study conducted in Scotland, assessed survival in first renal transplant recipients 
and demonstrated a long term reduction in the risk of death after 18 months (RR 0.18 
95% CI 0.08-0.82) compared to patients on dialysis. Projected life expectancy for 
transplant recipients was significantly higher (17.19 years transplant vs. 5.88 years 
on dialysis) (263).  
 
Improved survival is believed to be due to a number of factors including 
improvements in immunosuppression, organ procurement, patient selection and 
preparation, and surgical techniques.  However, cardiovascular death is very 
common in patients with functioning renal transplants and although renal 
transplantation confers a favourable cardiovascular survival benefit this is still 50-
fold higher than the general population: 
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• In a retrospective analysis from the United States Renal Database Service, Meier- 
Kriesche et al demonstrated a significant improvement in long term cardiovascular 
survival in 60 181 first kidney transplant recipients compared to patients that 
remained on the renal transplant waiting list.  CV death rates decreased as transplant 
vintage increased and this relationship existed for living and deceased donor 
transplants (202). 
 
This cardiovascular benefit is unexpected due to the deleterious effect of renal 
transplantation on established cardiovascular risk factors including 
immunosuppression related hypertension, dyslipidaemia, anaemia and diabetes 
mellitus (262).  Some investigators believe that renal transplantation may have an 
effect on uraemic cardiomyopathy, specifically regression of LVH. 
 
8.4.1 Renal transplantation and cardiac structure 
Given the close relationship between cardiomyopathy, long standing renal disease, 
and cardiovascular survival it has been postulated that improved renal function and 
better fluid volume control after renal transplantation may reverse or alleviate 
abnormalities of uraemic cardiomyopathy. 
 
Most studies have been performed in patients with pre-existing cardiac disease 
before transplantation: 
 
• Melchor et al prospectively investigated the effect of renal transplantation in 29 
recipients with echocardiographic evidence of LV dysfunction.  They demonstrated 
significant improvement in LVEF (pre transplant EF= 38.8%, post transplant EF= 
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58.2%; p<0.001) with a reduction in LVH prevalence (21% pre transplant to 18% 
post transplant) (264). 
• Wali et al investigated 138 patients with CKD 5, LV dysfunction (EF≤ 40%) and 
symptomatic chronic heart failure.  Repeat radionuclide ventriculograms performed 
at 6 and 12 months post transplant demonstrated improved mean LVEF (32 to 52%) 
which was associated with improvement in NYHA classification and lower mortality 
and hospitalisation (265). 
• Midvetdt et al demonstrated 15% reduction in LVMI after renal transplantation using 
echocardiography in a study comparing nifedipine and lisinopril to control blood 
pressure in hypertensive transplant recipients. (266). 
 
However in patients with LVH only, the effect of renal transplantation on cardiac 
structure remains controversial: 
 
• Peteiro et al examined 30 patients before and after (10±1.8 months) renal 
transplantation using M-mode echocardiography.  These patients had near normal 
LV ejection fraction.  They demonstrated a significant reduction in ESV, EDV and 
LVMI (201g/m2 pre transplant to 171g/m2 post transplant; p<0.01) but no significant 
change on LVEF (200). 
• Ferriera et al demonstrated a significant decrease in LVMI and LV dilatation after 
renal transplantation.  There was resolution of LVSD (8.3% of patients before 
transplantation to none after) but overall LVEF did not increase significantly (52.9% 
pre transplant to 60.0% 12 months post transplant; p=0.88) (267). 
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CMR scanning provides a more detailed characterisation of the left ventricular 
borders resulting in consistently reproducible measurements compared to 
echocardiography (Chapter 1).  In view of this, the present study was performed 
using CMR to provide accurate, volume independent assessment of LV mass.  There 
was no significant change in left ventricular mass index between patients who were 
receiving hospital haemodialysis for a period of 2-3 years and patients who 
underwent successful transplantation over the same time scale.  Similarly, there was 
no difference in LV chamber volumes or ejection fraction between the groups. 
 
8.4.2 Left ventricular mass after renal transplantation 
These findings cast doubt on the reversibility of left ventricular hypertrophy after 
renal transplantation.  As described in chapter 3, the main determinants of LV mass 
in haemodialysis patients are elevated cardiac preload (volume overload) and 
afterload (systemic hypertension and markers of vascular calcification).  These data 
suggest that some of these features persist after renal transplantation perpetuating 
development and/or preventing reversal of LVH.   
 
8.4.2(a) Hypertension 
Hypertension is the most common cardiovascular risk factor in transplant recipients 
and is significantly associated with adverse outcome: 
• Recent observational studies have demonstrated significant association between 
mortality and blood pressure in renal transplant recipients.  In the largest study to 
date, Kasiske et al demonstrated that a 10mm Hg increase in systolic BP was 
associated with an increase in death (RR 1,18 95% CI 1.12, 1.23), and total or death 
censored graft failure (268). 
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The most potent aetiological factors for post transplant hypertension are pre 
transplant hypertension and use of calcineurin inhibitors (260;262).  In this cohort, 
there was no significant reduction in BP after renal transplantation (Table 8.1) and 
all transplant recipients were immunosuppressed with either tacrolimus or 
cyclosporine. Together, these findings suggest that hypertension may be associated 
with increase in LVMI after renal transplantation. 
 
8.4.2(b) Bone mineral disorders 
The relationship in haemodialysis patients between LVMI and abnormal bone 
mineral metabolism (Chapters 1 and 3) has previously been discussed.   Although 
much has been published in dialysis population, there is a paucity of studies 
investigating the effect of correcting bone mineral parameters after renal 
transplantation. No data was obtained data regarding calcium and phosphate for this 
study. 
 
8.4.2 (c) Fluid overload 
One of the benefits of successful renal transplantation is a return to near normal body 
electrolyte and thus fluid composition (269). Unfortunately, the transplant is unable 
to achieve the same level of body volume control achieved by two native kidneys 
due to glucocorticoid therapy interfering with sodium handling, and calcineurin 
inhibitors altering glomerular filtration pressures and potassium handling.  The effect 
of a trend toward euvolaemia on cardiac preload and filling is controversial.  Most 
studies have used echocardiography to assess chamber dimensions: 
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• Ferreira et al investigated 28 patients with no evidence of pre-transplant LVSD on 
echocardiography.  They showed that there was a significant reduction in LV end 
diastolic diameter (LVEDD) 12 months after transplantation (267). 
• Dudziak et al performed a similar study in 23 transplant recipients and showed no 
significant reduction in LVEDD after 3 months from successful renal transplantation 
(260).  Similarly, Oppert et al showed no significant difference in LV chamber size 
one year after simultaneous pancreas kidney transplantation (270). 
 
The inconsistencies of previous published work highlight the weakness of 
echocardiography studies in ESRD and transplant recipients.  On the other hand, the 
strength of the present study lies with the use of CMR which allows precise 
visualisation of epicardial borders and volume independent measurement of the LV 
chamber and wall. 
 
Thus, based on these data, LV chamber size at end diastole and systole and LV 
ejection fraction are not affected by renal transplantation.  This presumably reflects 
action of the homeostatic mechanisms that control cardiac preload, such as venous 
tone, which increase in response to reduced intravascular volume.  In addition, 
increases in LV ejection fraction and reductions in LV mass are most likely an 
artefact of reduced extracellular and hence intraventricular fluid. 
 
8.4.3 Limitations 
Although the current study is limited by small sample size and variability in timing 
of scans it is the first study to serially evaluate the LVs of patients who have 
undergone renal transplantation using CMR.  Greater precision and reproducibility 
281 
 
of CMR permits smaller, adequately powered studies to be meaningful compared to 
echocardiography (137).  Furthermore, interdialytic changes of haemodialysis 
patients were reduced by standardising the timing of CMR (24 hours after end of last 
haemodialysis session) for both scans.  
 
8.5 CONCLUSIONS 
Cardiovascular disease remains a major cause of morbidity and mortality after renal 
transplantation, and this study supports a possible role for LVH.  These findings cast 
doubt on the reversibility of left ventricular hypertrophy in this population and it is 
likely that prevention, for example by tight blood pressure and bone mineral control, 
in the earliest phases of progressive renal disease with the aim of preventing 
development of left ventricular hypertrophy will be a more successful strategy. 
Moreover, it seems likely that the previous positive results are artefactual due to 
normalisation of intravascular volume following successful transplantation. 
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Chapter 9 
 
 
General discussion and conclusions 
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9.1 Utilisation of cardiovascular MRI to assess uraemic cardiomyopathy 
The principal aims of these studies were to elucidate features of uraemic 
cardiomyopathy using CMR which account for increased risk of CV (usually sudden 
cardiac) death in ESRD patients.  In particular, these studies addressed: 
• The prognostic effect of left atrial and ventricular abnormalities detected by CMR. 
• The pathophysiological features of uraemic cardiomyopathy using novel, non-
invasive techniques which have been evaluated in other patient populations. 
 
As stated in Chapter 1, greater accuracy and precision of CMR compared to 
echocardiography for measuring LV mass and chamber dimensions allows smaller 
sample size to be studied with no loss of statistical power. 
 
9.2 Summary of findings 
The strengths of these studies lie with the use of CMR to accurately assess LV 
abnormalities in ESRD patients.  Furthermore these are the largest observational 
studies using CMR to identify prognostic features of uraemic cardiomyopathy and 
present important, novel results.  Chapters 6 and 7 present data that are novel and 
provide valuable insight regarding the electrophysiological and metabolic changes 
associated with uraemic cardiomyopathy. 
 
9.2.1 Determinants and prognostic features of uraemic cardiomyopathy 
Figure 9.1 summarises findings from Chapters 3 to 5.  The cardiovascular changes of 
advancing renal disease predispose to development of uraemic cardiomyopathy, 
namely intravascular volume expansion, hypertension and reduced vascular 
284 
 
compliance.  As with other disease states (e.g. advancing heart failure) initial 
compensatory mechanisms, such as additional sarcomere proliferation, ultimately 
result in further deterioration of LV architecture.  One notable finding from Chapter 
3 was a close relationship between different LV abnormalities, which was postulated 
to represent differing stages of development of uraemic cardiomyopathy.  The 
prognostic effects of LV abnormalities on CV survival were also demonstrated in a 
large prospective CMR study of ESRD patients (Chapter 4) and results are also 
summarised in Figure 9.1.  Elevated end systolic LAV has been assessed in studies 
of ESRD patients (207) using echocardiography.  However, given the paucity of 
studies demonstrating convincing reversal of LVH in ESRD patients (which is very 
common and usually severe) using interventions trialled in the general population, 
other potentially modifiable cardiac factors independent of LV mass were evaluated 
(Chapter 5).  Elevated LAV also adversely reduced survival of ESRD patients.  
 
9.2.2 Novel pathophysiological features of uraemic cardiomyopathy 
Figure 9.2 shows some of the electrophysiological and metabolic abnormalities 
associated with uraemic cardiomyopathy which were presented in the later chapters 
of this thesis.  In the first study of ESRD patients, the effects of LV structural 
changes detected by CMR were investigated using MTWA to determine abnormal 
myocyte repolarisation.  MTWA has not previously been used to assess ESRD 
patients and, as discussed in Chapter 6, may provide additional information to 
identify subjects at risk of SCD.  As well as being independently associated with 
features of uraemic cardiomyopathy, MTWA was also associated with a clinical 
history of macrovascular atheromatous disease suggesting that even in the absence of 
LV abnormalities, patients with occlusive vascular disease develop abnormal 
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ventricular repolarisation.  These early changes are most likely due to microvascular 
changes and myocardial fibrosis, which may not be evident on CMR examination 
but are nonetheless common in ESRD patients (49;257).  In Chapter 8, novel data 
were presented demonstrating altered cardiac energetics and HEP metabolism in 
patients with features of uraemic cardiomyopathy compared to patients with 
hypertensive LVH.  Furthermore, reduced HEP metabolism was independently 
associated with LVSD of uraemic cardiomyopathy. A smaller study (149) has 
demonstrated a difference between 31P MRS results of diabetic patients and renal 
transplantation recipients, but this study uniquely demonstrates a significant 
association with LVSD and LV dilatation in ESRD subjects. 
 
9.2.3  Effect of successful renal transplantation on left ventricular mass 
In Chapter 9, data from a small observational study showed that successful renal 
transplantation was not associated with a significant regression of LVMI compared 
to patients who remained on the renal transplant waiting list. These data highlight 
two issues:   
• Previous studies that demonstrated significant reduction in LV mass using 
echocardiography, were most likely showing artefactual changes by measuring 
improvement in intravascular and hence LV chamber volume as opposed to 
reduction in myocardial wall thickness (260;261). 
• It is likely that factors, such as hypertension and vascular stiffness remain after 
renal transplantation and may perpetuate increases in LVMI.   
286 
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Figure 9.1 Determinants and prognostic features of uraemic cardiomyopathy  
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Figure 9.2 Pathophysiological features of uraemic cardiomyopathy 
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9.3 Limitations of current studies 
There are limitations in these studies.  In the initial study design, 24 hour ambulatory 
ECG monitoring was planned to assess sinus rhythm changes and provide more 
prognostic data for this patient cohort (115).   Unfortunately, this was not completed 
as many patients did not wish to wear ambulatory monitors overnight.  However 
with these data, presence of significant “resting” arrhythmias may have been 
detected and the additional effect on MTWA result and/or overall risk of CV 
mortality may have been evaluated.   Twenty four hour ECG monitoring is a cheaper 
and more readily available method of detecting cardiac electrophysiology 
abnormalities compared to MTWA, however the sensitivity and specificity for 
identifying ESRD patients at risk of SCD remains to be convincingly demonstrated.   
In addition, measurement of other cardiac electrophysiological parameters was 
proposed for study, namely QT dispersion and heart rate variability.  However, 
detection hardware and software were not available by the time of recruitment. 
 
As stated in Chapter 2, patients recruited into these studies were those being assessed 
for renal transplantation.  This cohort has previously been criticised as some 
investigators believe that this may not provide true cross sectional sampling of 
patients with ESRD.  Historically, patients considered (by a transplant surgeon or 
nephrologist) likely to survive the peri-operative period were referred for pre-
transplant CV assessment.  However, since these patients were considered fit enough 
to be considered for transplantation, it is likely that these results underestimate 
cardiac abnormalities of ESRD patients and would be relevant to other individuals 
with more significant co-morbidities.   
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Although our main aims and objectives were achieved, outcome data based on 
MTWA and HEP metabolism were not available.  Nonetheless, the MTWA study 
finished recruiting 12 months ago and there was a trend toward reduced survival in 
the abnormal MTWA group (Chapter 6).   
 
9.4 MTWA and HEP metabolism as predictors of sudden cardiac death 
In this thesis, data are presented demonstrating significant abnormalities of 
cardiomyocyte action potential (AP) propagation and recovery in ESRD patients 
using MTWA.  As stated in Chapter 1, any changes of cell function resulting in 
abnormal intracellular cation cycling and subsequent non uniform membrane de- and 
repolarisation may increase risk of re-entrant tachyarrhythmias. Abnormal MTWA 
results in ESRD patients were associated with features of uraemic cardiomyopathy 
on CMR examination.  T wave alternans develops at higher heart rates due to 
discordant repolarisation alternans between adjacent cardiomyocytes on an every- 
other- beat basis. This most likely develops in uraemic hearts due to pathological 
changes described including abnormal intracellular calcium handling, microvascular 
ischaemia, interstitial fibrosis and inadequate metabolic substrate availability.  
 
Abnormal MTWA was also independently predicted by clinical history of peripheral 
and cerebrovascular atheromatous disease, implying that other forms of 
macrovascular disease are associated with abnormal ventricular repolarisation. 
Metabolic abnormalities can be measured non- invasively using 31P MRS and in the 
future it will be interesting to evaluate the additional prognostic effect of these MRS 
results with MTWA on development of SCD. 
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9.5 Future studies  
A striking feature of these studies was the high proportion of ESRD patients with 
established LV abnormalities, even in the pre-dialysis period of renal disease, 
implying that these changes develop in the earlier stages of CKD. Regression of 
uraemic cardiomyopathy, especially LVH, has been difficult to achieve thus 
prevention needs to be assessed.  With the use of eGFR to identify patients with 
earlier stages of CKD, future studies may allow early cardiac assessment to detect 
onset of cardiomyopathy and potentially modifiable aetiological factors 
 
Prior to the discovery of anassociation with nephrogenic systemic fibrosis (NSF) in 
patients with advanced renal disease, gadolinium based contrast CMR provided 
useful diagnostic and prognostic information in ESRD patients.  These agents are no 
longer considered to be safe in patients with advanced renal dysfunction.  However 
macrocyclic chelating agents (such as gadoteridol) are associated with a lower risk of 
NSF and the only group of Food and Drink Administration approved agents for 
clinical investigation in patients with advanced renal disease (271).  Nonetheless, the 
use of these agents has to be weighed against the benefit of the diagnostic procedure 
and availability of other imaging modalities.  These agents are obviously not 
appropriate in a research setting. 
  
Blood oxygen level- dependent (BOLD) contrast CMR is based on the differing 
magnetic properties of oxyhaemoglobin and deoxyhaemoglobin which can be 
detected by T1 and T2* weighted scans.  As a result, areas where oxyhaemoglobin 
concentrations are high (coronary blood perfusion is greater than myocardial 
demand) can be visualised.  Conversely, areas of myocardial ischaemia can be 
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detected without the use of gadolinium based contrast agents.  Blood oxygen level- 
dependent CMR has been used to detect myocardial ischaemia in animal models of 
coronary artery occlusion and in patients with inducible myocardial ischaemia due to 
large and small vessel coronary artery disease (272-274).  The prognostic 
implications for BOLD contrast CMR remains to be elucidated, however given the 
high prevalence of small and large vessel ischaemic heart disease in ESRD patients, 
this may be a CMR technique that could be pursued in the future.  Alternative non 
gadolinium contrast agents include superparamagnetic iron oxide particles (SIOP) 
which has also been investigated for their potential role of quantifying not only 
myocardial stress perfusion but areas of fibrosis and previous myocardial infarction 
(similar to gadolinium contrast scans) (275).  To this end, these agents may also 
provide a safe means of performing contrast enhanced scans in patients with ESRD. 
 
Data from Chapter 7 support earlier studies performed in animal models of uraemic 
cardiomyopathy demonstrating abnormal metabolic function in apparently normally 
contracting myocardium.  Given the relative small size of this study, these data could 
be used to power larger prognostic studies in patients with ESRD once outcome data 
are available.   Furthermore, other nuclei have been investigated using MRS.  
1Hydrogen allows quantification of myocardial fat content, lactate, carnitine, 
deoxyhaemoglobin and total creatine levels which are reduced in patients with heart 
failure (276).  However these studies are limited due to the high level of 1H within 
cardiomyocytes (mostly in the form of water), which may provide even greater 
technical difficulties in patients with ESRD where total body water is increased. 
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Finally, further investigation of CV changes that occur after renal transplantation 
may provide insights to potential modifiable factors in patients with ESRD.  In this 
thesis, renal transplantation was not associated with significant regression of LV 
mass after a mean period of 1.8 years.  It is possible that a longer follow up would be 
necessary to demonstrate a significant reduction, however post transplant 
hypertension is one of the major side effects of long term immunosuppression and 
most likely perpetuates rising LV mass.  Alternative studies could include 31P MRS 
to determine the effect of reduced “uraemic” toxins and better intravascular fluid 
control after successful renal transplantation.  Similarly, measurement of aortic 
compliance and vascular stiffness using CMR has been performed in ESRD patients 
(203), and an interesting study would be to assess the effect of renal transplantation 
on these parameters.   
 
9.6 Reducing cardiovascular disease in ESRD patients 
The main aims of the KDIGO guidelines for identifying patients with early CKD 
was not only to slow progression of renal dysfunction, but to address the 
concomitant rise in CV disease (2).  Unfortunately, this subject has a paucity of well 
controlled and adequately powered interventional studies demonstrating convincing 
evidence of benefit for ESRD patients.  However, it is postulated that given the 
association of CV death and uraemic cardiomyopathy presented in Chapter 4, 
slowing or preventing development of LV architectural changes may be an attractive 
target for intervention. 
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9.6.1 Preventing development of uraemic cardiomyopathy 
Preventing development of uraemic cardiomyopathy remains an attractive target in 
early stages of kidney disease. Data presented in Chapter 3 demonstrate that features 
of CKD (e.g. hypertension, vascular stiffening) are associated with the development 
of uraemic cardiomyopathy and that LV abnormalities are closely associated once 
cardiomyopathy is established.  Unfortunately, attempts to alter other established CV 
risk factors in ESRD patients, such as dyslipidaemia, have shown no significant 
survival benefit (AURORA, 4D).  Although not entirely evidence based, aggressive 
management of other established cardiovascular risk factors in earlier stages of 
kidney disease, in particular hypertension, may slow or reduce prevalence of uraemic 
cardiomyopathy and subsequent CV morbidity and mortality.  In addition, other 
novel and renal specific risk factors need to be identified that predispose to CV 
disease and may be amenable to intervention to prevent development of uraemic 
cardiomyopathy.   
 
Chronic expansion of extravascular volume is a hallmark of advancing renal disease 
and has been shown in these and other studies to be a potential aetiological factor for 
development of LV abnormalities (169;170).  In practice, however, control of body 
fluid volume is predominately dictated by patient symptoms (peripheral and 
pulmonary oedema) and/or “dry” or “ideal” body weight in more advanced stages of 
CKD.  Tighter control of fluid balance with oral restriction and diuretic therapy at 
earlier stages of renal dysfunction may reduce development of uraemic 
cardiomyopathy.  Unfortunately, patient compliance remains a major restricting 
factor particularly when interventions have unpleasant side effects (e.g. xerostomia 
and excessive micturition).  More objective means of measuring body fluid status, 
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such as bioimpedance spectroscopy, may provide more convincing evidence to 
pursue these studies further (194). 
 
Furthermore, bone mineral disorder is associated with development of LVH in 
ESRD patients implicating arterial stiffness as an aetiological factor for uraemic 
cardiomyopathy.  Although not a conventional risk factor for CV disease, 
intervention at an early stage of bone mineral disorder, perhaps before development 
of significant secondary hyperparathyroidism would be appropriate (current Renal 
Association guidelines state that vitamin D analogue therapy should start when 
parathyroid hormone therapy is 2-4 times upper limit of normal range) (42).    Both 
KDIGO and Renal Association guidelines highlight the need for prospectively 
controlled studies addressing the benefit for treatment of bone mineral disorders in 
earlier stages of renal dysfunction (277). 
 
9.6.2 Reversing uraemic cardiomyopathy 
Preventing development of uraemic cardiomyopathy has been the most attractive 
option in patients with CKD because reversal, once established, has been very 
difficult to achieve.  The absence of prospective studies has made development of 
evidence based guidelines for reversal of uraemic cardiomyopathy in patients with 
established ESRD difficult.  There are a number of factors that have been presented 
in this thesis and other studies that merit further evaluation in such studies. 
 
Tight control of intravascular and extracellular volume is an important factor.  In 
Chapter 3, extracellular volume was a significant determinant of development of 
LVH, LVSD and LV dilatation.  As with CKD patients, this can be achieved with 
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rigorous adherence to fluid and salt restriction to reduce interdialytic weight gains 
for haemodialysis patients and use of diuretic therapy in patients with residual renal 
function.  Excessive intradialtytic ultrafiltration may provide some benefit, however 
this should be performed with caution given increased risk of myocardial stunning 
and intradialytic hypotension (70). A small (n=25) prospective study in Scottish 
haemodialysis patients has been performed to assess the effect of intradialytic 
bioimpedance monitoring over 6 months on a number of CV parameters including 
LV mass measured by CMR.  These data will be presented within the next 6 months. 
 
The use of antihypertensive pharmacological agents needs to be fully assessed.  
Blood pressure (including pulse pressure) control may be partially achieved by 
controlling intravascular volume adequately.  Nonetheless, from small prospective 
trials using beta blockers, angiotensin converting enzyme inhibitors and angiotensin 
II receptor blockers mentioned in Chapter 1, some benefit has been demonstrated in 
patients with ESRD (120;125).  Whether these agents improve outcome 
independently of blood pressure control in ESRD patients remains to be assessed. 
Despite these findings, cardioactive medications remain grossly underused even in 
ESRD patients who have developed significant CV morbidity (36) indicating that a 
change in clinical practice needs to be implemented.   
 
More frequent and greater quality of dialysis may reverse uraemic cardiomyopathy 
in haemodialysis patients.  Reduction of LV mass measured by CMR has been 
demonstrated in small prospective and observational studies in haemodialysis 
patients treated with frequent and/or nocturnal regimens compared to conventional 
thrice weekly haemodialysis (20;278). The findings of the Frequent Haemodialysis 
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Network randomised controlled trial investigating frequent haemodialysis (daily in-
centre and nocturnal home haemodialysis) with conventional thrice weekly regimen 
are due within the next 6 months and has CMR measured LVMI as a composite end 
point.  Furthermore, more efficient removal of solutes using high flux dialysis 
membranes has been associated with longer survival in hypoalbuminaemic 
haemodialysis patients compared to those treated with conventional low flux ones 
(279).  Whether this type of dialysis improves LV myocardial changes remains to be 
evaluated. 
 
In Chapter 8, absence of reduction of LV mass after renal transplantation was 
attributed to post transplant hypertension (possibly related to calcineurin inhibitor 
use), bone mineral disease and intravascular expansion.  Further study of transplant 
recipients with older grafts, tighter control of blood pressure and fluid status, or 
usage of lower dose/alternative immunosuppressive agents may also demonstrate 
significant changes in myocardial architecture. 
 
The effect of treatment of ESRD related bone mineral disorders on reversal of 
uraemic cardiomyopathy has not been established.  Use of non calcium based 
phosphate binders is associated with reduced coronary calcification and improved 
survival in haemodialysis patients (280).  Furthermore, in primary 
hyperparathyroidism patients with no renal disease parathyroidectomy is associated 
with reduction of LV mass (281).  Whether treatment of hyperparathyroidism by 
surgery or newer calcimimetic agents affect uraemic cardiomyopathy would be an 
interesting study to pursue. 
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Finally, the benefit of ICD insertion in ESRD patients needs to be established.  In a 
recent meta- analysis of dialysis patients with ICDs (n=89), there was still 
significantly elevated CV mortality in ESRD patients (282) compared to ICD 
recipients with milder renal diseases.  A prospective pilot study assessing ICD 
insertion in dialysis patients (ICD2) has recruited 200 patients in the Netherlands and 
plans to report outcome data in 2012 (283). 
 
As with studies in patients with heart failure, careful selection of patients is required 
to identify those who would benefit most from pharmacological or ICD intervention.  
The results of studies presented in this thesis aim to provide information for selecting 
ESRD patients at higher risk of CV or sudden cardiac death (Figure 9.3).  With these 
results in mind, further prospective studies will be able to carefully select groups of 
ESRD patients with differing left ventricular, left atrial, electrophysiological and 
biochemical properties to demonstrate survival benefit with specific interventional 
agents.  In this way, future therapies for ESRD patients can be tailored to improve 
cardiovascular survival. 
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Figure 9.3 Possible features of ESRD patients who are at an increased risk of 
cardiovascular or sudden cardiac death 
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9.7 CONCLUSIONS 
• Premature, usually sudden, cardiovascular death is the commonest cause of death in 
patients with end stage renal disease.   
• Elevated risk of cardiovascular death is due to higher prevalence of traditional, novel 
and uraemic specific cardiovascular risk factors.   
• Abnormalities of left ventricular structure (LV hypertrophy, dysfunction and 
dilatation), collectively termed uraemic cardiomyopathy have been implicated with 
higher cardiovascular mortality. 
• Cardiovascular magnetic resonance imaging is the most accurate and volume 
independent method of assessing myocardial structure in ESRD patients.  
Furthermore, 31P magnetic spectroscopy is a method which non- invasively assesses 
cardiac metabolic activity. 
• Hypertension, presence of bone mineral disorders and expanded extracellular volume 
are common features of advanced CKD and are major determinants of presence of 
LVH, LVSD and LV dilatation on CMR.   
• LVSD and LV dilation detected by CMR are associated with reduced all cause and 
CV survival in ESRD patients.  LVH is significantly associated with reduced 
cardiovascular survival. End stage renal disease patients with two or more cardiac 
abnormalities on CMR have a significantly poorer prognosis. 
• High LAV and presence of LVSD are associated with poorer all cause survival and 
independent predictors of mortality in ESRD patients with LVH.    
• Microvolt T Wave Alternans is a novel, non invasive electrophysiological technique 
of measuring variability in ventricular repolarisation and is associated with 
development of life threatening tachyarrhythmias.  Abnormal MTWA result is more 
common in ESRD patients compared to hypertensive LVH patients and is 
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significantly associated with uraemic cardiomyopathy and a history of 
macrovascular atheromatous disease in ESRD patients.   
• End stage renal disease patients have lower HEP metabolism compared to 
hypertensive LVH patients despite similar LV mass.  Lower PCr: βATP ratio is 
associated with features of uraemic cardiomyopathy  
• Successful renal transplantation is not associated with significant regression of LVH 
when measured by CMR. 
• Future studies may use these pathophysiological and prognostic features of uraemic 
cardiomyopathy to identify patients suitable for interventions which improve 
cardiovascular survival in ESRD patients. 
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